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PREFACE 
There is wide acceptance that in humans blood transfusions given to the recipient 
before grafting produce a strikingly beneficial effect on the post-transplant course 
of cadaveric or living related kidneys (Opelz eta! .. 1981b: Salvatierra eta!.. 1983). 
Recently it has been reported by several authors that blood transfusions to the 
donor prior to nephrectomy positively influence graft survival (Jeekel eta!.. 1980: 
1981: Frisk eta! .. 1981: 1983: Harder eta!.. 1984). However, retrospective studies 
by Berget a!. (1982), Bock eta!. (1984) and Opelz (1985a) could not confirm these 
reports. Many questions were raised by these retrospective observations and this 
made it necessary to experimentally investigate them in rigidly controlled studies. 
This thesis is the reflection of these experiments. Moreover. it contains an extensive 
introduction in the development of transplantation with special emphasis on the 
approaches to immune modulation in human kidney transplantation. 
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CHAPTER 1 
GENERAL INTRODUCTION IN TRANSPLANTATION 
1.1 A brief anthology of early transplantation history 
The idea of grafting parts of the body from one person to another has inspired a 
number of legends. The following quotation is from a translation of a Chinese 
document written about 300 B.C.: "One day two men, Lu and Chao. called on the 
surgeon Pien Ch'iao. He gave them a toxic drink and they were unconscious for 
three days. Pi en Ch'iao operated and opened their stomachs and explored the heart; 
after removing and interchanging their organs he gave a wonderful drug and the 
two men went home recovered" (Worshofsky. 1965). In the thirteenth century the 
Saints Cosmos and Damian transplanted a whole leg. According to this legend, the 
leg of a dead black man was successfully used to replace the cancerous leg of a white 
man (Worshofsky. 1965). In an attempt to save the life of Pope Innocent VIII by 
means of transplantation of young blood. two boys were bled to death in 1492 
(Worshofsky, 1965). 
The first description of a skin transplantation, performed to repair defects of the 
nose. is found in the Sushruta Sanhita, a document written by ancient Hindu 
surgeons about 700 B.C. (Bhisragratna, 1916). 
Transplantation of teeth was described by Arabian writers about A.D. 1000, by 
Ambroise Pare in Paris in the sixteenth century and by John Hunter. a Scottish 
surgeon. in the eighteenth century (Woodruff. 1960: Calne, 1967). He wrote about 
the operation: "Success of this operation is founded on the disposition of all living 
substances to unite when brought in contact with one another. although they are of 
different structure and even though the circulation is carried in one of them". 
In 1804, Baronio was the first to present a well-documented report of successful 
free autografts of skin of a sheep (Baronio. 1804). In 1823 Bunger (1823) reported 
the successful use of a free full-thickness human skin autograft to repair a nasal 
defect. In 1863. Paul Bert. a student of Claude Bernard. reported that autografts. 
allografts and xenografts behaved differently (Woodruff. 1960: Converse and 
Casson, 1968). The significance of these observations received little attention 
however. Nineteenth century authors generally failed to observe that the results of 
allografts and autografts of skin were different. 
The development of transplantation during the twentieth century has depended 
on advances in surgical techniques. on the understanding of the problem of rejec-
tion and on graft preservation and storage and artificial life support. The first 
reports of consistently reliable vascular anastomoses by suturing were those of 
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Carrel and Guthrie between !902 and 1912 (Carrel and Guthrie. 1905: Carrel. 
1908). As earlly as 1905 they succeeded in transplanting an allogeneic dog kidney to 
the abdominal cavity. 
As the technical problems had thus been overcome, transplantation studies 
would concentrate on the mechanism and prevention of rejection of the allograft. 
Many years elapsed before effective measures of prolonging allograft survival were 
reported. 
Landsteiner (1901) was one of the pioneers in the detection of blood groups. He 
reported the genetic system which later proved to be important for histocompatibil-
ity. In studies with transplantable tumors during the first two decades of this 
century Jensen (1903) and Little (1914) reported the influence of geneticfactors in 
transplantation. This oncological research led to important developments in trans-
plantation immunology. Williamson (1923) concluded from renal transplantation 
studies in the dog that failure of transplants was attributable to a biologic incom-
patibility between donor and recipient. Numerous authors studied grafts of tumors 
and of normal tissue in highly inbred strains of mice. Gorer (1936) demonstrated 
that antigenic determinants found on normal and neoplastic tissues in mice are 
genetically controlled. In 1948 his group described H-2 as a genetic locus con-
trolling strong histocompatibility antigens in the mouse: subsequently this locus 
and numerous minor histocompatibility loci were characterized in great detail 
(Snell eta!.. 1953). The detection of the major histocompatibility complex of man 
(Dausset and van Rood. 1965). rhesus monkeys (Bainer eta/.. 1965). chimpanzee 
(Bainer eta! .. 1974). dog (Vriesendorp. 1976) and rat (Gillet a! .. 1978) followed. 
In 1903 Jensen observed that a second graft did not survive as long as the first 
when a mouse received two grafts of a tumor separated by an interval of several 
days. and he suggested that immunity accounted for the difference (Jensen. 1903). 
More than 40 years later Medawar reported similar observations in controlled 
experiments with rabbits (Medawar. 1944: 1945). He demonstrated the immunolo-
gic specificity of the phenomenon, which was observed only when the same donor 
was used for both first and second sets of grafts. The specificity of the second set 
phenomenon had been described by Shinoi in Japan in 1932 (Stickel and Seigler. 
1981 ). This finding probably provided the most convincing evidence for the notion 
that the allograft rejection is based on immunological reactivity originating in the 
lymphatic system of the host and is induced by the disparity of the so-called 
histocompatibility antigens. 
Voronoy, a Russian surgeon living in Mexico, performed in 1936 the first renal 
allograft transplantation in man. The patient died the second day posttranspl::mt 
(Voronoy. 1936). Successful use of hemodialysis to substitute for renal function 
temporarily during a period of renal failure was developed by Kolff( 1946). In 1954 
Murray performed the first successful clinical transplantation using a monozygotic 
twin donor-host combination (Murray era/., 1955). The long term success of this 
and subsequent renal transplants between monozygotic twins was followed by a 
great increase in clinical studies with renal allografts. Initially some patients 
received ACTH or cortisone postoperatively, but adequate immunosuppression 
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was not applied unti11958 when graft rejection was favourably influenced by total 
body irradiaron (Murray e1 a! .. !960). 
Since the sixties transplantation has gained momentum. By now, over 100.000 
kidney transplantations have been performed in man. It is the generally accepted 
treatment of chronic renal failure or end-stage renal disease. One year survival of 
cadaver renal grafts has reached 70-80% (Rapaport, 1981: Monaco, 1985). After the 
first heart transplantation by Barnard (1967), clinical heart transplantation is at 
present in its second decade. At Stanford the one year survival is more than 70% 
(Jamieson. 1985). In 1963. Starzl performed the first orthotopic liver graft in man. 
Results have dramatically improved since the use of cyclosporin A as immuno-
suppressant. One year graft survival is at present about 70% (Starzl, 1985). The 
same can be stated concerning pancreas transplantation, although the success rate 
is still relatively low. One year graft survival is reported to be about 36% (Suther~ 
land and Kendall, 1985). 
At the end of this very brief review of the history of transplantation it can be 
stated that due to an increasingly effective donor/host selection (HLA matching) 
and an ever growing successful immune modulation of the host (transfusions, 
azathioprine. prednisolone. antilymphocyte globulins. monoclonal antibodies. 
cyclosporin A) substantial progress in transplantation during the last two decades 
has been accomplished. An extensive introduction in the development of trans~ 
plantation with special emphasis on these modern approaches to immune modula-
tion in human kidney transplantation will be presented in the next part of this. 
chapter. 
1.2 Approaches to immune modulation in human kidney transplantation 
1.2.1 lntroduClion 
After most of the surgical problems of organ grafting had been .solved it was 
understood that the graft should be protected against the inevitable rejection. In 
this chapter a bird's eye view of the major clinical approaches to avoid graft 
rejection will be presented. 
First of all tissue matching was employed as a way of improving graft survival 
(see section 1.2.2). Soon the employment of drugs acting indiscriminately. blocking 
or damaging all cells that happened to be in mytosis followed (see section 1.2.3). 
The use of these nonspecific drugs e.g. azathioprine was not entirely satisfactory 
and ways were explored to develop lymhocytotoxic drugs or procedures which were 
restricted to the elimination of the immunocompetent cells. This goal could partly 
be achieved by the use of fractionated total lymphoid irradiation (see section 1.2.4), 
thoracic duct drainage (see section 1.2.5). antilymphocyte globulin (see section 
1.2.6). steroids (see section 1.2.3) and splenectomy (see section 1.2.7). 
Currently a new. more biological. phase of immune modulation has been 
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entered. This phase is characterized by selective immune regulation using 
compounds or methods that specifically modulate defined subpopulations of 
immunocompetent cells. It is suggested that cyclosporin A (CsA) is such a drug (see 
section 1.2.8). Also monoclonal antibodies directed towards lymphocyte subsets 
may add to the therapeutic arsenal (see section 1.2.9). Certainly the discovery that 
blood and blood products given to the recipient do enhance allograft survival has 
resulted in such a biological approach to immune modulation (see section 1.2. 10). 
Finally, a different approach towards achieving non-respOnsiveness has been 
modification of the graft by donor pretreatment and culture procedures (see section 
1.2.11). 
These different clinical approaches to avoid graft rejection have been summarized 
in Table 1.1 and will now be discussed in more detail. 
Table 1.1. Approaches to immune modulation in human kidney transplantation. 
non specific methods 
specific methods 
1.2.2 Tissue ryping 
1.2.2.1 Introduction 
donor 
r 
matching 
recipient 
immunosuppressive drug e.g. azathioprine 
fractionated total lymphoid irradiation 
thoracic duct drainage 
antilymphocyte globulin 
steroids 
splenectomy 
I cyclosporin A 
I monoclonal antibodies 
J blood transfusions 
The genetic basis for the rejection of allografts lies in recipient recognition of 
foreign histocompatibility antigens coded for by multiple histocompatibility loci. 
Furthermore cells belonging to the donor immune system in the transplanted organ 
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(passenger leukocytes), which recognize the recipient antigens as ''non-selP', may 
also contribute to graft rejection (Elkins and Guttmann, 1968: van Schilfgaarde et 
aL 1980). 
In every mammalian species that has been examined so far, one complex ofloci is 
of overwhelming importance in determining the fate of allografts. This complex has 
been termed the major histocompatibility complex (MHC). There is a striking 
similarity with regard to the organization of the MHC of the mouse (the H-2 
system: Snell eta/.. 1953), of man (the HLA system: Dausset and van Rood, 1965), 
of the rhesus monkey (the RhLA system: Bainer eta!.. I 965), of the dog (the D LA 
system: Vriesendorp 1976) and of the rat (the RT-1 system: Gillet a!., 1978). These 
homologies indicate conservation of these gene families during evolution. From a 
practical standpoint, the similarity in structure and function ofMHC gene products 
between species make all of the experimental mammalian systems mentioned 
valuable models for understanding the MHC of man (Sachs, 1983). 
The MHC complex in human beings is localized on the short arm of chromosome 
six (Jongsma et a!.. 1973) where several distinct loci code for the highly poly-
morphic glycoprotein HLA antigens. The MHC can be subdivided into three such 
classes of genes, which all have specific functions in control of the different 
molecules involved in immunological responsiveness. 
Class I antigens (HLA-A. -B. -C) are thought to be expressed on the cell surfaces 
of all nucleated somatic cells (Berah et a!.. 1970). This idea has been based on 
cytotoxic assays of single cell suspensions or absorption assays of alloantisera or 
het~roantisera. Such assays have not been adequate in defining the detailed distri-
bution of class I antigens within the various organs of the body. A monoclonal 
antibody together with a sensitive immunoperoxidase staining technique has 
recently been used to examine the detailed distribution of HLA class I antigens 
throughout the body. This study suggests that HLA class I antigens can be detected 
on most. but not all the nucleated cells in the body and that these antigens are thus 
not ubiquitous in their distribution. as previously suggested (Daar eta!., 1984a). 
Class II antigens (IILA-D/DR and other !a like antigens as well as products of 
theIr or immune response genes) were initially thought to be mainly restricted to 
cells of the immune system. They have been described on B lymphocytes 
(Kissmeyer-Nielsen, 1975), epidermal Langerhans cells (Klareskog et a! .. 1977), 
endothelial cells (Hirschberg eta!.. 1979), activated T-cells (Fu eta! .. 1978) and 
during different stages of differentiation of both myeloid and erythroid precursors 
(Wincester. 1980). More recently it has been shown in guinea pigs (Wiman eta!.. 
1978). mice (Parr and McKenzie, 1979). rats (Hart and Fabre, 1981a) and humans 
(Hart eta!.. 1981: Natali eta!.. 1981) that class II antigens have a wider distribution. 
Daar eta!. ( 1984b) have recently examined the detailed tissue distribution of class II 
antigens using a monoclonal antibody and the peroxidase-antiperoxidase tech-
nique on freshly frozen normal human tissues. Their results indicate that this class 
of antigen has indeed a far wider distribution than was previously appreciated. 
Furthermore. there is increasing evidence in various species that class II antigen 
expression can be induced under physiological and pathological conditions 
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(Kiareskog eta/.. 1980: Lampert eta!.. 198 L Mason eta! .. 198!a: Daar eta! .. 1982: 
de Waal eta! .. 1983). Fuggle eta!. (1983) have observed an individual variation of 
expression of class II antigens on renal tubular epithelium which might be due to an 
induction of these antigens under certain circumstances. In other situations. for 
example on capillary endothelium (Fuggle eta! .. 1983) and dendritic cells (Daar et 
a!.. 1983), however. class II antigen expression is more likely to be constitutive 
(Daar et a/ .. 1984b ). 
It is reported that endothelial cells of rats lack these class II antigens (Hart and 
Fabre. !981a: Hart and Fabre. !981 b). However this finding of the absence of class 
II antigens from rat vascular endothelial cells conflicts with data published by Paul 
(Paul eta!.. 1982: Fabre eta! .. 1983: Paul and Carpenter. 1983). 
Finally. class III antigens of the MHC control complement components (Fu et 
a! .. 1974: Awdeh and Alper. 1980). 
Aside from histocompatibility antigens defined by the MHC there are antigens 
defined by systems other than the MHC. The difference between the MHC and non-
MHC antigens was first described in mice by Counce eta!. (1956). The blood-group 
system ABO can be considered as such a non-MHC system. There are also other red 
cell antigens such as rhesus factors. the Lewis system etc. that belong to it (Oriol et 
a/.. 1978). 
Furthermore an antigen system not detectable on lymphocytes. but expressed on 
renal capillary endothelium and monocytes (EM-antigens) has been described 
(Paul et al.. 1979). The system is polymorphic and has been identified recently 
(Baldwin eta/.. 1981). 
1.2.2.2 The effect of tissue matching on graft survival 
One of the dogmas of immunology dictates that the severity of allograft rejection 
is significantly influenced by the degree of histocompatibility between donor and 
recipient. Experimental and clinical experience has verified the dogma and corro-
borated the evidence. 
The importance of compatibility of donor and recipient for the MHC antigens in 
transplantation has been shown in organ grafts in various animal species. Borleffs 
has reviewed this subject extensively in his thesis (Borleffs. 1982). Here the expe-
riences in human kidney transplantation will be reviewed. 
Transplants from HLA-identical siblings have a superior survival compared with 
all other donor-recipient combinations. The survival of HLA identical sibling 
grafts is significantly better than that of one-haplotype mismatched grafts and 
unrelated grafts (Terasaki eta! .. 1981: Albrechtsen eta! .. 1983). 
The impact of matching for separate products of the HLA complex is less clear. 
The effect ofHLA-A and -B locus matching on the survival of cadaver kidney grafts 
is disputed (Opelz and Terasaki. 1982). although several large series show a 
significant influence (van Rood eta/ .. 1977: Opelz eta! .. 1977; Albrechtsen eta! .. 
1981: Festenstein eta!.. 1981; Moen eta! .. 1983: Sanfilippo eta! .. 1984c; Festenstein 
eta! .. 1985: 1986). Several authors have observed that matching for HLA-B is much 
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more effective in improving graft prognosis than matching for HLA-A (Festenstein 
e1 a!., 1976; d'Apice e1 a!., 1984b; Busson e1 a!.. 1984). 
Matching for HLA-C antigens has no significant influence on cadaver graft 
survival (Albrechtsen e1 a! .. 1981; 1983). 
Bach e1 a!. (1970) have suggested that mixed leukocyte culture (MLC) non-
responsiveness (matching for class II antigens) might be more important than 
matching for class I antigens. Indeed a superior graft survival has been reported in 
patients receiving grafts either from haploidentical family donors or from cadaver 
donors against which a low or non-response was recorded in MLC (indicating 
relative compatibility for HLA-D region products) (Ringcten and Berg, 1977; 
Walker era! .. 1978; Berg and Ringden, 1982). 
The cellular techniques used for defining HLA-D region products have been too 
time consuming to be useful for prospective matching of cadaver transplants. 
However, since serologic typing for HLA-DR has become available. the characteri-
zation of cadaver donors for HLA-DR is possible. A significant influence on 
cadaver graft survival of HLA-DR matching has been reported (Persijn era!., 1981; 
Albrechtsen e1 a!.. 1981; Festenstein era!., 1981; d'Apice era!., 1981; Goeken era!., 
1982; Ayoub and Terasaki, 1982; Albrechtsen era!.. 1983; Moen era! .. 1983; Berger 
a! .. 1983; Madsen era!.. 1983; d'Apice el a!.. 1984b; Busson era!., 1984; Madsen er 
a!.. 1985; Festenstein era!.. 1985; Lucas el a!.. 1985; Festenstein era!., 1986). 
Most authors have found that the positive effect ofHLA-DR matching on graft 
survival is independent of the recipient having received pretransplant blood trans-
fusions or not (Ting and Morris, I 980; Albrechtsen era!.. 1981; Goeken era!.. 1982; 
Moen er a!.. 1983; Madsen el a! .. 1985). However. some have reported a less 
pronounced effect either in transfused (Persijn eta!., 1981; Opelz, 1985a) or in non-
transfused (d'Apice e1 a!., 1981) patients. Vanrenterghem el a/. (!983a) have found 
that HLA-DR matching can significantly improve the survival of cadaveric kidney 
allografts in polytransfused recipients. Furthermore they found that the cumulative 
dose of corticosteroids during the first year after transplantation was significantly 
lower in transfused patients with no DR incompatibilities. These data have been 
confirmed by Madsen el a/. (1983). 
Excellent survival times have been reported in HLA-A, -B and -DR matched 
unrelated renal transplants (Persijn era! .. 1981 ). The effect of mismatching for DR 
antigens on the survival of renal allografts from related donors has been studied 
much less extensively (Watanabe e1 a!.. 1983). It has been reported that avoiding 
DR mismatches in recipients of renal allografts from living-related donors sharing 
one HLA-ABC haplotype may provide only a slight improvement in graft survival 
rate. but that the need for anti-rejection treatment is significantly reduced 
(Sutherland e1 a!., 1983a). 
A special status as a marker for "high responsiveness" in renal transplantation 
was ascribed to the HLA-DR w6 antigen by Hendriks era!. (1983). They found that 
recipients of HLA type DRw6 had a significantly lower kidney graft survival rate 
than DRw6-negative recipients. Furthermore. if DRw6-positive recipients were 
given a DR w6-positive kidney. graft survival was good, whereas survival was poor 
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if DRw6-negative kidneys were transplanted into DRw6-positive recipients. These 
findings were confirmed by some investigators (Kaplan eta!.. 1983: Pohanka eta!.. 
1983). others (Vanrenterghem et a! .. 1983c: Opelz. 1984), however. could not 
confirm the report of Hendriks eta!. (1983). 
As stated in the introduction of this section it is reported that apart from the 
MHC antigens also non-MHC histocompatibility antigens do exist. There is clear 
evidence that these non-MHC antigens are also involved in the rejection of kidney 
grafts. since kidney graft rejection has been reported in a number of transplan-
tations between HLA identical siblings. despite immunosuppressive therapy 
(Salaman eta/ .. 1976: Cheigh eta!.. 1977). The involvement of antibodies to non-
MHC antigens in relation to kidney transplantation in man. has been published by 
Paul eta/. ( 1979). They found that the presence of EM antibodies is associated with 
poor kidney graft prognosis. Thus donor-host incompatibility for EM-antigens 
may also be involved in the rejection process. 
For the ABO blood group antigens, it is known that incompatibility shortens 
allograft survival (Dausset and Rapaport. 1966). Rh incompatibility has long been 
thought not to be important in organ rejection in an unsensitized host (Gleason and 
Murray, 1967), but recently a case of renal graft rejection possibly attributable to 
Rh incompatibility. has been reported (Gluckman eta! .. 1981). 
Brynger eta!. (1984) have transplanted A2 donors into 0 recipients with good 
results. Recently it has been suggested that the use of ABO incompatible kidneys in 
closely HLA-DRw matched living related recipients may be successful (Siapak et 
a/ .. 1984). Alexandre eta!. (1985) have reported that ABO-incompatible live donor 
renal homo grafting may be achieved successfully. provided a protocol is followed 
including splenectomy of the recipients. 
The Lewis system (Oriol eta/.. 1978) is reported to be of importance as well. 
Transplantation of Lewis-positive kidneys into Lewis-negative. transfused reci-
pients has been uniformely unsuccessful. whereas matching gave excellent results 
(Pfaff eta! .. 1983). 
1.2.3 Azarhioprine and Prednisolone 
Attempts to transplant organs between individuals who were not identical twins 
were disappointing (Hume era!.. 1952) until experimental studies in dogs showed 
that 6-mercaptopurine and later its derivative azathioprine. could prevent rejection 
of renal allografts (Caine, 1960: Zukoski eta! .. 1960). The clinical application of 
azathioprine as an immunosuppressive agent in human kidney transplantation soon 
followed (Murray eta!.. 1963). 
Billingham eta!. (1951) have laid the experimental basis for the use of cortico-
steroids as immunosuppressive therapy in transplantation. An extensive review of 
the mode of action of glucocorticosteroids has been published recently (Dupont er 
a!.. 1984). 
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The combined use of glucocorticosteroids and azathioprine as pharmacological 
immunosuppression in man dates from 1963 when Starzl eta/. (1963a) reported 
excellent results in recipients treated with the combination of azathiprine and 
prednisolone. 
Azathioprine and prednisolone have remained the mainstay of immunosuppressive 
therapy in renal transplantation for over twenty years and they have proved to be a 
reasonable effective combination. However the side-effects of azathioprine and 
corticosteroids represent a major problem. 
Hypertension. Cushingoid face and body habitus, aseptic necrosis of the femoral 
head. posterior subcapsular cataracts. upper gastro-intestinal ulcerations and 
haemorrhage. psychosis. diabetes mellitus, gro-wth retardation in children, osteo-
porosis and increased frequency of infection have clinically been the most trouble-
some side-effects of steroids (McDonald eta/ .. 1976; Starzl eta/.. 1977). 
Hepatic toxicity and teratogenicity are side-effects of azathioprine (Schein and 
Winokur, 1975)~ bone marrow depression is also a dangerous complication (Fisher 
eta/.. 1976). 
Furthermore there is an increased incidence of lymphomas and other malignancies 
in immunosuppressed transplant recipients (Penn. 1983; Sheil eta!.. 1985; B!ohme 
and Brynger, 1985) as well as an increased incidence of cancer in patients on renal 
dialysis (Sheil et a/.. 1985). 
Despite the numerous complications associated with chronic immunosuppressive 
therapy, it is generally believed that these agents must be continued indefinitely to 
ensure graft survival (Naik eta!.. 1980; Zoller eta!.. 1980). The suggestion that 
continued administration of azathioprine and/or prednisolone may not be 
necessary in renal transplantation (Sheriff et a/ .. 1978; Dandavino et a!.. 1978; Di 
Pad ova eta!.. 1979) has been rejected by data obtained in a retrospective study in 165 
renal transplant units in the USA (Zoller eta!.. 1980). Forty-eight patients were 
identified who had discontinued all immunosuppressive therapy in a total transplant 
population of over 6000. The data learned that at no point after transplantation it is 
prudent to stop all immunosuppressive therapy barring in case of serious drug 
toxicity or infection. Furthermore, in patients who stop immunosuppressive therapy 
surreptitiously and in whom renal function remains normal. reinstitution of therapy 
is indicated. These results are consistent with isolated case reports of graft failure in 
humans. following cessation of therapy (Owens eta/.. 1975; Najarian. 1975. Hussey. 
1976; Uehling et a/.. 1976). However, Campos et a/. (1984) observed that graft 
survival rates in a group of patients where azathioprine therapy had to be dis-
continued as compared to a well-matched control group, showed no significant 
difference after a considerable follow-up. indicating that azathioprine may be 
discontinued when required. Recently Parfrey et a/. (1985) could not confirm this. 
To diminish the side-effects related to steroid administration. several schedules for 
decreasing the total dose administered and consequently the inherent side-effects, 
have been developed. 
Alternate day steroid regimens have been proposed to reduce long term complica-
tions and side-effects of the drug. In three randomized prospective studies this has 
22 
been evaluated (McDonald eta/., 1976; De Vecchi eta/., 1980; Dumler eta/., 1982). 
McDonald eta/. (1976) did not observe any advantage of alternate day prednisolone 
treatment, whereas the other authors (De Vecchi eta/., 1980; Dumler eta!., 1982) did 
find a reduction of long term complications and side-effects of the drug. Dumler et 
a/. (1982) reported a significant decrease of the prevalence of clinical osteonecrosis 
and the rate of infectious complications requiring hospitalization in patients on 
alternate day methylprednisolone. Furthermore the therapy was as effective as daily 
steroids for the maintenance of graft function. 
McGeown et a/. (1980) have shown in a retrospective study that the use of lower 
steroid doses in kidney transplantation can reduce morbidity considerably without 
decreasing the graft survival rate. These results have been confirmed by several other 
groups (Chan eta!.. 1980; Morris eta/., 1982; Cheigh eta/.. 1982). However recent 
data suggest that the combination of low-dose steroids and low-dose azathioprine 
provides inadequate immunosuppression in renal transplantation. although higher 
doses of azathioprine(> 1. 75 mg/kg/ day) allow the use of! ow-dose steroids without 
significantly more graft losses than without high-dose steroids (d~Apice eta!.. 
1984a). 
1.2.4 Total lymphoid irradiation 
Hamburger eta/. (1962) explored nearly 25 years ago the immunosuppressive 
effects of ionizing irradiation on transplantation by treatment of the prospective 
renal allograft recipient with whole body irradiation. The dose required to prolong 
allograft survival did also produce severe bone marrow and gastrointestinal 
toxicity which prevented further clinical use. Other less toxic applications of X-
irradiation were directed at immunocompetent lymphoid cells. Experimental and 
clinical use of local graft irradiation (Hume and Wolf. 1967). intralymphatic 
administration of radioisotopes and extra corporeal irradiation of blood (Cronkit 
eta/., 1965) and lymph (Monden eta/.. 1981) were all tested experimentally and 
clinically. However, the clinical applicability has so far remained limited. 
It has been found that patients with Hodgkin's disease who have been treated 
with fractionated total nodal iJr~Q~~tion_sustain a long lasting impairment of cell 
mediated immune functions (Fuks eta/., 1976). These results have initiated a series 
of experimental studies in several animals and it has been demonstrated that after 
fractionated total lymphoid irradiation (FTLI) of the recipient skin and organ 
grafts follow a delayed rejection course (Slavin eta/., 1976; 1978; Bieber eta/., 1979; 
Howard eta/., 198la). Furthermore it has been observed that skin allografts in 
FILl-treated rodents given donor bone marrow simultaneously with the graft 
survive permanently. The animals were chimeric and graft-versus-host disease did 
not occur (Slavin et a/.. 1977). Such chimeras have also been produced in mongrel 
dogs (Slavin eta/., 1979). The lack of toxicity to bone marrow and gastrointestinal 
tract using this protocoL while maintaining a strong immunosuppressive effect 
encouraged a clinical trial of FTLI in a group of renal transplant patients at high 
risk of rejection of their grafts. 
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Najarian eta/. (1982) found in a group of twenty-two high risk patients all treated 
with FTLI a 72% two-year graft survival compared with 38% graft survival in a 
historical control group of recipients receiving secondary or tertiary grafts and 
treated with conventional immunosuppression. It was also shown that the 
immunosuppressive effects of pretransplant FTLI were diminished when trans-
plantation was delayed. The administration of donor bone marrow at the time of 
transplantation did not produce chimerism. Seventeen patients had significant 
complications, including one death and two lymphomas (Najarian eta/., 1982). 
Nevertheless the side effects. the results suggest that. when properly utilized. FTLI 
can produce effective immunosuppression for clinical transplantation in high risk 
patients. This was further emphasized in a recent report of Levin eta/. (1985) where 
cadaveric renal transplant recipients were treated with total lymphoid irradiation, 
antithymocyte globulin, and low-dose prednisone. Comparison of patients given 
FTLI with a group given cyclosporin A showed similar graft survival but better 
graft function in the FTLI group. Sutherland era/. (1983b) have shown that 
cyclosporin A treatment in recipients who have rapidly rejected previous renal 
allografts, is as effective as FTLI and less cumbersome. It can be concluded that 
FTLI might definitely be of use as an alternative treatment for those patients who 
reject a renal allograft while on cyclosporin A. 
Finally, it should be noticed that local graft irradiation has been proposed to 
reverse rejection (Fidler eta!.. 1973). However, in a recently reported randomized 
study no beneficial effect of such a treatment of acute rejection of renal transplants 
when used in combination with high-dose steroids was found (Pilepich eta!.. 1983). 
1.2.5 Thoracic duct drainage 
Removal of circulating lymphocytes by thoracic duct drainage (TDD) depresses 
the immune response to tissue transplants. As early as 1964 McGregor and Gowans 
demonstrated a beneficial effect of TDD on skin graft survival in rats (McGregor 
and Gowans. 1964). TDD has been infrequently used for immunosuppression in 
tissue transplantation in man. This may be attributed to the technically cumber-
some procedure as well as the need for a month hospitalization prior to trans-
plantation (Klintmalm et a!., 198lc). However, several experienced clinics have 
reported a beneficial effect on renal graft survival (Sarles era!., 1970; Tilney eta!., 
1970; Franksson et a!., 1976; Starzl er a!.. 1979; Fish et a!., 1981) without a 
reciprocal increase in patient mortality. 
Despite the fact that the effectiveness in preventing rejection and prolonging 
allograft survival has been demonstrated, the exact mechanism of this beneficial 
effect is not clearly understood. In a recent study Bell eta/. (1983) have shown by 
using monoclonal antibodies, which characterize specific human T -lymphocyte 
subpopulaticms. that significant alterations occur in both thoracic duct and 
peripheral blood lymphocytes duringTDD. The data showed that as TDD progres-
sed, a significant fall occurred in the percentage of thoracic lymph and peripheral 
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blood lymphocytes with surface antigens typical of most peripheral T-cells 
(OKT 3). Additionally they showed a reduction in the T-helper (OKT 4) toT-sup-
pressor/cytotoxic (OKT 8) cell ratio in TDD. Finally, Beller a/. (1983) noted a 
significant increase in cells bearing a surface antigen typical for lymphocytes under-
going intrathymic maturation (OKT 10). This led to the suggestion that TDD 
produces a state of immunologic immaturity with a relative increase in suppressor 
T cells and thus creates an optimal condition of nonresponsiveness in the host at the 
time of grafting. 
1.2.6 Antilymphocyte globulin 
The injection of lymphocytes, thymocytes or other lymphoid cells into a non-
compatible recipient leads to the production of a serum, which gives a depression of 
the number of circulating T-cells when injected into the donor of the lymphoid cells 
(Woodruff and Anderson, 1963). The antilymphocyte (ALG) or antithymocyte 
globulins (A TG) have proved to be remarkable successful in prolonging allograft 
survival in most animal models (Levey and Medawar, 1966: Monaco eta!.. 1966: 
Starzl er a/.. I 967). 
However the effectiveness of these agents for clinical immunosuppression has 
been more difficult to evaluate. Only recently evidence for true clinical effectiveness 
in organ transplantation has been achieved. The reasons for this were numerous, 
including variability among individual batches, inadequate dosage schedules, lack 
of randomly selected control data, limited numbers of evaluable patients leading to 
multicenter trials with all their attendant problems. Furthermore, during the early 
years of ALG testing. numerous factors (age. blood transfusions. HLA typing etc.) 
were identified to influence kidney transplantation outcome. Many early ALG 
trials were not appropriately stratified for these factors in test and control groups. 
Finally, early trials were restricted to ALG use as an additional immunosuppressive 
agent administered with conventional doses of azathioprine and prednisone. 
The early ALG trials invariably showed reduced incidence and severity of early 
rejections with greater ease of reversibility (Turcotte eta!.. 1973: Sheil era/ .. 1973: 
Cosimi et a!.. 1976: Wechter eta/.. 1979). ALG treatment favoured long term 
survival (Taylor era!.. 1976: Monaco and Codish, 1976: Levey. 1979), but usually 
not significantly (Groth, 1981). Cosimi (1981) found that ATG added to 
prednisone and azathioprine reduced early rejection without an increased incidence 
of infections. decreased the overall steroid requirement and reduced the incidence 
of avascular necrosis. Patient survival was the same with or without A TG but graft 
survival was 10-15% better with adjunctive ATG. 
Recently, Novick era/. (1983) compared adjunctive antilymphoblast globulin used 
with prednisone and azathioprine versus prednisone and azathioprine alone in a 
prospective randomized study of cadaver kidney transplants. ALG recipients had 
no major side effects secondary to ALG, had delayed onset of rejection, reduced 
number of rejection episodes, fewer in hospital days. reduced cost of transplan-
tation. improved graft survival and equivalent patient survival. These authors 
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concluded that antilymphoblast globulin was safe, cost-effective, and of definite 
benefit in cadaver renal transplantation. 
Despite the increasing evidence for the efficacy of this type of protocoL many 
groups now prefer to reserve A TG for treatment of established rejection. Shield et 
at (1979) compared in recipients ofliving related donor allografts the effectiveness 
of A TG alone with high dose steroids as the treatment of choice of rejection 
episodes. This randomized trial favoured the A TO treated group. Similar results 
have been found in the treatment of established rejection in recipients of cadaver 
donor renal allografts. Hoitsma era!. (1985) have compared rabbit antithymocyte 
globulin (RA TG) with high dose prednisone. They found RA TG to be at least as 
good as steroid treatment, with the RA TG protocol obviously adding a major 
steroid sparing effect. Other groups have combined ATG with high dose steroids 
and found this to be more effective than steroids alone (Filo era!.. 1980: Howard er 
a!.. 1981b: Nowygrod eta!.. 1981; Simonian era!.. 1983). 
It can be concluded that the experience now suggests that addition of ATG at the 
time of rejection may be the most efficacious way to use the agent. Further refine-
ments of this therapy are being explored (see section 1.2.9: monoclonal antibodies). 
1.2. 7 Splenectomy 
The value of splenectomy as an adjunctive procedure to improve renal allograft 
survival has been controversial since its introduction by Starzl et a!. (1963b). 
Retrospective analysis by several transplant groups have shown a beneficial effect 
of splenectomy (Pierce and Hume, 1968: Kauffman era!.. 1974: Schulak eta!.. 
1978): others however have not shown a difference (Opelz and Terasaki, 1973) or 
have suggested an adverse effect of splenectomy on patient survival (Rai et a!.. 
1978). 
These early retrospective analyses were performed before numerous other 
factors like age, blood transfusions, HLA typing etc. were identified to influence 
kidney graft survival. Most of these studies were not appropriately stratified for 
these factors and thus the conclusions drawn bear limited weight. 
There is a general agreement that splenectomy corrects the leukopenia associated 
with the hypersplenism of chronic renal failure and minimizes the leukopenic effect 
of the immunosuppressive regimen. and thus allows a higher dose of azathioprine 
to be administered (Woods eta! .. 1971: Kauffman eta!.. 1974; Schulak eta!.. 1978). 
On the other hand. splenectomy is a major operation with potential complications. 
Especially the risk for death due to overwhelming bacterial infection is generally 
feared (Krivit eta!.. 1979; Sherman, 1980). Schroter era!. (1977) have observed 
overwhelming postsplenectomy sepsis in transplant patients. 
Two prospective studies have shown that splenectomy had a beneficial effect for at 
least the fir~t two years posttransplant without a detrimental effect on patient 
survival (Stuart era!., 1980: Fryd eta!.. 1981). These studies have been followed-up 
by a reanalysis of the long-term effect of splenectomy versus no splenectomy on 
renal allograft survival. Sutherland eta!. (1985a) showed that the differences in 
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graft survival rates between splenectomized and non-splenectomized recipients 
were no longer significant. Furthermore there were more late deaths from sepsis in 
the splenectomized group, although the overall patient survival rates were similar 
in splenectomized and non-splenectomized recipients. Rohrer eta/. (1985) have 
reported a continuing overall benefit of splenectomy even after five years. 
However, after certain subgroups, e.g. patients over 50 years of age. were analyzed, 
it became apparent that splenectomy might have a detrimental effect on patient and 
graft survival. 
Recently it has been proposed to perform only splenectomy after transplantation 
in a selected group of patients which are characterized by the development of a 
persistent leukopenia that requires discontinuation of or a significant reduction in 
cytotoxic drug therapy (Lewis eta!.. 1983). The preliminary results of these authors 
are encouraging and indicate that selective posttransplant splenectomy may be a 
reasonable alternative to routine prophylactic splenectomy in recipients of 
cadaveric renal allografts. Very much in favour of such a policy are the data as 
reported by Alexander eta/. (1984). They have published the late adverse effect of 
splenectomy on patient survival following cadaveric renal transplantation. Their 
conclusion is that splenectomy should not be performed routinely in the prepara-
tion for a cadaveric transplant because of an unacceptably high late mortality rate 
that is primarily caused by sepsis. These findings are consistent with those ofPeters 
eta/. (1983). 
Finally, it should be mentioned that we recently found in an experimental dog 
transplantation model that splenectomy can interfere with immunoregulatory 
responses induced by blood transfusions (Marquet eta!.. 1984). Shelby eta/. (1985) 
have confirmed this finding. This forms an other reason to support a conservative 
attitude towards splenectomy in transplant patients. 
1.2.8 Cyclosporin A 
Cyclosporin A (CsA) is a fungal peptide first isolated from mycelia of two strains 
of fungi imperfecti of the species Tolypocladium inflatum Gams in a soil sample 
from HardangerVidda, a high, treeless plateau in southern Norway (Kahan eta!., 
1985). Its immunosuppressive activity was first discovered in 1972 by Borel (Borel 
et a/., 1976). Subsequent experimental studies revealed a strong immunosup-
pressive activity without myelosuppression. Experimental organ transplantation in 
the rat (Kostakis eta!.. 1979), rabbit (Green and Allison, 1978), dog (Homan eta/., 
1980), pig (Caine eta/., 1978a) and non-human primate (Reitz eta/., 1981) have 
demonstrated the potent influence of CsA in preventing acute allograft rejection. 
The remarkable experimental results led Caine era/. (1978b) to first initiate a 
clinical trial using CsA as the sole immunosuppressive agent in renal transplan-
tation. Seven patients on dialysis with renal failure received transplants from mis-
matched cadaver donors. Rejection prophylaxis did occur, however an unexpected 
impairment of renal function in oliguric patients was noted. This led to additional 
immunosuppression with steroids and Cytimun® in the mistaken belief that this 
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impairment of renal function was a manifestation of rejection, though histological 
changes did not indicate severe immune reactions. The result of this excessive 
immunosuppression was a high incidence of bacterial, viral and fungal infections, 
and the development of several lymphomas. 
A revised protocol of CsA dosage was introduced that included the routine use of 
mannitol at operation and the administration of CsA, beginning at 6 hr after the 
end of the operation and then only if an adequate diuresis was present. Subsequent-
ly, CsA improved the !-year actuarial graft survival from a previous 50-55% to over 
80% in recipients of renal grafts from unmatched cadaveric donors (Caine eta!.. 
1981). Furthermore, it was observed that CsA can be steroid-sparing (Caine eta!.. 
1981 ). 
Starzl et a/. (1980) evaluated the combination of early CsA therapy alone 
followed by the delayed addition of corticosteroids. They obtained excellent 
results: graft survival being almost 80% at 1 year in a series of 66 consecutive 
recipients of 67 cadaver renal grafts (Starzl eta!.. 1981). This combination yielded 
fewer rejection episodes and allowed a decreased dose of CsA to be used, thus 
decreasing the nephrotoxicity observed. This happened without an increase in 
infectious complications. 
Recently the results of many controlled clinical trials have been reported (Morris, 
1981: Ferguson et a/ .. 1982: Morris et a/., 1983; Report on the European 
Multicentre Trial, 1982; 1983; Sells, 1983: The Canadian Multicentre Transplant 
Study Group, 1983; Stiller, 1983; Najarian eta!.. 1983: Sheil eta/.. 1983: Kahan et 
a!.. 1983: Rosenthal eta/., 1983; Wood RFM eta!.. 1985; Johnson eta!.. 1985: 
Sutherland et a!.. !985b: Squifflet et a!.. 1985; Caine and Wood, 1985: The 
Canadian Multicentre Transplant Study Group, 1986). 
Morris eta/. ( 1983), and Wood RFM eta/. ( 1985) have compared the use of CsA 
in the first three months after transplantation with conventional immunosuppres· 
sion (azathioprine and low-dose prednisone). In the first trial, including only 
patients with diuresing kidneys and HLA-DR incompatible grafts, they found 
essentially no difference in graft survival between the two relatively small groups 
(Morris eta/., 1983). In the second trial including all patients who had received a 
cadaver kidney, it was demonstrated that short term CsA with conversion to 
conventional immunosuppression resulted in a significant improvement in graft 
survival compared to conventional therapy (Wood RMF eta/., 1985). In two trials 
CsA as a monotherapy has been compared with conventional therapy (Report on 
the European Multicentre Trial, 1983; Sheil eta/., 1983). The one year patient 
survival was in neither of the two trials significantly different in the two treatment 
groups (respectively 98.3% vs. 93.9% in the European trial and 92% vs. 100% in the 
Australian trial). In the European trial the one year graft survival was 72% in the 
CsA group and 52% in the control group. In the Australian trial the one year graft 
survival was 80% in the CsA group and 76% in the control group, where in contrast 
with the European trial, ALG was added to the conventional azathioprine and 
prednisone therapy regimen. Recently, Caine and Wood ( 1985) reported that in the 
European trial, the better graft survival in the CsA group, which was apparent at 
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one year, has been maintained for more than three years, without an increase in 
morbidity and mortality. 
In the other trials CsA has been combined with low-dose prednisone (Ferguson 
eta!.. 1982: The Canadian Multicentre Transplant Study Group. 1983: Stiller. 1983: 
Najarian eta!.. 1983: Kahan eta!.. 1983: Rosenthal eta! .. 1983). This seems not to 
have affected patient survival negatively, for none of the studies shows a 
detrimental influence of the addition of prednisone to the CsA treatment as 
compared to the conventional treatment scheme. On the contrary, in two studies a 
significant difference in patient survival in favour of the CsA groups was found 
(The Canadian Multicentre Transplant Study Group. 1983: Stiller. 1983: Kahan et 
a!.. 1983). The result of CsA plus prednisone treatment as compared to conven-
tional therapy showed an equally good (Najarian et a!.. 1983: Sutherland er a!.. 
l985b: Squifflet era!.. 1985) or significantly better (Stiller. 1983: Kahan era! .. 1983: 
Rosenthal era!.. 1983) graft survival. Very recently. the Canadian Multicentre 
Transplant Study Group ( 1986) reported that analysis at three years still showed 
better graft and patient survival in recipients of cadaveric renal transplants treated 
with CsA plus low-dose prednisone as compared with alternative forms of 
immunosuppressive therapy. 
The prevalence of infections was in most of the forementioned studies evenly 
distributed between the two treatment groups or significantly lower in the CsA 
group (Najarian et a/., 1983: Sutherland era! .. l985b). In a recently published 
randomized study of early infections in transplant patients on CsA it was found 
that CsA treated patients had significantly less overall infections and less nonviral 
infections as compared to azathioprine treated patients (Dummer era/., 1983: Ho et 
a!., 1983). 
In some studies a trend towards a lower occurrence of rejection episodes in CsA 
treated patients has been noticed (Najarian er a/., 1983: Sheil er a!.. 1983: 
Sutherland er a!.. 1985b ). 
Conflicting data concerning the effect ofpretransplant blood transfusions to the 
recipient in CsA treated patients have appeared. In the European Multicentre Trial 
previously non-transfused patients in the CsA group had a better graft survival 
than multiple transfused patients (Sells. 1983). Gardner et a/. (1985) have con-
firmed this finding. Other studies have shown no positive correlation between the 
number of pretransplant blood transfusions and improved graft survival in the CsA 
group (Kahan era!., !983: Klintmalm era!.. 1985). Opelz(l985a)and Woods RFM 
et a!. (1985) reported a significant benefit from blood transfusions in the CsA 
group. Thus, claims that CsA abrogate the transfusion effect must be interpreted 
with caution. 
In the European Multicentre Trial there was a negative relationship noted 
between the degree ofHLA-A and -B match between donor and recipient and graft 
survival in the CsA treated patients (Sells, 1983). Kahan era!. (1983) could not con-
firm these findings. 
Opelz for the Collaborative Transplant Study ( 1985b) has analyzed the correlation 
of HLA matching with kidney graft survival in patients with or without CsA 
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treatment. Matching for HLA-B and HLA-DR loci was shown to have an additive 
positive effect on graft survival in CsA treated recipients of cadaver kidney grafts. 
However. several single centre retrospective analyses of DR matching with CsA 
immunosuppression has demonstrated that CsA seems to negate the effect of DR 
matching in cadaveric renal transplantation (Taylor eta/., 1985; Harris eta/., 1985). 
If these results are confirmed by others, the role of prospective DR matching in 
cadaveric renal transplantation treated with CsA may be of little importance. 
The most frequently reported side-effects in CsA treated patients are nephrotoxi-
city and hepatotoxicity. In order to clarify both, renal function has been studied in 
liver transplant recipients (Klintmalm eta/., 198la; Hamilton eta/., 1981; Powell-
Jackson eta/.. 1983) and liver function in renal transplant patients (Klintmalm et 
a/.. 1981b; Rodger eta/.. 1983). In liver transplant recipients nephrotoxicity was 
noted but could be reversed easily with dosage reduction (Klintmalm eta/., l98la). 
Most authors in the previously mentioned randomized clincial trials have found a 
poorer renal function in the CsA treated patients as compared to the conventional 
treated patient group. However, the renal functions did not deteriorate further and 
remained stable at a subnormal level. 
Frequently, in renal transplantation, it is extremely difficult to distinguish 
between CsA-induced nephrotoxicity and rejection. Several methods have been 
described to differentiate between these two clinical entities (Klintmalm et a/., 
1983). 
Initially it was thought that anuria posttransplant was a contraindication to use 
CsA (Caine et a/., 1981). However there are now a number of reports in the 
literature suggesting that CsA can be safely used in renal transplant recipients with 
early nonfunction (Rynasiewicz er a!., 1981; Flechner eta/., 1983; Castro eta/., 
1983). 
Other major side-effects mentioned in the literature include tremor, hirsutism, gum 
hypertrophy. hyperaesthesia. central nervous system toxicity, and gastrointestinal 
intolerance. All side-effects have shown to be dose-related and reversible on 
stopping the drug (Sells. 1983; Najarian eta!., 1983; Wilczek eta/., 1985). Soon after 
the introduction ofCsA considerable concern arose that lymphomas might be more 
frequently observed after CsA treatment than with conventional immunosuppres-
sion (Caine eta/.. 1981). In subsequent studies of patients treated with CsA such a 
trend could not be substantiated (Penn, 1983), but long-term follow-up of large 
numbers of patients treated exclusively with CsA are needed to clarify the 
carcinogenic potential of this agent in man. 
Studies have indicated that the immunosuppressive properties ofCsA are mostly 
limited toT-lymphocyte-dependent immune responses (Borel eta/., 1977; Green 
and Allison 1978; Caine eta/.. 1978a). The specific mechanism by which CsA exerts 
its immunosuppressive effects on lymphocytes remains unclear. Recent studies 
have demonstrated that this agent. in vitro. inhibits the induction of cytolytic 
lymphocytes in primary mixed lymphocyte response (MLR) while permitting the 
activation and expression of suppressor cells. a process that leads to a state of 
specific allo-antigen tolerance that is maintained by a nylon-wool-adherent 
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suppressor cell (Hess eta/., 1982). Recently, the inhibitory effect of CsA on the 
production of interleukin 2 (IL-2) and on the development of responsiveness to this 
lymphokine have been implicated as some of the major reasons accounting for CsA 
mediated immunosuppression (Hess, 1985). Yoshimura and Kahan (1985) have 
examined the effect of CsA administered in vivo on the capacity of kidney 
transplant recipient lymphocytes to generate IL-2 after mitogen (phytohemagglu-
tinin [PHA]) stimulation. They found that CsA treatment impairs the generation of 
IL-2 by patient lymphocytes and that failure to display this response is associated 
with a poor level of immunosuppression and allograft rejection. 
Several centres have used monoclonal antibodies to monitor human T-lymphocyte 
subsets in renal allograft recipients receiving CsA-prednisone immunosuppression. 
Some authors were unable to demonstrate a change in OKT 4 +I OKT 8 +ratios 
(Hakala et a/., 1983), whereas others did find a decrease in OKT 4 +IOKT 8 + 
lymphocyte ratio in the peripheral blood of these patients (Vanburen eta/.. 1983). 
The decreased ratio was mainly due to a drop in the percentage of OKT 4 + 
lymphocytes following transplantation. This alteration in OKT 4 +IOKT 8 +ratio 
was not noted in azathioprine-treated patients with stable allograft function 
(Vanburen eta/.. 1982). However. CsA combined with prednisone therapy may 
have a different influence upon lymphocyte subpopulations than CsA alone 
(Vanburen eta/.. 1983). This remains to be clarified. 
1.2.9 Monoclonal antibodies 
In section 1.2.6 the results obtained with antilymphocyte globulin have been 
reviewed. Despite the steroid sparing effect and the increased specificity offered by 
polyclonal antilymphocyte preparations, they still fail to provide optimal suppres-
sion. It has recently become possible to distinguish a number of antigens on T 
lymphocytes by producing monoclonal antibodies against them using the hybri-
doma technique of Kohler and Milstein (1975). Thus. a second generation of 
antilymphocyte antibodies has become available (Cosimi eta/.. 198la). A number 
of studies of these reagents have begun to indicate where there future application 
may be most useful. 
Preclinical studies in non-human primates are very promising. Renal allograft 
survival was significantly prolonged after treatment of Cynomolgus with OKT 4 
monoclonal antibody (Cosimi eta! .. 198lb). Similar results have been recorded in 
skin grafting in Rhesus monkeys (Jonker eta/.. 1983). Cosimi eta/. (198lc) reported 
the first clinical trial of OKT 3 monoclonal antibody directed against the antigen 
specific T-cell receptor for rejection therapy after cadaver kidney transplantation. 
Established rejection episodes were reversed within two to seven days in all eight 
cases given OKT 3 antibody without other treatment and with concomitant 
lowering of steroid treatment. In the following 3-13 months period. further 
rejection episodes occurred in five of these patients. two of which were irreversible. 
although six remained well with excellent function. Many patients in this first group 
treated with a monoclonal antibody, developed antibodies to the monoclonal 
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reagent, a factor which, in most patients, would apparently limit the duration of 
this therapy (Jaffers er a!., 1983). However it has recently been reported that 
modifications in the protocol have led to still very successful treatment of rejection 
episodes with limited sensitization to the monoclonal reagent (Thistlethwaite et al., 
1984). 
Other authors have confirmed the effectiveness of monoclonal antibody therapy 
for rejection episodes (Norman eta!., 1985: Takahashi eta!., 1985). 
At present a prospective randomized trial is being performed comparing OKT 3 
therapy with high dose steroids, and ATG if necessary, for reversal of rejection in 
cadaver donor allograft recipients. It is reported that the results are encouraging in 
the OKT 3 treated group (Cosimi, 1983: Goldstein et al., 1985; Ortho Multicenter 
Transplant Study Group, 1985). 
It is clear that this second generation of antilymphocyte antibodies constitutes a 
major potential advance in antilymphocyte antibody therapy. The future prospects 
for the treatment of rejection episodes appear to be exciting. 
The use of monoclonal antibodies for the prophylaxis, but not the treatment, of 
cadaver kidney rejection is still experimental and it is difficult to predict their future 
in renal transplantation (Kreis era/., 1985). However, the availability of mono-
clonal antibodies against the human interleukin-2 (IL-2) receptor on activated T 
cells and the favourable results on allograft survival in mice of anti-IL-2 receptor 
monoclonal antibodies (Kirkman era!., 1985), raises hope of achieving specific 
immunosuppression. 
1.2.10 Bload transfusions to the recipient 
There is now wide acceptance that pretransplant blood transfusions to the 
recipient produce a strikingly beneficial effect on transplant survival, whether the 
kidney is from cadaveric or living related sources. 
Dosseter era/. ( 1967) were the first to state a beneficial effect of blood transfusion 
on cadaver renal allograft survival. Opelz eta/. (1973) did enhance the interest in 
this phenomenon and since then there has been confirmation in many separate 
studies (Opelz and Terasaki. 1980). There are, however, significant discrepancies 
among the results published by different investigators (Opelz eta/., 198la). A recent 
analysis of the long-term effects of blood transfusions suggests that the graft 
survival rate in transfused recipients is not permanently better than that in non-
transfused recipients. However the patient survival rate is much better in these 
transfused recipients (Fehrman era/., 1985). 
Regarding the number of transfusions it has been reported that multiple trans-
fusions more potently produce the transfusion effect ( Opelz eta/., 1981 b; Fehrman, 
1982: Kerman era/., 1983: Horimi era! .. 1983; Opelz, 1985a). However, a single 
transfusion from a random donor is reported to be effective as well (Persijn eta!., 
1979; Opelz, 1985a). In one study the difference in survival rates between grafts in 
patients with no transfusions and those with one transfusion is reported to be about 
5% at one year with a progressive increase in graft survival up to 10-15 transfusions. 
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Additional transfusions did not increase the survival rate (Horimi eta!., 1983). 
Opelz (1985a) for the Collaborative Transplant Study has reported that patients 
with 6-10 pretransplant transfusions had the highest success rate. whereas the rate 
was lower again in patients with more than 10 transfusions. Several authors have 
reported a lack of correlation between cadaver kidney transplant survival and the 
number of pretransplant transfusions (Feduska eta/.. 1982: Zeicher eta! .. 1983). 
It is suggested that the active cells in blood transfusions required to elicit the 
blood transfusion phenomenon are probably leukocytes (Rapaport and Dausset. 
1983). This suggestion is supported by the finding that white blood cell free blood is 
ineffective in producing the transfusion effect (Persijn eta!.. 1979). The use of 
frozen. washed or HLA-A and B matched blood has been advocated by some 
groups in an attempt to reduce the risk of patient sensitization or disease trans-
mission. Several studies have suggested that recipients receiving only frozen blood 
have no significant benefit in terms of graft survival (Opelz and Terasaki, 1974: 
Persijn eta!.. 1979), but others found that frozen blood was effective in providing 
increased graft survival (Fuller et a!., 1982: Horimi et a/ .. 1983). In a recently 
published retrospective study examining the effect of transfusions with packed. 
washed. frozen and mixed blood products on graft survival. an association of any of 
these blood products with a significant increase in graft survival was found 
(Sanfilippo eta/., !984a). Furthermore. the same authors reported that the effect on 
graft survival was not significantly different among the various blood product 
groups. Finally, they found that only minor differences in the degree of patient 
sensitization were associated with the type of blood product (Sanfilippo et a! .. 
1984a). These results are in agreement with the earlier report ofOpelz and Terasaki 
(1980). who compared the effect of whole blood. packed cell and washed packed 
cell transfusions on graft survival. 
Nube eta/. (1983) have shown that prospective administration ofHLA-A and B 
matched identical or compatible pretransplant blood transfusions have a beneficial 
effect on graft survival while avoiding sensitization as indicated by a significant 
reduction of lymphocytotoxic antibodies. However. reports from other centers 
have suggested that this treatment is ineffective (Albert eta! .. 1981: Vanrenterghem 
et a/.. 1983b ). 
One group has employed randomly selected thrombocyte- and leukocyte-enriched 
buffy coat transfusions in potential cadaver recipients. They have reported an 
improved renal allograft survival over that of whole blood transfused recipients 
(Okazaki eta!., 1985). Borleffs eta/. (1982) have reported that platelet transfusions 
improve kidney allograft survival in Rhesus monkeys without inducing cytotoxic 
antibodies. This report has generated considerable interest because of its great 
potential for clinical transplantation. In dogs however. platelet transfusions were 
found to be ineffective (Marque! et a/.. 1983: Bijnen eta/., 1984). Furthermore 
Opelz (1985a) and Chapman eta/. (1985: 1986) have observed in humans that 
platelet transfusions given to nontransfused recipients do not simulate the 
transfusion effect. 
Transfusion are reported to be effective only when given prior to transplantation 
rather than at the time of transplantation (Hourmant et a! .. 1979: Opelz and 
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Terasaki, 1981; Glass et a!., 1982; Opelz, l985a). It has been reported that the 
interval beween transfusion and transplantation is not critical as long as enough 
time has elapsed for the effect to be induced (Opelz et a!.. l98la). For the 
Collaborative Transplant Study Opelz (1985a) has reported that patients who 
received transfusions during transplantation surgery did somewhat better than 
patients who were not transfused at all: however, they did much worse than patients 
with pretransplant transfusions. 
Glass eta!. (1982) have reported that peroperative blood transfusions are without 
significant benefit in previously untransfused patients, and significantly lower 
allograft survival in previously transfused patients. However, this is a matter of 
debate as several studies, including one prospective study, have been published 
suggesting a beneficial effect of peroperative transfusions (Stiller et a!., 1978; 
Williams et a/., 1980). The matter has become even more complicated after the 
recent publication of a report which indicates that peroperative transfusions alone 
were beneficial in decreasing allograft rejection, did not provide an apparent risk 
for patients who had already received pretransplant transfusions and finally 
seemed to influence beneficially graft survival in sensitized regrafted patients who 
received pretransplant transfusions (Sanfilippo eta/., l984b). 
As mentioned earlier the greatest objection against transfusions has been the 
development of cytotoxic antibodies, which has generally been thought to mean 
that the patient is sensitized with as a result a poor graft survival (Terasaki eta!., 
1971). This view is logical. However. evidence has accumulated that transfused 
patients with antibodies have a higher graft survival than those without antibodies 
who have not been transfused (Werner-Favre eta/., 1979; Spees eta/., 1980; Horimi 
et a/.. 1983). It has been suggested that highly sensitized patients with cytotoxins 
can be successfully grafted and that it is only necessary to avoid transplants in 
patients who have cytotoxins directly reactive to the donor's cells, that is, patients 
who have positive crossmatches (Horimi eta/., 1983). 
Several mechanisms have been proposed to explain the beneficial effect of pre-
transplant transfusion to recipients of cadaveric renal allografts. It has been 
proposed that the transfusion effect may be attributable to donor preselection 
(Opelz eta/., 1972). This means that the degree of presensitization, and thus the 
transplantability, of recipients by blood transfusions distinguishes "responders" 
with a high level of cytotoxic antibodies and a higher rejection rate from "non-
responders" with a negative antibody response and a lower rejection rate (Opelz et 
a/., 1972). It has also been proposed that blood transfusions may play an active role 
by inducing anti-idiotypic or anti-Fab antibodies (Singal eta!., 1982; Fagnilli and 
Singal. 1982; Chia eta/., 1982; Singal eta/., 1983). Others favourthe hypothesis that 
blood transfusions modify the immune response by the induction of suppressor T 
cells (Maki et a/., 1981; Lenhard eta/., 1982; Smith eta/., 1983). According to 
Bianchi eta/. (1983)the alloantigen-specific suppressorT cells canal so suppress the 
in vivo immune response to unrelated alloantigens. Finally, recently Terasaki 
( 1984) has proposed the "clonal deletion theory" to explain the beneficial effect of 
transfusions. The decloning hypothesis states that a blood transfusion activates 
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allor.eactive clones causing a secondary antidonor response shortly after trans-
plantation. The patient is thought to be '"decloned'" by high doses of steroids or 
other immunosuppressive agents, either deliberately administered at the time of 
grafting or released endogenously in response to surgical stress. 
In an attempt to extent the beneficial effect of random blood transfusions on 
cadaveric renal allograft survival. Salvatierra eta!. (1980) did start a deliberate 
donor specific blood transfusion (DST) scheme prior to living related renal trans-
plantation. Since donor blood transfusions given to recipients before renal 
allografting might result in sensitization to the donor and subsequent hyperacute 
rejection. clinicians previously have been very hesitant to employ this technique in 
human renal transplantation. However, reported results have thus far been very 
encouraging, and patients receiving related kidneys from theircrossmatch-negative 
blood donors appeared to have an outcome and post-transplant course similar to 
that achieved with HLA identical siblings (Salvatierra et a!., 1983). The graft 
survival rates at one, two and three year in the DST and non-DST one haplotype 
match recipient groups are reported to be 94%,91% and 87%, and 67%,62% and 
56% respectively (Salvatierra et a!.. 1983). Other centres that have adopted the 
protocol have reported similar results (Whelchel eta!., 1982; Mendez eta!.. 1982: 
Takahashi eta!.. 1982; Yamauchi eta!., 1984; Glass eta!., 1985). 
The DST protocol has been extended with good results to two-haplotype-
mismatch siblings, distant relatives, and unrelated individuals (Sollinger et a!., 
1984). 
As mentioned earlier the sensitization of a recipient to his prospective related 
donor is a major concern when using DST. Salvatierra eta/. (1980) reported that 
31% of the patients receiving fresh DSTs developed positive white blood cell cross-
matches with their blood donor. However. other groups have reported much lower 
sensitization rates (Mendez eta!.. 1982: Yamauchi eta!.. 1983). The sensitization 
rate is noted to decrease when stored blood is used without a detrimental influence 
on the beneficial DST effect (Whelchel eta/., 1985). Anderson eta/. (1985) have 
reported that the administration of azathioprine to patients during the period of 
transfusions from the donor did reduce the rate of sensitization. This has been con-
firmed by Glass eta!. (1985). They found that the importance of the azathioprine 
plus DST protocol lays in the reduced incidence of sensitization and the increase in 
the number of transplants that can be done. 
Recently Okazaki eta/. (1985) have reported significant reduction of sensitization 
and improved allograft outcome after donor-specific buffy coat transfusion of the 
recipient. 
Bijnen era!. (1985) have tried to diminish the incidence of sensitization by using 
donor-specific thrombocyte transfusions in one-haplotype related dogs. It was 
found that donor-specific thrombocyte transfusions did not sensitize the recipients 
but also had no favourable effect on kidney graft survival. It is generally felt that the 
excellent graft survival in DST-treated recipients does far outweigh- the risk of 
sensitization (Salvatierra eta!., 1981). 
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The mechanism of action of DST's which allows for improved graft survival, is 
not totally clear. Several alternative hypotheses have been proposed to explain this 
phenomenon. These include: recipient selection, decloning, and autoregulation. 
Salvatierre et al. (1980) postulated that both recipient selection of "responders" 
and ''non-responders'' to a potential donor and the modification of the host 
immune response may occur with DST's. The experience with stored blood and the 
azathioprine plus DST protocol seem to indicate that recipient selection might only 
be a minor contributing factor (Whelchel et al.. I 982; Anderson eta/., 1985; Glass et 
al.. I985). 
The decloning hypothesis. recently proposed by Terasaki (1984), states that DST 
activates alloreactive clones causing a secondary antidonor response shortly after 
transplantation. As stated in a previous part of this chapter, the patient is thought 
to be "decloned" by high doses of steroids or other immunosuppressive agents, 
either deliberately administered at the time of grafting or released endogenously in 
response to surgical stress. 
In contrast. the various autoregulation hypotheses, based on experimental and 
clinical studies, state that DST induces inhibition of antidonor immune response 
rather than stimulation. Specifically, the proposed regulatory mechanisms include 
induction of suppressor cells (Marque! and Heystek, I 981; Marque! er al.. I 982) 
that specifically inhibit MLC or CML responses to donor alloantigens (Leivestad et 
a! .. 1982; Nagarkatti and Singal. 1983; Wood eta! .. I984; Leivestad and Thorsby, 
1984; Cheigh er a! .. 1984) and induction of antibodies to host T cell antigen 
receptors for donor alloantigens as measured by inhibition of MLC or CML 
responses (Nagarkatti and Singal. I983; Nagarkatti eta/., I983; Sollinger eta! .. 
1984; Cheigh era! .. 1984; Burlingham eta! .. !985). 
It can be concluded that there is now wide acceptance that pretransplant blood 
transfusions to the recipient produce a favourable effect on graft survival. Only few 
studies have appeared on the effect on graft survival of transfusions given to the 
donor. The available literature concerning transfusions to the donor will be 
reviewed in chapter 2. 
1.2.11 Reduction of immunogeniciry of the graft 
According to the classical view of allograft rejection, the transplanted tissue is the 
source of antigen that stimulates a T-cell and B-cell response of the host which in 
turn leads to the rejection process. Central to this concept about graft rejection is 
the idea that antigen recognition is a sufficient requirement for lymphocyte 
activation (Medawar, 1944). In recent years however evidence has accumulated 
that one signal is not sufficient and that two signals are required for lymphocyte 
activation (Lafferty. 1980). 
Snell ( 1957) has proposed that donor leukocytes in grafts play a major role in this 
process because of their capacity to carry along draining lymphatics antigen to the 
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host lymphoid system. Steinmuller (1967) and Elkins and Guttmann (1968) 
actually showed in rodents that sensitization of the host after transplantation might 
be attributable to non-parenchymal hemopoietic cells. Elkins and Guttmann 
(1968) did also suggest that the rejection of organ allografts might be initiated by 
the immune interaction of host lymphocytes with donor leukocytes carried as 
passengers within grafts. They introduced the term "passenger leukocytes". 
Furthermore. in an elegant model. Guttmann era/. (1969} and Guttmann and 
Lindquist (1969) used rat bone marrow chimeras to demonstrate that the trigger 
site of immunogenicity seems to reside on donor cells of hemopoietic origin and 
that these cells seem to be sensitive to cytotoxic agents which might prolong 
allograft survival by reducing allograft immunogenicity. Steinmuller and Hart 
(1971) have confirmed that bone marrow derived leukocytes make a significant 
contribution to graft immunogenicity in rodents. 
Until recently these antigen presenting passenger leukocytes have remained a 
theoretical entity. A candidate for the passenger leukocyte has appeared when it 
was shown that all tissues, except brain. are populated with a migrant population of 
bone marrow derived Ia positive dendritic cells (Hart and Fabre. 198lc) and that 
these cells are extremely potent stimulators of the mixed lymphocyte reaction 
(Steinman and Witmer. 1978: Masoner a/.. 198!b). Dendritic cells were recently 
shown to be a major immunogenic stimulus of a kidney allograft. Lechler and 
Batchelor (1982) were able to restore immunogenicity with as few as 10'-5xl0' 
dendritic cells in long surviving renal allograft bearing rats. 
It is thought that in rodents the ability to present antigens is confined to these 
specialist cells and that it is unlikely that the graft parenchymal cells themselves 
induce the rejection process. The transplantation antigens of the graft are 
presumably processed and presented by antigen presenting cells (dendritic 
cells/macrophages) of the host (Mason. 1983). Batchelor er a/. (1978) have 
suggested that this indirect antigen presentation to the recipient's immune system is 
much less efficient than the process of direct antigen presentation. Lechler and 
Batchelor (1982) have added the observation that the immune response evoked by 
MHC-incompatible tissues devoid of dendritic cells more closely resembles that 
produced by a minor histocompatibility antigen disparate graft than one with 
major histocompatibility differences. 
As a result of these observations Batchelor (1983) has proposed two routes ofallo-
immunization. In route 1, which is a very powerful form of immunizat-ion, 
allodendritic cells present in graft tissue directly present major histocompatibility 
antigens of donor type to recipient T cells. If the donor and recipient differ at the 
major histocompatibility complex. T cells will be specifically activated against the 
major histocompatibility antigens carried by the transplant. This direct stimulation 
of recipient T cells will thus lead to the generation of cells reactive to both class I and 
class II antigens of the donor. The route 2 involves the breakdown. phagocytosis 
and handling of alloantigen by the recipient's own antigen presenting cells. The 
crux of this route is that alloantigen is finally presented to the recipient's T helper 
cells by the recipient's own dendritic cells/macrophages, which route in principle is 
37 
the same as that involved for minor histocompatibility antigens. This process, 
which is termed indirect antigen presentation, will activate T cells in the recipient 
that are specific for graft antigens presented in association with the restricting 
element of the host antigen-presenting cell, the class II antigen of the host (Schwartz 
era! .. 1978). This indirect antigen presentation will also lead to a graft-specific T-
cell response~ these T cells, however, do recognize the graft antigens in association 
with recipient type class II antigens. and thus are unable to attack cells of the graft 
directly. Although the responding T-cells are not specific for the transplanted 
tissue, they could act as helper cells forB cells that have picked up antigens from the 
transplant. Such responses might as a result lead to the production of an amount of 
graft specific antibody. Such antibodies could potentially act as enhancing 
antibodies. 
Lafferty (1980) has proposed a different model concerning lymphocyte activa-
tion. This model is called the stimulator cell model and he makes two postulates 
concerning the process of immunocyte activation. The first is the "Bretscher-
Cohn" postulate (Bretscher and Cohn. 1970): two signals are required for 
lymphocyte activation. Signal 1 is provided by antigen binding to the potentially 
responsive lymphocyte. Signal 2 is provided by an inductive molecule, which is said 
to possess costimulator activity. According to the "Bretscher-Cohn" postulate, 
signal 1 alone is a negative signal which leads to the development of tolerance 
(Bretscher and Cohn. 1970). A corollary of this postulate is the notion that a 
stimulator cell is required for lymphocyte activation. The stimulator cell is the cell 
that provides the source of costimulator activity. According to this model, antigen-
presenting cells are stimulator cells. 
The second postulate is "the control postulate": a control molecule on the surface 
of the stimulator cell regulates production and/or release of costimulator activity. 
Costimulator activity is released only when the control structure is engaged by the 
potentially responsive lymphocyte. The implications of this stimulator cell concept 
for the understanding of alloreactivity are three fold (Lafferty era/.. !983a. Lafferty 
and Prowse. 1984). The first implication of the model is that only cells expressing 
the stimulator phenotype will stimulate allogeneic T cells in vitro, and that this 
capacity of stimulator cells to stimulate is dependent on their metabolic activity. 
Indeed metabolic inactivation of the stimulator cell population with ultraviolet 
destroyed the capacity to activate an antigen-specific T-cell response (Lafferty et 
a/ .. 1978). It is suggested that the most likely candidate for the physiologically 
relevant stimulator cell is the !a-rich dendritic cell (Steinman and Witmer. 1978). 
The second implication derived from the stimulator cell model is that there will be 
two distinct classes of alloantigen. One will be highly immunogeneic for allogeneic 
T cells in vitro and the other will be non immunog~neic. Experimentally. it has been 
shown that major histocompatibility molecules behave as the control structures 
defined by this model. Other cell surface antigens behave as minor histo-
compatibility antigens (Bevan. 1975). 
The third implication of the model is that alloantigen carried on the surface of 
donor stimulator cells in the graft constitutes the major source of tissue immuno-
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genicity. To summarize, the antigen presenting cell plays an active role in the 
immune induction because this cell, in addition to presenting antigen (a source of 
signal 1), provides a source of the second signal (costimulator activity) required for 
the lymphocyte activation (Lafferty and Prowse. 1984). 
It can be concluded that the antigen presenting cell, whether it be called 
passenger leukocyte or dendritic cell, carried in the grafted tissue is a major source 
of tissue immunogenicity and it is suggested that an efficient way of ensuming 
minimum sensitization is to eliminate these functionally active cells from the 
allograft before it is transplanted (Batchelor, 1983: Lafferty era!.. 1983b). 
Indeed, attempts at elimination of these antigen-presenting cells by treatment of 
the donor with irradiation. antilymphocyte globulin or cytotoxic drugs (Guttmann 
and Lindquist, 1969: Freeman eta!., 1971: Steinmuller eta!.. 1971: Stuart era!. 
1971a: 197lb: Zincke and Woods, 1974) as well as by in vitro culture (Lafferty er al .. 
1975; Naji eta!., 1979: Lacy eta!.. 1982) have resulted in prolongation of allograft 
survival in animals. In 1973 Guttmann eta!. (1973) were the first to describe a 
decrease in the number of graft rejections in man after pretreatment of the donor 
with methylprednisolone and cyclophosphamide before nephrectomy. Studies 
reporting an improved kidney graft survival after donor drug pretreatment in man 
followed (Beaudoin et al .. 1973: Guttmann era!.. 1975: Zincke and Woods. 1977: 
Zincke eta!.. 1978: Corry eta! .. 1980: Guttmann eta!.. 1980). These studies did not 
definitely prove its beneficial effect, since most of them compared the survival of 
donor drug pretreated kidney grafts with historical controls and all dealt with a 
small number of patients. 
Prospective studies on the effectiveness of donor drug pretreatment on renal allo-
graft survival could not establish its effectiveness with the exception of the study of 
Corry era/. (Chatterjee er al .. 1977: Dienst, 1977: Barry and Bennett, 1978: Jeffery 
era!., 1978: Soulillou era!., 1979: Corry eta!., 1980). Thus. the clinical results of 
donor drug pretreatment are inconclusive. 
One reason might be the inadequate removal of interstitial dendritic cells by the 
clinically used pretreatment protocols. McKenzie et a!. ( 1984a: 1984b) recently 
examined the effect of donor pretreatment on the interstitial dendritic cell (or 
passenger leukocyte) content of rat heart grafts. In rat heart, where class II major 
histocompatibility antigens are most likely restricted to interstitial dendritic cells 
(Hart and Fabre, 198Ic), direct cell counts were made on frozen sections stained 
with monoclonal antibodies. It was possible for the first time to compare the effect 
of a pretreatment regimen on the target cell population and subsequently to observe 
the survival of pretreated heart grafts transplanted into untreated recipients. It was 
found that pretreatment (cyclophosphamide and/or total-body irradiation) of the 
donor only resulted in prolonged graft survival when more than 95% of the 
interstitial dendritic cells were removed. Very small numbers were still sufficient to 
cause rapid rejection. Furthermore. to be effective, donor pretreatment schedules 
had to be initiated 5 days prior to transplantation. Pretreatment 6 hr prior to 
transplantation failed to deplete the graft interstitial dendritic cells or prolong graft 
survival. 
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An other reason for the different results of donor pretreatment between animals 
and men might be more structural. In man it has been suggested that in addition to 
the presentation of antigens by dendritic cells, endothelial cells of vascular 
endothelium may also perform this function (Hirschberg eta! .. 1980). In contrast 
with the antigen presenting dendritic cells which are a migrant population with a 
limited lifespan, the vascular endothelial cells of an allograft are fixed and persist 
the lifetime of the graft. Thus, it follows that, if indeed vascular endothelium can 
serve as an antigen presenting celL a human organ allograft contains a permanent 
population of antigen presenting cells of donor origin. This difference in antigen 
presenting cell population between rodents and man might explain the divergent 
results in both groups seen after the elimination of passenger leukocytes as a result 
of donor or graft pretreatment. 
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CHAPTER 2 
TRANSFUSION TO THE DONOR: RATIONALE, OBJECTIVES AND 
DESIGN OF THE EXPERIMENTS PERFORMED 
Blood transfusions may have a profound effect on the immune response, as 
established by many investigators, in renal transplant recipients (Chapter 1.2.10). 
In this chapter data will be reviewed which indicate that blood transfusions given to 
the transplant donor shortly before transplantation may affect graft survival in dog 
and man. 
The first authors who described an effect of blood transfusions to the donor on 
kidney graft survival have been J eekel eta!. ( 1980). They described that in dogs the 
prolonged kidney graft survival achieved by one peroperative blood transfusion 
could be abolished by transfusion of the donor on day-! with 100 ml third party 
blood. 
Subsequently in 7 retrospective studies the effect of blood transfusions given to 
the donor on cadaver kidney graft survival in man has been evaluated. In 4 studies a 
significant beneficial effect has been found. 
In Leiden 44 patients, who never received blood transfusions before transplan-
tation, but were transfused at the time of transplantation, were studied (Jeekel et 
a/ .. 1980; 1981; 1982; 1983). The overall one year graft survival in these 44 patients 
was 27.5%, which is comparable to the 32% one year graft survival in nontrans-
fused recipients from Eurotransplant, reported in a previous study (Persijn eta! .. 
1979). Of the cadaveric donors of these 44 kidneys, 26 donors were not transfused 
during the period immediately preceeding their death, whereas 18 donors did 
receive at least one blood transfusion. The 26 recipients of kidney grafts from non-
transfused donors rejected their grafts significantly earlier than the group of 18 
patients with renal grafts from transfused donors, the corresponding one year graft 
survival being 11.5% and 50%, respectively. Comparison of the recipients in the 
two groups for sex, age and dialysis period did not reveal significant differences. 
The number of HLA-A and B locus mismatches were comparable in the two 
groups. 
In Basel the study covered 96 first kidney grafts transplanted between 1971 and 
1979 (Jeekel era!., 1980; 1981; 1982; 1983). Of these 96 grafts, 79 were transplanted 
as a first graft to transfused recipients, and 17 to nontransfused recipients. The 
group of 79 patients was divided into subgroups; depending on whether the donor 
had been transfused or not in the period immediately preceeding death. The 38 
patients whp received a graft from transfused donors fared better. Graft survival in 
these patients at one year was 84% versus 53.1% for the 41 nontransfused grafts. 
This is a statistically significant difference .. In the 17 nontransfused recipients, the 
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survival of 12 non transfused grafts was 42%, whereas the survival of 5 transfused 
grafts was 60%. 
The transfused donors received from I till more than 10 units of blood. No clear 
dose-effect relationship was noted. The amount of corticosteroids and mannitol 
given to the donor in the period between admission and nephrectomy was not 
different in transfused and nontransfused donors. The recipient groups were 
comparable for sex, age, dialysis period and HLA-A and B mismatch. 
A retrospective study performed in Gothenburg on the effect of blood trans-
fusion to the cadaveric kidney donor and graft survival in 129 primary transplan-
tations has been reported (Frisk eta/., 1981; 1983; Jeekel eta/., 1983). Of these 129 
grafts, 109 were transplanted to transfused recipients and 20 to nontransfused 
recipients. Of 109 transfused recipients of kidney grafts, 55 received kidneys from 
transfused donors and 54 from nontransfused donors. A significantly better graft 
survival was found up to 36 months after grafting in transfused recipients when the 
kidneys came from transfused as compared to nontransfused donors. Graft 
survival at one year was 76.3% versus 55.4% respectively. In nontransfused 
recipients no difference in graft survival was found between kidneys from trans-
fused and nontransfused donors; graft survival among these recipients was very 
poor with either type of kidney (8% and 25% one year graft survival respectively). 
HLA-A, B matching, age and number of transfusions in the recipient did not differ 
between the two groups. There was a difference in sex distribution among the 
recipients who were given kidneys from transfused and nontransfused donors. 
However, the six months graft survival was similar in male and female recipients. 
Furthermore a significant difference in the distribution of diagnosis of fatal disease 
of the donors was found. More traumatic injuries and fewer intracerebral 
hemorrhage were recorded among transfused than among nontransfused donors. 
However, further analysis did not reveal a relation with graft survival in the two 
groups. Finally the amount of steroids given was similar in the two groups of 
donors, and there was no significant difference in graft survival of kidneys 
harvested from donors treated with steroids. 
Recently Harder eta/. ( 1984) have reported the results of a prospective collection 
of relevant donor- and recipient-data in 6 Swiss transplantation centers. They 
found that at 2 months, 90% of the 30 transfused kidneys were functioning versus 
67% of the 70 non transfused. At I year 77% of the transfused kidneys and 57% of 
the nontransfused kidneys did function in transfused first graft recipients. In the 
two groups, recipients did not differ in sex, age, HLA-A,B matching and cytotoxic 
antibodies and the donors did not differ in steroid dose, vasoactive drugs, blood 
pressure and urine production until nephrectomy. However, there were 73% 
trauma patients in the transfused versus 45% in the nontransfused donor group. 
Three reports have been published that do not support the forementioned data 
which suggest that there is a beneficial effect of transfusion of the donor prior to 
nephrectomy. 
Berget a/. (1982) from Iowa did a retrospective analysis of293 kidney recipients 
of whom 110 received kidneys from nontransfused donors. Actuarial analysis 
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revealed no significant differences in graft survival rates between nontransfused 
kidney donors and transfused kidney donors. One year graft survival in both 
groups was 59%. Considering only first transplant recipients, there was no 
difference in graft survival rates between nontransfused (n=l51) and transfused 
(n=80) donor kidneys. One year graft survival was64% versus65%. When only pre-
operatively transfused recipients receiving first transplants were examined, there 
was no difference in graft survival rates between nontransfused kidney donors 
(n=81) and transfused kidney donors (n=43). One year graft survival in both groups 
was 68%. The recipient groups were comparable for HLA-A,B and DR mismatch. 
Bock eta/. (1984) from Detroit did a retrospective analysis of 47 kidney recipients 
of whom 21 received kidneys from transfused donors. Actuarial analysis revealed 
no significant differences in graft survival rates between the nontransfused and 
transfused kidney donors, 41.9% and 47.6% at one year respectively. It was 
reported that when transfused recipients receiving grafts were examined, there was 
not a difference in graft survival rates between nontransfused and transfused 
kidney donors either. The number of HLA mismatches was comparable between 
the two groups. 
Opelz for the Collaborative Transplant Study (l985a) has analyzed the effect of 
transfusions given to kidney donors on first cadaver transplants. According to this 
analysis, it did not matter whether the kidney donor was transfused (n=l452) or not 
(n=l937). Neither in the overall material, nor in a subset of patients without 
pretransplant transfusions, was there an influence of the donor's transfusion status 
on graft outcome. 
In Table 2.1 the relevant clinical data are summarized. 
With regard to the mechanism underlying the donor transfusion phenomenon, it 
has been suggested that the presence of passenger leukocytes of two origins in the 
kidney at the time of transplantation, i.e. donor leukocytes and third party cells 
from the blood donor, may be responsible for the altered immunologic reactivity 
either in the graft or in the host (Frisk eta/., 1983; Jeekel eta/., 1983). 
It has also been speculated that, assuming there is an effect of peroperative 
recipient blood transfusion, transplantation of a transfused donor kidney might 
represent additional peroperative transfusion of blood-donor leukocytes (Berg et 
a/., 1982). 
Batchelor has offered the hypothesis that dendritic cells in the donor kidney 
might be mobilized in response to a transfusion, thereby rendering the kidney 
depleted of dendritic cells and less immunogenic (Opelz and van Rood, 1983). 
It is clear that many questions have been raised by the retrospective finding of a 
possibly beneficial effect of blood transfusions given to the donor. Therefore, it was 
thought to be important to investigate some of these questions in rigidly controlled 
experimental studies. 
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Table 2.1. Effect of blood transfusions to the donor on (first) kidney graft survival. 
Center Donor No. Recipient One year graft p-value 
survival (chi square test) 
Lei den Transfused 18 per-op. transf. 50 % p < 0.05 (Jeekel) 26 per-op. transf. 11.5% 
Basel Transfused 38 pre-op. transf. 84 % p < 0.05 (Jeekel) 41 pre-op. transf. 53.1% 
Transfused 5 60 % p < 0.05 12 42 % 
Swiss Transplant Transfused 30 pre-op. transf. 77 % p < 0.05 
Centers (Harder) 70 pre-op. transf. 57 % 
Gothenburg Transfused 55 pre-op. transf. 76.3% p < 0.05 (Frisk) 54 pre-op. transf. 55.4% 
Transfused 12 8 % p > 0.05 8 25 % 
Iowa Transfused 43 pre-op. transf. 68 % p > 0.05 (Berg) 81 pre-op. transf. 68 % 
Detroit Transfused 21 ? 47.6% p > 0.05 (Bock) 26 ? 41.9% 
Collaborative Transfused 1452 ? ±68% p > 0.05 Transplant Study 1937 ? ±68% 
(Ope1z) 
Data from four different retrospective studies do show that blood transfusions to the donor prior to 
nephrectomy positively influence graft survival in transfused recipients (Jeekel et al .. 1980, 1981; 1982; 
1983: Frisk et aL. 1981; 1983; Harder eta! .. 1984). Three other retrospective studies could not confirm 
these results (Berget a!.. 1982; Bock eta!., 1984; Opelz for the Collaborative Transplant Study, 1985a). 
The experiments described in this thesis had the following three objectives: 
I. to study the effect of different whole blood transfusions and transfusions of 
blood components to the donor on graft survival. 
2. to determine, in case such an effect was apparent, the underlying mechanism(s). 
3. to contemplate possible implications for clinical transplantation. 
Since the introduction of microvascular surgical techniques for organ grafting in 
the mid-1960's it has been possible to study questions relevant to clinical organ 
transplantation in inbred rats (Abbott eta!., 1964; Fisher and Lee, 1965). 
Many investigators have used inbred rat transplantation models over the past 15 
years. It has become increasingly clear that one should proceed with caution in the 
interpretation of the data obtained in rats as to their potential importance for 
clinical transplantation. This subject has been lucidly reviewed by Fabre in his 
article titled "Rat kidney allograft model. Was it all too good to be true?" (Fabre, 
1982). 
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According to Hart and Fabre (1981a; 198lb) the essential difference between rat 
and man in this context is that the rat lacks Ia antigens on its endothelial cells, 
whereas man has abundant !a (DR) antigens on endothelial cells, at least in the 
capillaries of the kidney (Hart eta!., 1981). However, it should be mentioned that 
this finding of the absence of class II antigens from rat vascular endothelial cells 
conflicts with data as published by Paul eta!. (Paul eta!" 1982; Paul and Carpenter 
1983; Fabre et a/" 1983). 
In both man and rat this Ia positive cell has been demonstrated in the interstitial 
connective tissue (Hart and Fabre, 1981c; Hart et a!., 1981), although definite 
identification in human connective tissue is more difficult because ofthe Ia positive 
endothelium of the capillaries. The !a positive cell isolated from the lymhoid tissues 
of rodents has as its most prominent characteristics that it is the major cell involved 
in antigen presentation (Nussenzweig and Steinman, 1980) and mixed lymphocyte 
culture (MLC) stimulation (Nussenzweig et a/" 1980). In man the !a positive 
endothelial cells have been shown to be capable of MLC stimulation and antigen 
presentation (Hirschberg eta/" 1980), capacities which, according to Fabre (1982), 
the !a negative endothelium of the rat (Hart and Fabre, 198la; 1981b) is most 
unlikely to possess. 
In summary, the fresh rat allograft is likely to have only one cell type, the inter-
stitial dendritic cell, with a specialized capacity for stimulation of host lymphocytes 
and for antigen presentation, whereas the fresh human graft has in addition the 
vascular endothelial cell which has these properties. As a result the data obtained in 
the ·rat must be interpreted with caution, but doing this, experiments can be done 
fruitfully with potentially important implications for clinical transplantation 
(Fabre, 1982). 
Taking the above mentioned contemplations into account we decided to use the 
rat heterotopic heart- and kidney-transplantation models for our investigations. 
A part of the results of these experiments in rats have already been published in 
the literature and presented at scientific meetings (Jeekel eta!.. 1980; 1981; 1982; 
Heineman eta!., 1983a-b; 1985; in press a-b). However, quite a substantial number 
of experiments has not yet been reported. Taking this into consideration it was 
decided to rewrite the articles and abstracts already published and to complete the 
material with new data. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Animals 
Animals of six highly inbred rat strains were used. These were male Brown-
Norway (BN), male WAG, male Brofo, male Lewis (LEW), female RI and male 
(WAG x LEW) F, hybrid rats. 
Between theBN, WAG, BrofoandLEW strainsamajorRT-1 histoincompatibil-
ity exists. The BN strain is homozygous for the RT-ln haplotype, the WAG strain 
for the RT-1" haplotype, the Brofo strain for the RT-1' haplotype and the LEW 
strain for the RT-11 haplotype (Palm and Black, 1971; Festing and Staats, 1973). 
The Rl (RT-lP) has a recombination within its major histocompatibility complex. 
For class I antigens, the Rl is similar with the WAG strain (RT-1"), whereas for 
class II antigens it is associated with the LEW strain (RT-1 1) (Vaessen eta!., 1979). 
The animals were obtained frorri the Laboratory Animals Center of the Erasmus 
University Rotterdam, The Netherlands. They were kept clean under conventional 
con~itions. The strains are tested regularly by skin transplant in order to 
demonstrate the absence of genetic drift. 
In all transplantation experiments (330 heterotopic heart transplantations and 37 
heterotopic kidney transplantations), animals of 12-16 weeks of age, weighing 220-
250 grams were used. In the popliteal lymph node assay 32 (WAG x LEW) F 1 
hybrids were used~ they were six weeks old and weighed about 100 grams. 
3.2 Heart and kidney transplantation 
3.2.1 General 
Operations were performed under standardized conditions. The majority of 
transplantations was performed by the author, but especially in the first group of 
experiments highly appreciated support was received from other microsurgeons. 
In all transplantations the interruption of the blood flow(ischemic period) lasted 
forty minutes or less on the average, which did not produce lasting functional 
damage to the hind legs of the animals. Ether anesthesia was used throughout the 
operation. 
The cardiac grafting was done according to the technique described by Abbott et 
a/. (1964) and by Bui-Mong-Hung and Vigano (1966) and as modified by Ono and 
Lindsey ( 1969). Kidney transplantation was performed according to the technique 
of Fisher and Lee (1965) and Lee (1967) with the modifications of Lameijer eta/. 
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(1972"* for the ureter-bladder anastomosis. All heart and kidney donors were 
heparinized with 500 units ofNa-heparine (Thromboliquine®) dissolved in I ml of 
saline injected into the tail or penile vein. 
No food limitations were imposed before and after grafting and no antibiotic 
treatment was given. 
3.2.2 Heart transplantation 
3.2.2.1 Surgical technique 
Donor: after shaving and desinfection with chlorohexidine (hibitane) the thoracic 
cavity is opened. The anterior chest wall is separated from the diaphragm and the 
anterior rib cage is divided with heavy scissors on both sides of the sternum from the 
lower rib margin to the clavicles. The whole cage is then reflected superiorly in 
order to provide maximum exposure. The pericardium is incised and the heart is 
depressed inferiorly. The ascending aorta and the pulmonary trunk are freed from 
one another by careful dissection. The ascending aorta is cut with irridectomy 
scissors close to the origin of the innominate artery. Next the pulmonary trunk is 
cut close to the bifurcation into the left and right pulmonary arteries. This trans-
section of the main arterial vessels leaves enough length attached to the heart to 
allow for the performance of micro anastomoses. The heart is lifted up and one 
ligature is placed around the caval veins and pulmonary veins. After cutting these 
veins distal to the ligature, the heart is removed. Finally the heart is perfused with 4 
ml of Hank's balanced salt solution (HBSS) through the ascending aorta in a retro-
grade direction using a blunt needle, in order to clean the coronary vessels from 
blood. The heart is stored in HBSS at 4°C. 
Recipient: after shaving and desinfection with chlorohexidine (hibitane) a long 
abdominal mid-line incision is made to expose the great vessels. First the intestines 
are wrapped in a moistered gauze and are retracted to the left. Next the aorta and 
caval vein are dissected and freed from surrounding tissues with the use of cotton 
wool tipped applicators. Longitudinal openings of 2-3 mm are made in both the 
aorta and caval vein after being clamped together below the renal vessels with a 
curved hemostat. Through the openings the vessels are flushed with HBSS to 
remove thrombi. 
The donor heart is placed transversely in the right side of the abdominal cavity of 
the recipient. Stay sutures (7 .0 silk, Ethicon) are placed at the proximal and distal 
ends in the recipient and donor aorta and are used for continuous suturing. After 
completion of the left side of the aortic anastomosis, the heart is flipped-over to 
allow placement of the right half of the suture line. The pulmonary artery is 
connected end-to-side to the inferior caval vein in a similar manner. The aortic 
anastomosis restricts access to the left side of the caval vein, thus it is necessary to 
place the first half (left side) of the pulmonary artery-caval vein suture line from 
within the lumen. In the author's experience it is easier to make the longitudinal 
opening in the caval vein more proximal to avoid the restriction caused by the aortic 
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anastomosis. Torsion of the vessels is carefully avoided. After completion of the 
anastomoses the hemostat is removed and a gauze is gently pressed onto the anas-
tomoses until hemostasis is complete. Restoration of graft circulation is followed 
within a few seconds by a resumption of myocardial contractions. The mechanics of 
circulation are essentially those described by Mann eta/. (1933). The transplanted 
heart is perfused through its coronary vessels. Blood is returned to the recipient's 
inferior caval vein through the right atrium, right ventricle and pulmonary artery of 
the donor heart. In this fashion the left side of the heart is bypassed. although 
perfusion of the left myocardium is maintained. 
If the heart does not attain its normal colour and pulsations fail to show the 
appropriate rate, the graft is considered technically unsuccessful and discarded. 
The heart is placed retroperitoneally on the right side of the abdominal cavity, the 
intestines are replaced and the abdominal wall is closed in one layer. 
3.2.2.2 Evaluation of function 
It has been found that cessation of electrical activity of the heart as determined by 
electrocardiographic monitoring fits in very well with the cessation of palpable 
heart beats (van Schilfgaarde, I 978). The electrocardiographic monitoring does not 
yield more or better information (van Schilfgaarde, 1978). As palpation is 
techilically the easiest way of monitoring cardiac function, we assumed that 
complete rejection had taken place when pulsations could no longer be felt. 
Technical failures, mainly due to thrombosis were only occasionally encountered. 
In these cases. the hearts stopped beating within one or two days and were excluded 
from the experimental groups. 
3.2.3 Kidney transplantation 
3.2.3. I Surgical technique 
Donor: After shaving and desinfection with chlorohexidine (hibitane) the 
abdominal cavity is opened through an abdominal mid-line incision. The intestines 
are wrapped in moistened gauze and retracted laterally to the left side. The right 
kidney is used preferably. provided it does not show double arteries, evident 
hydronephrosis or dilatation of the ureter. The abdominal aorta and inferior caval 
vein. adrenal, and left renal arteries are identified and the latter three vessels are 
double ligated close to the aorta and are divided. The kidney is dissected from the 
perirenal fatty tissue and retracted medially to free the right renal artery from the 
renal vein in retrograde fashion. After the dissection is completed the aorta is 
clamped proximal to the origin of the renal artery. Next the aorta is cut. leaving a 
segment with the renal artery. This segment is made into a patch. The renal vein is 
cut with an elliptical excision of the caval vein. The ureter is easily mobilized, but 
care must be taken not to strip it. It is transected near the bladder. The kidney is 
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removed and placed in HESS at 4°C. A blunt neddle is inserted into the renal artery 
and the kidney is very gently flushed with 4 ml of HESS. 
Recipient: The procedure is similar as described for the heterotopic heart trans-
plantation. Torsion of the vessels is carefully avoided. After re-establishing the 
blood flow, the kidney should show its normal colour within a few moments: if not, 
either an inflow or an outflow tract obstruction (stenosis, torsion) should be 
suspected. In these cases the graft is considered technically unsuccessful and 
discarded. 
The ureter is pulled through the posterior wall of the dome of the bladder having 
first opened the bladder from the front. A stich of 7.0 silk is passed from the outside 
through the bladder wall and one wall of the ureter and to the outside again. The 
stich is tied outside the bladder and the bladder is closed. 
Bilateral nephrectomy is performed at the time of operation. The graft is placed 
retroperitoneally in the right half of the abdominal cavity. Intestines are replaced 
and the abdominal wall is closed in one layer. 
3.2.3.2 Evaluation of function 
Renal function was evaluated by serial determination (at days 3, 7, 10, 14.17 and 
21 posttransplantation) of blood urea nitrogen level (BUN). BUN levels in rat 
serum were determined by the photometric method nr 2410 of the Netherlands 
Normalisatie-lnstituut (published by the Rijks lnstituut voor de Volksgezondheid, 
Utrecht, 1966). Concentrations are expressed in mmoVl. 
Blood samples were taken by bleeding the rats from the tail or orbita and were 
centrifuged at 1500 rpm for ten minutes. Sera for BUN determination were kept at 
4°C until the tests were performed. Per test a quantity of 20 1'1 serum was required. 
All serum BUN concentrations were assessed in duplicate. 
Rejection was defined by the BUN value exceeding 60 mmol/1 value (Lameijer et 
a!.. 1972; van Schilfgaarde, 1978). At autopsy the diagnosis was confirmed macros-
copically. If hydronephrosis was present the graft was excluded. 
3.3 Transfusions 
3.3.1 Whole blood 
Donors and recipients in several experimental groups received intravenously (i.v.) 
via the penile vein transfusions of whole blood. These consisted of different amounts 
of fresh pooled heparinized blood and were given at different intervals before trans-
plantation. Blood donors were not used as heart or kidney donors. Blood was 
obtained by cardiac puncture or puncture of the abdominal aorta. 
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3.3.2 Irradiated whole blood 
In one experimental group donors received fresh whole blood irradiated in vitro 
with 10 Gy just prior to transfusion (see 3.5). 
3.3.3 Erythrocytes 
Erythrocyte transfusates were prepared by using the cotton wool column 
technique as described by Diepenhorst er a!. (1972). The equivalent number of 
erythrocytes present in I ml of whole t>lood (5 x 109 ) was given i.v. The final 
contamination with leukocytes was less than 1% of the number found in normal 
blood. 
3.3.4 Leukocytes 
Leukocyte suspensions were prepared by three successive incubations of buffy 
coat suspensions. with hemolytic buffer (Iris-buffered ammonium chloride 0.17 m) 
and subsequent washing in HBSS. A marked reduction in the number of 
erythrocytes (<0.1%) could be achieved by this procedure. The viability of the 
remaining leukocytes was determined by trypan blue exclusion, and this was 
usually more than 95%. About 5-7 X 106 leukocytes suspended in 2 ml ofHBSS were 
injected i.v. 
3.4 Cyclosporin A 
In several experimental groups the recipients were treated postoperatively with 
Cyclosporin A (CsA). The CsA was supplied as a white powder and was a gift from 
the Sandoz Corp., Basle, Switzerland. It was dissolved in olive oil by continuous 
stirring at a temperature of 60°C for 2 hours. The solution was injected intra-
muscularly in the hind legs of the rats as described by Niessen et a!. (1982). 
Recipients of heart transplants received a single dose of 15 mg/kg body weight 
which was administered after transplantation on the day of grafting. Kidney graft 
recipients were given a single dose of 5 mg/kg body weight on the day of grafting. 
3.5 Irradiation 
A 137Cs (y) source (Atomic Energy of Canada, Ltd.) was used in the radiation 
experiments. Animals were irradiated with a whole body dose of 10 Gy. 
The period of time between donor irradiation and transplantation was either 
5 days or less than I day. The peripheral blood leukocyte counts were uniformly less 
than 500 cells per cubic millimeter in donors irradiated 5 days before grafting. 
Donors irradiated on the day of grafting did not show any decrease in peripheral 
blood leukocyte counts as compared to non-irradiated controls. 
Similar conditions were used for ex vivo irradiation of fresh whole blood. 
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3.6 Popliteal lymph node (PLN) assay 
The basis of the popliteal lymph node (PLN) assay has been described by Ford et 
al. (1970). Parental lymphoid cells injected into the hind footpad ofF1 hybrids will 
induce a Graft versus Host (GvH) reaction in the draining popliteal lymph node. 
leading to an increase in weight as well as cellularity. The enlargement of the 
popliteal node, ·v;thich peaks at 5-7 days after inoculation, is related to the number of 
parental cells injected and can be quantified by simple weighing. The main 
immunological attack is exhibited by the injected donor T cells against the histo-
compatibility antigens of the host. The local GvH reaction can be used to quantify 
specific cell mediated immunity. if the relevant parenteral strain and F 1 hybrids are 
used. States of sensitization as well as immunosuppression can be monitored in a 
relatively simple manner. 
In the present experiments, (WAG x LEW) F 1 hybrids were used to monitor 
specific cell mediated immunity of WAG rats subjected to various treatments and 
allografting. Spleen cells of the WAG rats under investigation were pooled and a 
cell suspension was made in Hank's balanced salt solution (HBSS). Erythrocytes 
were lysed by hemolytic buffer. In all cases the different numbers of spleen cells 
from the WAG rats were injected in a constant volume of 0.2 ml into the hind 
footpads ofF 1 rats. Two hybrids were used per parental strain under investigation 
and the spleen cells were injected into both hind footpads, thus four weights were 
recorded per animal to be monitored. One week after injection, the popliteal nodes 
were excised, cleaned on filter paper and weighed to the nearest 0.1 mg. 
Dose response curves were obtained with normal and treated WAG spleen cells 
and were used to assess the degree of GvH activity. The significance of differences 
in node weights was determined by using the Wilcoxon-rank sum test. 
3.7 Statistical analysis 
For statistical analysis of the results obtained in the various experiments the 
Wilcoxon-rank sum test (Wilcoxon, 1945) and chi square test (Yates, !934; 
Armitage, 1971) were used. P values are given in the text. 
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CHAPTER 4 
MODIFICATION OF RAT CARDIAC ALLOGRAFT SURVIVAL BY 
ADMINISTRATION OF THIRD PARTY BLOOD TRANSFUSION(S) TO 
THE DONOR 
This chapter was published in a modified form in Transplant. Proc. 1983: 15: 994 and 
Transplantation 1983: 36: 362. 
4.1 Introduction 
There is now wide acceptance that in humans blood transfusions given to the 
recipient before grafting produce a strikingly beneficial effect on the post-
transplant course of cadaveric or living related kidneys (Opelz et a!.. 1981b; 
Salvatierra et a!.. 1983). 
Recently it has been reported by several authors that blood transfusions to the 
donor prior to nephrectomy positively influence graft survival in transfused 
recipients (Jeekel eta!., 1980; 1981; Frisk eta/., 1981; 1983; Harder eta!., 1984). 
However, retrospective studies by Berget a!. (1982), Bock eta!. (1984) and Opelz 
(1985a) could not confirm these reports. 
The effect of third party blood transfusions given to the donor has been further 
evaluated in experimental studies in animals. 
In the dog it was found that the beneficial effect of a peroperative transfusion was 
abolished by transfusion of the donor one day before grafting (Jeekel eta!. 1980). 
Berg et a/. (1982) reported animal studies in (Lewis x Brown Norway) F 1 
(LBN F 1) hybrid rat hearts transplanted heterotopically to LEW recipients. Non-
transfused LBN F 1 heart grafts had a mean survival time of 8.0 ± I. I days. LBN F 1 
hearts from rats receiving 2 ml of heparinized whole blood from Charles River(CD) 
rats 24 hr before heart transplantation, had a mean survival time of 6.6 ± 0.9 days, 
which was reported to be significantly less than the survival times of untransfused 
donor hearts (Berget a!., 1982). 
This chapter describes the effect of third party whole blood transfusion(s) of the 
donor on heterotopic heart allograft survival. 
The following variables were studied: 
I. The effect of donor transfusion in different donor-host combinations 
2. The effect of donor transfusion after different types of immune modulation of 
the host. 
3. The effect of varying number and timing of donor transfusion. 
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4.2 Experimental protocol 
Five main experimental groups can be distinguished, they are shown in Table 4. I. 
In the first experimental group the effect of third party (Brofo) whole blood 
transfusion(s) to the BN and RI donor on heart allograft survival in the unmodified 
WAG host was studied. The BN donor differs at the major histocompatibility 
complex from the WAG host, whereas the Rl strain has a recombination within its 
major histocompatibility complex. For class I antigens, the Rl is similar with the 
WAG strain and for class II antigens, the Rl is similar with the LEW strain 
(Vaessen eta!., 1979). 
In the second experimental group the effect of third party (Brofo or LEW) whole 
blood transfusion(s) to the BN donor on heart allograft survival in WAG hosts pre-
treated with one donor-specific transfusion (DST) was studied. Furthermore, the 
effect of varying number and timing of transfusions was investigated. 
In the third experimental group it was studied whether third party (Brofo) whole 
blood transfusion of the WAG donor would influence heart allograft survival in 
BN hosts pretreated with one DST. 
In the fourth experimental group the effect of third party (Brofo) whole blood 
transfusion(s) to the BN donor on heart allograft survival in LEW hosts pretreated 
with one DST was studied. 
In the fifth experimental group the effect of third party (Brofo of LEW) whole 
blood transfusion(s) to the BN donor on heart allograft survival in the Cyclospo-
rin A (CsA) treated WAG host was studied. The recipients received 15 mg/kg 
bodyweight CsA intramuscularly after the operation on the day oftransplantation. 
In all experiments each blood transfusion consisted of I ml fresh pooled 
heparinized whole blood. Cardiac function was assessed as evaluated in chapter 
3.2.2.2. The results were analyzed using the chi-square and Wilcoxon-rank sum 
tests. 
4.3 Results 
4.3.1 The effect of third party whole blood transfusion to the BN and Rl donor on 
heart allograft survival in the unmodified WAG host 
The survival times observed in the different experimental groups are shown in 
Table 4.2 and Figure 4.1. No significant difference was found between survival 
times achieved in nontransfused and transfused donors in the BN/W AG and 
Rl/W AG donor/host combinations when the WAG host was not treated. A single 
Brofo transfusion to the BN donor at 2 days before transplantation had no effect on 
graft survival. As in the control animals the hearts were rejected in 8-9 days (groups 
I and 2). In the RI/W AG donor/host combination a graft survival between 8 and 
13 days was found when donor and host were not treated. When the Rl donor was 
treated with two Brofo transfusions at 2 days and I day before grafting the survival 
times did not change and were of the same magnitude as in the nontransfused 
animals (groups 3 and 4). 
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Table 4.1. Experimental protocol. 
Experiment Group Donor/Host Donor transfusion Host treatment 
combination 
1 BN/WAG 
2 BN/WAG day -2, Brofo I ml 
3 Rl/WAG 
4 Rl/WAG day -2, Brofo 1 ml 
II BN/WAG day -7. BN 1 ml 
2 BN/WAG day -2. Brofo 1 ml day -7, BN 1 ml 
3 BN/WAG day -2. LEW 1 ml day -7. BN I ml 
4 BN/WAG day -2.-I. Brofo 1 ml day -7. BN I ml 
5 BN/WAG day -2.-l. LEW I ml day -7. BN 1 ml 
6 BN/WAG day -7. LEW I ml day -7. BN 1 ml 
·············································································-········· 
1I1 
2 
3 
WAG/BN 
WAG/BN 
WAG/BN day -2. Brofo I ml 
day -7, WAG 1 ml 
day -7. WAG l ml 
IV BN/LEW 
2 BN/LEW day -7. BN I ml 
3 BN/LEW day -2,-1. Brofo l ml day -7. BN I ml 
······················································································· 
v 
2 
3 
BN/WAG 
BN/WAG day -2.-1. Brofo l ml 
BN/WAG day -2.-l. LEW l ml 
day 0. CsA 15 mg/kg 
day 0. CsA 15 mg/kg 
day 0. CsA 15 mg/kg 
4.3.2 The effect of third party whole blood transfusion to the BN donor on heart 
allograft survival in WAG hosts pretreated with DST 
The survival times observed in the different experimental groups are shown in 
Table 4.3 and Figure 4.2. It was found that grafts from nontransfused donors did 
survive indefinitely in recipients which were transfused with a donor-specific 
transfusion 7 days before grafting (group 1). These animals served as controls for 
the experimental groups 2-6. A single Brofo or LEW transfusion given to the donor 
2 days before grafting shortened graft survival significantly. A Brofo transfusion 
led to a shortened survival time in 73% of the transplantations (group 2, p<O.OOl), 
a LEW transfusion led to the same result in 66% of the cases (group 3, p < 0.05). 
Brofo or LEW transfusions given to the donor at 2 days and 1 day before grafting 
had the same effect. Shortened graft survival times were found in 75% and 40% of 
the animals, respectively (group 4 and group 5, p < 0.05). A single LEW transfusion 
given to the donor 7 days before grafting also shortened graft survival time. The 
grafts were .rejected in 42% of the cases (group 6, p < 0.05). 
Table 4.2. The effect of third party whole blood transfusion to the BN and Rl donor on heart allograft survival in the unmodified WAG host. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
I BN - WAG - 10 8,8,8,8,8,8 ,8,8 ,9 '9 
2 BN day -2, Brofo I ml WAG - 6 8,8,8,9,9,9 
3 Rl - WAG - 10 8,10,10,10,11 ,11,11,11' 13,13 
4 Rl day -2, and -I, Brofo I ml WAG - 8 11,11 ,11,11,11,12,12,12 
The donors were transfused i.v. at different intervals (day -1 and/or -2) with I m! of whole Brofo blood. The recipients were not treated. 
Table 4.3. The effect of third party whole blood transfusion to the BN donor on heart allograft survival in transfused WAG hosts. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
I BN - WAG day -7, BN 1 ml 25 permanent 
2 BN day -2, Brofo I ml WAG day -7, BN I ml 15 5,7 ,7 ,8,8,8,9,9,10,21,28, 
permanent 4X 
3 BN day -2, LEW I ml WAG day -7, BN I ml 9 7,10,14,17,18,26, 
permanent 3X 
4 BN day -2,-1, Brofo I ml WAG day -7, BN I ml 4 15,16,20, permanent IX 
5 BN day -2,-1, LEW 1 ml WAG day -7, BN I ml 10 11,14,16,16,17,30, 
permanent 4X 
6 BN day -7, LEW 1 ml WAG day -7, BN I ml 7 26,28,30, permanent 4X 
The donors were transfused i.v. at different intervals (day -1 and/or -2 or -7) with I ml of whole third party (Brofo or LEW) blood. 
The recipients were transfused at day -7 with I ml of BN blood, 
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Figure 4.1. The effect of third party whole blood transfusion to the BN and RI donor on heart allograft 
survival in the unmodified WAG hosts (see Table 4.2). 
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Figure 4.2. The effect of third party whole blood trailsfusion(s) to the BN donor on heart allograft 
survival in transfused WAG hosts (see Table 4.3). 
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4.3.3 The effect of third party whole blood transfusion to the WAG donor on heart 
allograft survival in EN hosts pretreated with DST 
The survival times observed in the different experimental groups are shown in 
Table 4.4 and Figure 4.3. In theW AG to BN donor/host model a donor-type trans-
fusion to the recipient always led to accelerated rejection in 5 days compared to the 
8-9 days graft survival in the controls (groups l and 2). A single Brofo transfusion 
given to the donor 2 days before grafting resulted in a further acceleration of 
rejection in 66% of the cases (group 3, p < 0.05). 
4.3.4 The effect of third party whole blood transfusions to the EN donor on heart 
allograft survival in LEW hosts pretreated with DST 
The survival times observed in the different experimental groups are shown in 
Table 4.5 and Figure 4.4. In the unmodified BN/LEW donor/host combination 
cardiac grafts survived 6-7 days (group 1), which is similar to the survival times 
reported by van Schilfgaarde (1979). Grafts from nontransfused BN donors did 
survive significantly longer in LEW hosts pretreated with DST. Rejection was 
observed after 12-13 days (group 2). These animals served as controls for group 3. 
In this experimental group it was found that Brofo transfusions given to the donor 
at 2 days and l day before grafting abrogated the beneficial DST effect in 85% of the 
cases (group 3, p < 0.05). 
4.3.5 The effect of third party whole blood transfusion to the EN donor on heart 
allograft survival in WAG hosts treated with Cyclosporin A (CsA) 
The survival times observed in the different experimental groups are shown in 
Table 4.6 and Figure 4.5. In all experimental groups the WAG recipients were 
treated intramuscularly on the day of operation with 15 mg/kg CsA. When using an 
unmodified BN donor, a single injection of CsA led to a graft survival of 9-15 days 
(group !). This group forms the control group. If the donor was modified by trans-
fusion with Brofo or with LEW blood at 2 days and I day before transplantation, 
the effect of CsA treatment on graft survival was enhanced. Brofo transfusions to 
the donor led to prolongation of graft survival in 75% of the transplantations: LEW 
transfusions had this effect in 100% of the transplantations (groups 3 and 4, p < 
0.05). 
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4.4 Discussion 
In rats, it was investigated whether third party transfusion(s) to the donor would 
influence the survival of heterotopically transplanted hearts in nontransfused, 
transfused and CsA treated recipients. 
The effect of third party transfusion(s) to the donor in the unmodified WAG host 
was tested in the first experiment. Two donor/host combinations, the BN to WAG 
and the RI toW AG combination were employed. Graft survival in the BN toW AG 
model was 8-9 days (group I) and was not influenced by donor pretreatment (group 
2). In the RI to WAG model, where there is compatibility for class I antigens 
between donor and recipient (Vaessen eta/., 1979), graft survival was 8-13 days 
(group 3). It was tested whether in this "weaker" donor/host combination blood 
transfusions to the donor would influence graft survival. However, even twice as 
many Brofo transfusions as employed in the BN to WAG combination, did not 
show any effect on graft survival. Grafts were rejected in 11-12 days (group 4). It 
can be concluded that there is no measurable effect of third party transfusion to the 
donor on heart allograft survival in the unmodified WAG hosts, even if there is 
compatibility for class I antigens. Our results are in contrast with those obtained by 
Berg et a/. (1982). These authors reported a significant detrimental influence of 
blood transfusion to the donor on heart allograft survival in unmodified hosts. 
However, they used a different donor/host combination, the (LEW x BN) F 1 to 
LEW combination. 
In the next three experiments we investigated the effect of third party transfu-
sion(s) to the donor on heart allograft survival in DST transfused recipients. Three 
different donor-host combinations were employed, the BN to WAG, the reverse 
WAG to BN, and the BN to LEW combination. 
It was found that in the BN toW AG combination, in which a donor-type trans-
fusion to the recipient always leads to permanent graft acceptance (group I) 
(Marquet eta/., 1971), a single third party transfusion to the donor 2 days before 
grafting resulted in a significant abrogation of the beneficial DST effect (groups 2 
and 3). Two third party transfusions to the donor 2 days and I day before grafting 
had the same effect (groups 4 and 5). Thus, no dose-effect relation was noticed. 
Further it was found that both Brofo and LEW transfusion to the donor did 
diminish the favourable effect of a donor-type transfusion to the same degree. 
Consequently, the expression ofthe donor transfusion phenomenon is not confined 
to blood from a single strain. 
Finally we tested in the BN to WAG combination the effect of a single donor 
transfusion at 7 days before transplantation. Graft survival in transfused recipients 
was reduced in a significant number of animals (group 6). The results were similar 
as those obtained for donors transfused shortly before transplantation. It can be 
concluded that there was no effect of timing. 
In the third group of experiments it was tested whether donor transfusion had an 
effect in theW AG/BN donor-host combination. In this model a donor-type trans-
fusion to the recipient always results in accelerated rejection of cardiac grafts in 5 
Table 4.4. The effect of third party whole blood transfusion to the WAG donor on heart allograft survival in transfused BN hosts. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
I WAG - DN - 10 8,8,8 ,8,8 ,8,8,8,9 ,9 
2 WAG 
-
BN day -7, WAG I ml 25 5 25X 
3 WAG day -2, Brofo I ml BN day -7, WAG I ml 9 2,3,3,3,3,4,5,7 ,8 
The donors were transfused at day -2 with I ml of whole Brofo blood. The recipients were transfused at day -7 with I ml of BN blood. 
s 
Table 4.5. The effect of third party whole blood transfusions to the BN donor on heart allograft survival in the transfused LEW hosts. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
I BN LEW - 6 6,7,7,7,7,7 
2 BN - LEW day -7, BN I ml 8 12,12,12,13,13,13, I 3,13 
3 BN day -2,-1, Brofo I ml LEW day -7, BN I ml 7 6,7, 10,10,10,11' 12 
The donors were transfused at day -2 and -1 with I ml of whole Brofo blood. The recipients were transfused at day -7 with I ml of BN blood. 
--- nontransfused WAG donor, 
------ nontransfused WAG donor, 
transfused WAG donor, 
%graft survival 
100~~~--~---. 
80 
60 
20 
' 
' I 
' I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
: •••• -1:: 
~ 
E.. ..••••• , l . '-
I 
' 
2 
61 
nontransfused BN host ( n=l 0} 
transfused BN host (n=25} 
transfused BN host (n= 9) 
3 
weeks after transplantation 
4 5 
Figure 4.3. The effect of third party whole blood transfusion to the WAG donor on heart allograft 
survival in transfused BN hosts (see Table 4.4). 
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Figure 4.4. The effect of third party whole blood transfusions to the BN donor on heart allograft survival 
in the transfused LEW host (see Table 4.5). 
Table 4.6. The effect of third party whole blood transfusions to the BN donor on heart allograft survival in Cyclosporin A (CsA) treated WAG hosts. 
Donor Donor treatment Recipient Recipient treatment Number Survival in days 
BN - WAG day 0, CsA 15 mg/kg 12 9, I 0,11, 12, 13,13, 13, 14, 14, 
14,15,15 
2 BN day ~2,-1, Brofo I ml WAG day 0, CsA 15 mg/kg 8 11,12,18,19,22,26,28, 
permanent I X 
3 BN day -2,-1, LEW I ml WAG day 0, CsA 15 mg/kg 10 16, 16,16,21 ,23,29 ,29,34,35, 
permanent I X 
The donors were transfused i.v. at day -2 and ~I with I ml whole blood from Brofo or LEW rats. The recipients were injected on the day of grafting i.m. 
in the hind leg with CsA in a dose of 15 mg/kg body weight in a volume of 0.1 mi. 
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Figure 4.5. The effect of third party whole blood transfusions to the BN donor on heart allograft survival 
in Cyclos.porin A (CsA) treated WAG hosts (see Table 4.6). 
days (group 2) (Marque! and van Bekkum, 1973) as compared to the 8-9 days in 
controls (group 1). It was found that donor transfusions with third party blood 
resulted in a further acceleration of rejection in a significant number of the cases 
(group 3). 
In the fourth group of experiments it was tested whether third party transfusion 
of the BN donor had an effect on allograft survival in the DST transfused LEW 
host. First it was observed that donor-type blood transfusion to the recipient led to 
a significantly prolonged cardiac graft survival. In the unmodified donor/host 
combination grafts were rejected after 6-7 days (group 1 ), whereas in the transfused 
hosts grafts were only rejected after 12-13 days (group 2). Third party transfusion of 
the donor had a detrimental influence on graft survival in a significant number of 
the cases (group 3). 
From the results obtained in the second, third and fourth group of experiments it 
can be concluded that third party transfusion of the donor has an effect on cardiac 
allograft survival in hosts pretreated with DST. It is clear that this effect is not 
confined to one single donor/host combination, but that it is manifest in various 
donor-recipient combinations. Furthermore, in all these combinations it was found 
that in DST transfused recipients grafts from transfused donors fared worse than 
grafts from non transfused donors. Thus, a detrimental influence of third party 
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donor transfusion on graft survival was observed. However, the results obtained in 
the fifth group of experiments show that third party blood transfusion to the donor 
can have a beneficial effect on graft survival when the recipient has been treated 
with CsA. Brofo transfusions to the donor led to prolongation of allograft survival 
in 75% of the cases (group 2) whereas LEW transfusions to the donor had this effect 
in even 100% of the animals (group 3). 
4.5 Summary 
In a rat heterotopic heart transplantation model blood transfusion(s) given to the 
donor did markedly influence graft survival in transfused or immunosuppressed 
recipients. 
When the recipient was pretreated with a donor-specific transfusion, which 
leads, depending on the donor-host combination employed, to a shortened, 
prolonged or even permanent graft survival, the effect of blood transfusions to the 
donor on graft survival was predominantly detrimental. When the recipient had 
been treated with a single injection of 15 mg/kg CsA on the day of operation. the 
effect of blood transfusions to the donor was beneficial. 
The donor transfusion phenomenon was not linked to one particular donor-host 
combination. 
Furthermore, the donor transfusion phenomenon was not linked to one single 
type of blood. Different sources of third party derived blood did have the same 
influence on graft survival. 
Finally, there was no difference in graft survival after a single or multiple 
transfusions of the donor, nor was there an effect of timing. 
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CHAPTER 5 
MODIFICATION OF RAT KIDNEY ALLOGRAFT SURVIVAL BY 
ADMINISTRATION OF THIRD PARTY BLOOD TRANSFUSIONS 
TO THE DONOR 
This chapter has been accepted for publication in Transplant. Proc. 
5 .I Introduction 
It has been reported by several authors that in the clinic transfusions to the donor 
prior to nephrectomy have a positive influence on graft survival (Jeekel eta!., 1980; 
1981; Frisk et al., 1981; 1983; Harder et al., 1984). Retrospective studies by other 
authors however, could not confirm these reports (Berg et al., 1982; Bock et al .. 
1984; Opelz, 1985a). 
The effect of third party blood transfusions given to the donor has been further 
evaluated in experimental studies in animals. We showed in the BN toW AG donor-
host combination, in which a donor-specific transfusion to the recipient always 
leads to permanent cardiac graft acceptance (Marquet et al., 1971), that a single 
transfusion to the donor resulted in abrogation of the beneficial transfusion effect 
in 75% of all cases (Jeekel eta/., 1982; Heineman eta/., l983a). Ina further study we 
showed that third party blood transfusions to the donor can have a beneficial effect 
on cardiac graft survival too, when the recipient has been treated with Cyclosporin 
A (CsA) (Heineman eta! .. !983b). 
This chapter describes the effect of third party whole blood transfusion of the 
donor on the function and survival of kidney allografts. 
5.2 Experimental protocol 
Two different groups of experiments can be distinguished, as shown in Table 5.1. 
In the first experimental group the effect of third party blood transfusions to the 
BN donor on kidney graft function in the unmodified WAG host was studied. The 
donors were transfused intravenously at day -1 and -2 with l ml of whole Brofo 
blood. 
In the second experimental group the effect of third party blood transfusions to 
the BN donor on kidney graft function in the Cyclosporin A (CsA) treated WAG 
host was studied. The donors were transfused intravenously at day -1 and -2 with 
either l ml or 3 ml of whole Brofo blood. The recipients received 5 mg/kg body 
weight CsA intramuscularly after the operation on the day of transplantation. 
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Table 5.1. Experimental protocol. 
Experiment 
II 
Group 
2 
3 
4 
5 
Donor/Host Donor treatment 
combination 
BN/WAG 
BN/WAG 
BN/WAG 
BN/WAG 
BN/WAG 
day -2.-l. Brofo I ml 
day -2.-l. Brofo I ml 
day -2.-l. Brofo 3 ml 
Host treatment 
day 0, CsA 5 mg/kg 
day 0. CsA 5 mg/kg 
day 0. CsA 5 mglkg 
Renal function was evaluated as described in chapter 3.2.3.2. Rejection was defined 
by the blood urea nitrogen (BUN) level exceeding the 60 mmol/1 value. The renal 
function and moment of rejection were analyzed using the Wilcoxon-rank sum test 
and chi square test respectively. 
5.3 Results 
The renal function in the various experimental groups is presented in Tables 5.2 
and 5.3 and in Figures 5.1, 5.2 and 5.3. 
Table 5.2. The effect of third party whole blood transfusions (1 ml) at day -2 and-1 to the BN donor on 
kidney graft function in the unmodified WAG host. 
Rat no. 
9 
10 
12 
13 
14 
16 
17 
2 VL I 
2 VL4 
2 VL 5 
2 VL 6 
2 VL 7 
2 VL 13 
2 VL 14 
Group 
(control) 
2 
(experimental) 
Blood urea nitrogen (BUN) mmol/1 
day 3 day 7 day!O 
6.1 93.4 
5.8 62.0 175.2 
5.8 85.3 123.6 
15.2 67.4 175.4 
1l.l 73.4 198.0 
13.0 61.2 80.8 
21.2 92.2 188.2 
17.8 71.0 137.0 
13.4 54.7 125.6 
20.2 95.7 137.8 
21.0 61.2 123.7 
13.7 74.3 147.8 
15.2 34.5 157.5 
23.4 49.5 150.8 
Rejection was defined by the blood urea nitrogen (BUN) level exceeding the 60 mmol/1 value. From 
the day the graft was considered to be rejected the BUN value is printed in italics. 
There were no significant differences in either the renal function or the moment of rejection between 
the two groups. 
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Figure 5.1. The effect of third party whole blood transfusions (1 ml) at dat-2 and-! to the BN donor on 
kidney graft function in the unmodified WAG host (see Table 5.2). 
In the first group of experiments it was found that there was no significant 
difference in renal function or the moment of rejection between transfused and non-
transfused BN donors when the WAG hosts were not treated. The majority of the 
grafts lost their function after? days and all were rejected after 10 days (group 1 and 
2) (Fig. 5.1 ). 
In the second group of experiments the WAG hosts were postoperatively treated 
with a single intramuscular injection of5 mg/kg CsA, which led to graft rejection in 
64% of the recipients (group 3) during an observation period of 3 weeks. Blood 
transfusion to the donor of 1 ml did lead to graft rejection in 50% of the cases (group 
4) (Fig. 5.2). However, transfusions to the donor of3 ml did lead to graft rejection in 
only 17% of the animals (group 5). There was a significant difference in renal 
function and in the number of rejected grafts from day 14 posttransplant onwards 
between the non-transfused and 3 ml transfused animals (group 3 vs. group 5) 
(Wilcoxon-rank sum test, p < 0.05, and chi square test, p < 0.05, respectively) 
(Fig. 5.3). 
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Table 5.3. The effect of third party whole blood transfusions of 1 ml (group 4) or 3 ml (group 5) at 
day -2 and -I to the BN donor on kidney graft function in the CsA treated (5 mg/kg i.m. inj.) WAG host. 
Rat no. Group Blood urea nitrogen (BUN) mmol/1 
day 3 day 7 day 10 day 14 day 17 day 21 
C I 9.2 16.4 40.6 118.0 71.2 
C3 17.5 16.8 34.6 64.6 75.4 63.8 
C4 11.0 10.6 19.6 38.6 36.8 40.2 
C6 27.8 18.6 17.8 33.8 44.0 43.6 
c 15 3 14.2 31.4 36.1 104.7 83.2 25.4 
E I (control) 13.8 16.4 25.2 86.2 54.6 55.2 
E4 12.6 14.2 15.0 61.8 52.8 52.2 
E5 15.8 14.0 19.2 37.2 43.0 31.8 
E6 11.4 17.2 32.2 123.6 83.8 36.2 
E9 24.4 16.2 27.0 57.4 60.2 
E!O 16.2 16.4 16.2 41.6 48.6 44.8 
EV I 12.0 14.6 27.6 71.2 65.6 
EV2 11.0 15.6 20.0 48.0 48.2 46.4 
EV 3 4 9.6 26.0 68.4 93.2 55.6 
EV4 (experimental) 20.0 19.2 23.4 51.4 59.2 52.0 
EV 5 15.8 16.2 19.0 30.0 32.8 24.4 
EV 6 23.0 38.0 77.4 80.8 82.2 
EP 1 12.4 19.0 19.2 22.9 22.0 19.8 
EP 3 15.8 18.2 12.4 25.6 19.3 16.4 
EP 4 5 27.0 14.6 24.6 31.8 31.2 32.4 
EP 5 (experimental) 19.2 20.2 17.4 20.6 19.6 19.8 
EP 6 18.6 17.1 13.8 19.7 20.0 18.2 
EP 7 15.4 101.5 159.2 
Rejection was defined by the blood urea nitrogen (BUN) level exceeding the 60 mmo\/1 value. From 
the day the graft was considered to be rejected the BUN value is printed in italics. 
There was a significant difference in renal function and in the number of rejected grafts from day 14 
onwards between group 3 (control) and group 5 (experimental. 2X3 ml donor transfusion) (Wilcoxon-
rank sum test. p < 0.05. and chi square test. p < 0.05. respectively). 
5.4 Discussion 
In rats, it was investigated whether third party transfusions to the donor would 
influence the function and survival of heterotopically transplanted kidneys in non-
treated and CsA treated recipients. 
It was found that neither graft function nor graft survival were influenced by 
donor pretreatment with third party blood when the recipient was not treated 
(group 1 and 2). This result in the kidney transplantation model is in· accordance 
with the results obtained in the heart transplantation model, where we observed no 
effect of third party blood transfusion when the immune response of the recipient 
was not modulated (Heineman et al., 1983a; 1983b). 
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Figure 5.2. The effect of third party whole blood transfusions (I ml) at day -2 and -I to the BN donor on 
kidney graft function in the CsA treated (5 mg/kg i.m. inj.) WAG host (see Table 5.3). 
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Figure 5.3. The effect of third party whole blood transfusions(3 ml) at day-2 and-! to the BN donor on 
kidney graft function in the CsA treated (5 mg/kg i.m. inj.) WAG host (see Table 5.3). 
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Next it was tested whether CsA treatment of the host could facilitate the 
expression of the donor transfusion effect in the kidney transplantation model. It 
was found that two transfusions of l ml third party blood to the donor had no 
significant effect on renal function and graft survival (group 3 vs. group 4), 
however, when the transfused dose was tripled, a significant beneficial effect on 
graft function and survival could be noted (group 3 vs. group 5). From these results 
it can be concluded that there is a beneficial effect on kidney graft function and 
survival of third party transfusion to the donor in the CsA treated host like there is 
in the cardiac transplantation model (Heineman et a/., l983b ). Furthermore, it is 
demonstrated that there is a dose dependancy of this effect in this model. This is in 
contrast with our results in the heart transplantation model where we did not notice 
a difference in graft survival after different volumes of transfused third party blood. 
In those experiments however, we did not search for a critical minimum volume of 
third party blood required to elicit the phenomenon (Heineman et a/., 1983a; 
1983b). 
The mechanism responsible for the donor transfusion phenomenon is not clear. 
It has been suggested that tJ;le presence of cells of two origins in the graft at the time 
of transplantation, i.e. donor leukocytes (passenger leukocytes) and third party 
cells from the blood donor, may be responsible for an altered immunologic 
reactivity either in the graft or in the host (Frisk eta!.. 1983; Jeekel eta!., 1983). We 
have suggested that there might be an interaction between leukocytes from the 
transfusate and the highly immunogenic Ia antigen carrying passenger cell popula-
tion in the graft, leading to an altered immunogenicity of these cells (Heineman et 
a/., 1983b ). (This is further discussed in chapter 9). If this hypothesis holds true than 
there might be a relation between the amount of transfused blood and the number 
of passenger leukocytes in the graft. Several authors have demonstrated that the BN 
kidney contains at least four times as many passenger leukocytes as the BN heart 
(van Schilfgaarde et a/., 1979; Bouwman, personal communication). Thus, 
assuming that transfused third party blood does in equal quantities reach the 
different organs and that there is indeed an interaction between third party blood 
derived cells and the passenger leukocytes in the graft, than it can be deduced that 
the kidney graft needs more third party blood than the cardiac graft to show the 
effect of donor transfusion. This is indeed what we observed and this finding lends 
support to the role of passenger leukocytes in the manifestation of the donor 
transfusion phenomenon. 
5.5 Summary 
In the present experiments the donor transfusion phenomenon was studied in a 
rat kidney allograft modeL It was observed that a beneficial effect of third party 
blood transfusions to the donor on graft function and survival could be elicited 
under the condition that the recipient was moderately immunosuppressed with 
CsA. Wben the host was not treated no effect on graft function or survival could be 
71 
recorded. Furthermore, it was shown that the phenomenon was dose dependent. It 
is discussed that this finding lends support to the role of passenger leukocytes in the 
manifestation of the donor transfusion phenomenon, as the rat kidney contains at 
least four times as many passenger leukocytes as the rat heart. 
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CHAPTER 6 
CHARACTERISTICS OF THE TRANSFUSATE RESPONSIBLE FOR 
THE DONOR TRANSFUSION PHENOMENON 
This chapter was published in a modified form in Transplant. Proc. 1983; 15: 994 and 
Transplantation 1983: 36: 362. 
6.1 Introduction 
It has been described in the previous two chapters that third party whole blood 
transfusion of the donor does markedly influence cardiac graft and kidney graft 
survival in immunosuppressed recipients. When the recipient was pretreated with a 
donor-specific transfusion, which led, depending on the donor-host combination 
employed, to a shortened, prolonged or even permanent heart allograft survival, 
the effect of blood transfusions to the donor on graft survival was predominantly 
detrimental. When the recipient had been treated with a single injection ofCyclo-
sporin A (CsA) on the day of operation, the effect of blood transfusions to the 
donor on heart and kidney- graft survival was beneficial. 
This chapter describes the characteristics of the transfusate required to elicit a 
donor transfusion effect in the heart transplantation model. More in particular the 
importance of the presence of leukocytes in the transfusate and of the degree of 
compatibility for MHC antigens between transfusate and host were studied. 
6.2 Experimental protocol 
Two different groups of experiments can be distinguished, as shown in Table 6.1. 
In the first experimental group the importance of the composition of the third 
party transfusate was studied. The BN cardiac graft donors were transfused two 
days before grafting with either I ml fresh whole third party (Brofo) blood or with 
third party (Brofo) erythrocyte or leukocyte suspensions. The suspensions were 
prepared as described in chapter 3. The equivalent number of erythrocytes present 
in I ml of whole blood (5 Xl09) was given intravenously (i.v.). The equivalent 
number of leukocytes present in 0.5-0.7 ml of whole blood (I ml equals 107 
leukocytes) was given i.v .. In one experimental group, donors received I ml fresh 
whole third party (Brofo) blood irradiated with 10 Gy just prior to transfusion. In 
the control group non transfused donors were used. The WAG recipients were 
injected i.v. -with I ml of fresh whole donor (BN) blood 7 days before transplanta-
tion. 
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Table 6.1. Experimental protocol. 
Experiment Group Donor/Host Donor transfusion Host treatment 
combination 
I BN/WAG day -7, BN I ml 
2 BN/WAG day -2, Brofo I ml day -7. BN I mi 
3 BN/WAG day -2, Brofo 1 ml irrad. day -7, BN l m\ 
4 BN/WAG day -2, Brofo erythrocytes day -7. BN l m\ 
5 BN/WAG day -2. Brofo leukocytes day -7. BN I ml 
lla I BN/WAG day -7. BN 1 ml 
2 BN/WAG day -2, Brofo I ml day -7, BN 1 ml 
3 BN/WAG day -2. Rl 1 ml day -7. BN 1m\ 
lib 4 BN/LEW day -7. BN I ml 
5 BN/LEW day -2.-l. Brofo l ml day -7. BN 1 ml 
6 BN/LEW day -2.-l. Rl I ml day -7. BN 1m\ 
lie I BN/WAG day -7. BN 1 ml 
2 BN/WAG day -2. Brofo 1 ml day -7. BN I ml 
7 BN/WAG day -2. WAG 1 ml day -7. BN I ml 
ln the second experimental group the effect of histocompatibility for class I 
and/or class ll antigens between blood donor and graft recipient on the donor 
transfusion phenomenon in the heart transplantation model was studied. 
Compatibility for class I and incompatibility for class II antigens between blood 
donor and host was studied in the BN/WAG donor-host combination where the 
BN donor received I ml of whole R I blood two days before transplantation. The Rl 
strain is for class l antigens identical with the WAG strain (Vaessen et al., 1979). 
The control animals consisted of a group of non transfused BN donors and of a 
group of third party (Brofo) transfused BN donors (Table 6.1 Experiment Ila). 
Compatibility for class I! and incompatibility for class l antigens between blood 
donor and host was studied in the BN/LEW donor-host combination where the BN 
donor received I ml of whole Rl blood two days and one day before transplan-
tation. The Rl strain is for class II antigens identical with the LEW strain (Vaessen 
et al., 1979). The control animals consisted of a group of non transfused BN-donors 
and of a group of third party (Brofo) transfused BN donors (Table 6.1 Experiment 
llb). 
Compatibility for both class I and class ll antigens between blood donor and host 
was studied in the BN/W AG donor-host combination where the BN donor 
received I ml of whole WAG blood two days before transplantation. The control 
animals consisted of a group of non transfused BN donors and of a group of third 
party (Brofo) transfused BN donors (Table 6.1 Experiment !!c). 
All recipients were injected intravenously with I ml of fresh whole donor (BN) 
blood 7 days before transplantation. 
ln all experiments cardiac function was assessed as evaluated in chapter 3.2.2.2. 
The results were analyzed using the chi square and Wilcoxon-rank sum tests. 
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6.3 Results 
6.3.1 The importance of the composztwn of the third party transfusate for the 
manifestation of the donor transfusion phenomenon 
The survival times observed in the first experimental group are shown in Table 
6.2 and Figure 6.1. 
It was found that grafts from nontransfused donors did survive indefinitely in 
recipients which were transfused with a donor-specific transfusion 7 days before 
grafting (group 1). These animals served as controls for the experimental groups 2-
5. A single Brofo transfusion given to the donor 2 days before grafting significantly 
shortened graft survival. This transfusion led to a reduced graft survival in 73% of 
the transplantations (group 2. p < 0.001 ). The detrimental effect of a Brofo 
transfusion on graft survival was absent if irradiated (10 Gy) blood or purified 
erythrocytes were used. All grafts survived permanently (group 3 and 4). However, 
a Brofo leukocyte transfusion to the donor did lead to reduced graft survival in a 
small but significant number of cases. Here the grafts were rejected in 42% of the 
cases (group 5, p < 0.01). 
6.3.2 The importance of histocompatibility for class I and/or class II antigens be-
tween blood donor and graft recipient for the manifestation of the donor 
transfusion phenomenon 
The survival times observed in the second experimental group are shown in Table 
6.3 and Figures 6.2, 6.3 and 6.4. 
First the effect of donor transfusion with blood compatible for class I antigens with 
the WAG host was tested. It was found that the Rl blood transfusion did not 
influence graft survival in transfused recipients, whereas third party blood (Brofo) 
did significantly reduce graft survival (group 1 vs. group 3, p > 0.05: group 1 vs. 
group 2, p < 0.001) (Figure 6.2). 
Second, the effect of donor transfusion with blood compatible for class II antigens 
with the LEW host was tested. It was found that the Rl blood transfusion did 
significantly reduce graft survival in transfused recipients (group 4 vs. group 6, p < 
0.05). This effect was in the same order of magnitude as the effect observed in this 
model after third party blood (Brofo) transfusion (group 4 vs. group 5, p < 0.05) 
(Figure 6.3). 
Finally the effect of donor transfusion with blood compatible for both class I and II 
antigens with the WAG host was tested. It was found that the WAG blood 
transfusion did not influence graft survival in transfused recipients, whereas third 
party blood (Brofo) transfusion did significantly reduce graft survival (group 1 vs. 
group 7, p > 0.05; group 1 vs. group 2, p < 0.001) (Figure 6.4). 
Table 6.2. The effect of different composition of third party blood transfusion to the BN donor on heart allograft survival in transfused WAG hosts. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
BN WAG day -7, BN I ml 25 permanent 
2 BN day -2, Brofo 1 ml WAG day -7, BN 1 ml 15 5,7 ,7 ,8,8,8,9,9, 10,2I ,28, 
permanent 4X 
3 BN day -2, Brofo I ml WAG day -7, DN I ml 6 permanent 
irradiated (10 Gy) 
4 BN day -2, Brofo erythrocytes WAG day -7, DN I ml 5 permanent 
5 BN day -2, Drofo leukocytes WAG day -7, BN I ml 7 18,23,30, permanent 4X 
The donors were transfused i.v. at day -2 with I ml of whole blood or irradiated (10 Gy) whole blood, or with erythrocyte or leukocyte suspensions. 
The recipients were transfused at day -7 with I ml of BN blood. 
Table 6.3. The effect of histocompatibility for class I and/or class II antigens between blood donor and graft recipient on the donor trans-
fusion phenomenon. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
I BN - WAG day -7, BN I ml 25 permanent 
2 BN day -2, Brofo I ml WAG day -7, BN I ml I5 5,7 ,7,8,8,8,9,9, I0,2I ,28, 
permanent 4X 
3 BN day -2, RI 1 ml WAG day -7, BN I ml 12 I7,18, permanent lOX 
(class I identic. class II differ.) 
4 BN - LEW day -7, BN I ml 8 I 2, I 2, I2, 13,13, I3, I3,13 
5 BN day -2,-1, Brofo I ml LEW day -7, BN I ml 7 6, 7 ,10,10,10,11, I 2 
6 BN day -2,-1, Rl I ml LEW day -7, BN I ml 6 6,6,7,IO,IO,I3 
(class I differ. class II identic.) 
7 BN day -2, WAG I mi WAG day -7, BN I ml 5 permanent 
(clas.•; I identic. class II identic.) 
·n1e donoP.> were transfused i.v. at day -2 and/or -1 with I ml of whole blood which had different compatibility with the recipient. The recipients were 
transfused at day -7 with I ml of BN blood. 
__, 
"' 
77 
--- nontransfused 
------at day -2 Brofo transfused 
··················at day -2 Brofo irradiated blood transfused 
---------at day -2 Brofo erythrocytes transfused 
----at day -2 Brofo leukocytes transfused 
~graft survival 
BN donor ( n=25) 
BN donor ( n=lS) 
BN donor ( n= 6) 
BN donor { n= 5) 
BN donor ( n= 7) 
1001<~~~~~~~~~~~~~~~~~==~~~~~~~~~~~~~~~ ~-=-~~:··:.::.::..:...M-::.:.::.;,..::.:..:..:.:.:.:·.:::..:.:.:::.:.:..;::,•40'''';''''':'' --·-·-- oooo,•;.:.,o,•••••:=·-·..:.:.·.·.:..;.·.·= 
80 
50 
40 
20 
i L_ 
' •-, 
' I
I 
' I 
•-, 
' 
' L, 
' 
--, 
I L ___ , 
I L ___ _ 
'------------ ---, 
' 
'------------] 
' 
'----------------
2 3 • 5 
weeks of transplantation 
Figure 6.1. The effect of different composition of third party blood transfusion to the BN donor on heart 
allograft survival in transfused WAG hosts (see Table 6.2). 
---non transfused 
------·at day -2 Brofo transfused 
·· ·······--at day -2 Rl transfused 
'b graft survival 
100 •••••.•••••• ::-.;'!. .• 
80 
50 
' L--, 
' 
' 
' •-, 
' 
' I 
I 
I 
L~ 
' I 
' L, 
' 
BN donor (n=25) 
BN donor {n=15) 
BN donor (n=l 2) 
L.. 
"' 
L---- ----------, 
' L--------1 
' L--------------
20 
2 3 4 5 
weeks after transplantation 
Figure 6.2. The effect of histocompatibility for class I antigens between Rl blood donor and WAG graft 
re~ipient on the donor transfusion phenomenon (see Table 6.3). 
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6.4 D.iscussion 
This study shows that the donor transfusion phenomenon was manifest if viable 
third party leukocytes were part of the transfusate. Third party erythrocytes or 
irradiated third party blood did not have an effect on graft survival. For the 
induction of the phenomenon, mere third party antigen presentation was not 
sufficient; viable leukocytes appeared to be mandatory. 
Furthermore it was observed that histoincompatibility for class I antigens 
between blood donor and graft recipient seemed to be of importance. The Rl and 
Brofo strains differ for class II antigens from the WAG strain, whereas only Brofo 
differs for class l antigens (Vaessen eta!.. 1979). Brofo blood clearly induced the 
donor transfusion phenomenon, Rl blood did not. This is compatible with the fact 
that Rl blood did very significantly induce a transfusion effect when the host 
concerned a LEW rat, which only differs from the R I for class l antigens (Vaessen et 
a!., 1979). 
It appears from these experiments that viable leukocytes that differ from the host 
for class I antigens are responsible for the induction of the donor transfusion effect. 
It has been suggested that passenger leukocytes play a major role in the realization 
of the effect on graft survival (Frisk et a!., 1983; Jeekel et a!., 1983). It can be 
speculated that the third party derived leukocytes interact with the passenger 
leukocytes in such a way that the immun9Iogical reactivity of these cells and/ or the 
host changes with subsequent consequences for graft survival. It should be noticed 
that class I difference between blood donor and graft recipient seemed to play a 
crucial role in this process, neither class II difference nor class I and class II 
compatibility showed the effect. Speculating further, it can be assumed that the 
passenger leukocyte, arriving with the graft in the recipient. presents to the recipient 
immune system all the antigens it has collected. However, only the presence of the 
"extra" third party class I antigens resulted in the described phenomenon. After its 
recognition by the recipient the route of immunization and subsequent graft 
rejection changed. 
Concerning the "classical'" transfusion effect, either donor-specific or third 
party, many studies have been done to determine the most effective composition of 
the transfusate. These analyses have produced conflicting results, although 
lymphocytes, erythrocytes, and platelets have all been shown to be effective in 
rodents (Marque! eta!., 1971: Jenkins and Woodruff, 1971; Fabre and Morris, 
1972; Welsh eta! .. 1977; Jeekel eta!., 1977; Heslop and Heslop, 1979; Lanehart et 
a!., 1980; Majoor and van Breda Vriesman, 1983: El-Malik eta!., 1984; Nagata et 
a!., 1984; Wood KJ eta! .. 1985). In most of these studies the transfusion was only 
effective in influencing allograft survival if it was given at least a week before 
transplantation. 
Concerning the genetics of the '"classical"' blood transfusion effect it has been 
demonstrated that the transfusion effect is MHC-specific and cannot be induced in 
every strain combination. Furthermore gene products of all three R Tl gene regions 
can be involved, but those of the RTl B region (coding for class II antigens) are 
most prominent (Soulillou et a!., 1984). 
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Figure 6.3. The effect of histocompatibility for class II antigens between Rl blooddonorand LEW graft 
recipient on the donor transfusion phenomenon (see Table 6.3). 
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Figure 6.4. The effect of histocompatibility for class I and class II antigens between WAG blood donor 
and WAG graft recipient on the donor transfusion phenomenon (see Table 6.3). 
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7.2 Experimental protocol 
Two different groups of experiments can be distinguished, as shown in Tables 7 .I 
and 7.2. 
In the first experiment the effect on BN heart allograft survival of a peroperative 
transfusion of I ml of Brofo blood to the WAG recipient treated with Cyclosporin 
A (CsA) was :-itudied. Tht= n::cipienls n:ceivc:d 15 mg/kg bodyweight CsA intra-
muscularly after the operation on the day of transplantation. 
Cardiac function was assessed as described in chapter 3.2.2.2. The results were 
analyzed using the Wilcoxon-rank sum test (Table 7.1 Experimental protocol I). 
In the second group of experiments (WAG x LEW) F1 hybrids were used to 
monitor in a PLN assay LEW -specific cell mediated immunity of WAG rats 
subjected to various treatments. The assay has been described in chapter 3.6. 
First a dose response curve between popliteal lymph node weight and number of 
injected, normal, WAG spleen cells was obtained. Five WAG recipients were used. 
The F1 hybrids received 2-60 x 105 spleen cells in both hind foot-pads. 
Thereafter it was tested whether intravenous injection of LEW antigen into 
WAG recipients resulted in measurable "immunological memory". Five WAG 
recipients were injected with I ml of LEW blood. After 7 days the spleens were 
harvested. The F 1 hybrids received 5-20 X 105 spleen cells in both hind foot-pads 
(Table 7.2 Experiment Ila). 
In the crucial experiments it was studied whether donor transfusion would lead 
to a specific immune response in the recipient. BN donors were transfused two days 
before heterotopic heart transplantation with I ml Brofo or LEW blood. WAG 
recipients were transfused with l ml BN blood on day -7. The spleens of the 
recipients (3 animals per group) were harvested 30 days after BN heart transplanta-
tion, thus in a situation where donor transfusion had not evoked abrogation of the 
donor specific transfusion effect (see chapter4.3.2). The F 1 hybrids received 10-50 x 
105 spleen cells in both hind foot-pads (Table 7.2 Experiment lib). 
In all these experiments two F 1 hybrids were used per dosis injected spleen cells. 
The significance of differences in node weights were analyzed by using the 
Wilcoxon-rank sum test. 
7.3 Results 
7.3.1 The effect of a peroperative third party blood transfusion on BN heart allograft 
survival in WAG hosts treated with Cyclosporin A (CsA) 
The survival times observed in this experiment are shown in Table 7.3 and Figure 
7.1. No significant difference was found between survival times achieved in :rion-
transfused and peroperatively transfused recipients. The majority of the grafts was 
rejected after 9-15 days (group I and 2, p > 0.05). 
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Table 7.1. Experimental protocol!. 
Experiment Group 
2 
Donor/Host Donor transfusion 
combination 
BN/WAG 
BN/WAG 
Tabel 7.2. Experimental protocol II. 
Experiment Group Spleen Cell Treatment Spleen Cell 
II a 
2 
lib 3 
4 
Donor Donor 
WAG 
WAG 
WAG 
WAG 
day -7. LEW 1 ml 
day -37. BN 1 ml 
day -30. BN heart pre-
treated with Brofo I ml 
day -37. BN 1 ml 
day -30. BN heart pre-
treated with LEW 1 ml 
Host treatment 
day 0. CsA 15 rng!kg 
day 0. CsA 15 rng/kg 
day 0, Brofo I ml 
Number of cells (X 10~) injected in 
(WAG X LEW)F1 hybrids 
2.5.10.15.20.30.60 
5. 10. 20 
10. 20. 50 
10, 20. 50 
7.3.2 The effect of transfusion of the donor on specific immune responsiveness of 
the recipient 
The dose response curves obtained with normal WAG spleen cells and WAG 
spleen cells from transfused animals are depicted in Figure 7 .2. The corresponding 
lymph node weights and number of injected spleen cells are shown in Table 7.4. 
It was found that there was a clear dose relationship between the number of 
injected normal WAG spleen cells or WAG spleen cells from transfused animals 
and the degree of popliteal node enlargement in (WAG X LEW) F, hybrids. 
Furthermore it was observed that intravenous injection of third party antigen 
(LEW transfusion) led to a significant reduced specific immune competence. 
The dose response curves obtained with spleen cells from WAG rats bearing 
heart allografts from donors which were either Brofo or LEW transfused are 
depicted in Figure 7.3. 
The corresponding lymph node weights and number of injected spleen cells are 
shown in Table 7.5. 
It was found that again there was a clear dose response relationship between the 
number of injected WAG spleen cells from the two experimental groups and the_ 
degree of popliteal node enlargement in (WAG X LEW)F, hybrids. Furthermore. it 
was noticed that transfer of LEW antigen via the donor to the recipient led to 
immunological ~~memory~· in the recipient as reflected by a reduced specific 
immune compentence to LEW antigens in the recipient. 
Table 7 .3. The effect of a peroperative third party transfusion on BN heart allograft survival in the Cyclosporin A (CsA) treated WAG host. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
BN - WAG day 0, CsA 15 mg/kg 12 9, 10, II, 12, 13, I 3, 13, 14, 14, 
14,15,15 
2 BN - WAG day 0, CsA 15 mg/kg 7 10,11,12, 13, 13, 17,19 
day 0, Brofo 1 ml 
Third party blood (Brofo) transfusions of 1 ml were given intravenously peroperative to the WAG recipients. The recipients were injected on the day of 
grafting intramuscularly in the hind leg with Cyclosporin A (CsA) in a dose of 15 mg/kg body weight in a volume of 0.1 mi. '$: 
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Figure 7.1. The effect on BN heart allograft survival of a peroperative third party(Brofo) transfusion in 
the Cyclosporin A (CsA) treated WAG recipient (see Table 7.3). 
7.4 Discussion 
The results obtained in this study show that a peroperative third party trans-
fusion has no enhancing effect on graft survival when the recipient has been treated 
with CsA, whereas donor transfusion clearly resulted in a significant beneficial 
effect in the same model (Heineman et a!., 1983b ). Thus, the suggestion of Berget 
a!. ( 1982) that transplantation of a graft from a transfused donor might represent an 
additional (peroperative) transfusion of random donor leukocytes, resulting in a 
beneficial effect on graft survival, does not seem to be the explanation for the donor 
transfusion phenomenon. 
In the second part of the study it was tested whether transfusion of the donor 
leads to a specific immune response in the recipient which might be held responsible 
for the observed effect of donor transfusion. The test employed was a local graft 
versus host (GvH) assay, called the popliteal lymph node (PLN)assay, described by 
Ford eta!. (1970). The basis ofthis regional lymph node assay is the finding that 
parental spleen cells injected into the hind footpad of F 1 hybrids induce a GvH 
reaction in the draining popliteal lymph node, leading to an increase in weight as 
well as cellularity. The enlargement of the popliteal node, which peaks at 5-7 days 
after inoculation, is related to the number of parental cells injected and can be 
quantified by simple weighing. The main immunological attack is exhibited by the 
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Table 7.4. Popliteal lymph node weights in (WAG X LEW)F 1 hybrids after injection of different 
dosages of normal WAG spleen cells and WAG spleen cells after a LEW blood transfusion. 
Number of injected cells 
(X 10') 
lymph 
node 
weight 
(mg) 
20 
15 
10 
5 
0 
2 
5 
10 
15 
20 
30 
60 
2 5 
mean lymph node weight (mg ± SD) 
Non-transfused LEW-transfused 
7.25 ± 0.9 
8.0 ± 0.7 
11.8 ± 1.5 
13.0 ± 2.0 
15.0 ± 2.7 
18.0 ± 0.8 
22.0 ± 2.8 
10 20 5 so 
cell dose {x 10 ) 
0 
5.5 ± 0.6 
9.5 ± 0.6 
11.5 ± 3.0 
nontransfused 
(y=2. 14+10.34x) 
{ R=O. 93) 
LEW-transfused 
(y=-1.17+10x) 
{R=0.96) 
100 
Figure 7.2. Relation between the number of normal WAG spleen cells and LEW-transfused WAG 
spleen cells and the degree of popliteal node enlargement in (WAGXLEW)F 1 hybrids (see Table 7.4). 
injected donor T cells against the histocompatibility antigens of the host. This local 
GvH assay can be used to quantify specific cell mediated immunity, if the relevant 
parental strain and F 1 hybrids are used. States of sensitization as well as 
immunosuppression can be monitored in a relatively simple manner. 
In the present experiments (WAG x LEW) F 1 hybrids were used to monitor 
LEW -specific cell mediated immunity ofW AG rats subjected to various treatments 
and allografting. Spleen cells of the animals to be tested were injected into the hind 
footpads of F 1 rats. 
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Table 7.5. Popliteal lymph node weights in (WAG X LEW)F1 hybrids after injection of different 
dosages of spleen cells obtained from WAG rats bearing either Brofo- or LEW-transfused BN 
heart allografts. 
Number of injected cells 
(X 10') 
lymph 
node 
weight 
(mg) 
20 
15 
10 
5 
0 
10 
20 
50 
2 5 
mean lymph node weight (mg ± SD) 
Brofo-transfused graft 
10.75 ± 0.95 
14.0 ± 1.63 
18.75 ± 1.50 
10 20 
cell dose (x toS) 
50 
LEW-transfused graft 
8.0 ± 0.8 
10.75 ± 1.25 
15.0 ± 2.5 
Br-ofo-transfused 
graft donor 
(y=-0. 77+1 1. 45x)( R=l) 
LEW-transfused graft donor 
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Figure 7.3. Relation between the number of spleen cells obtained from WAG rats bearing either Brofo or 
LEW transfused BN heart allografts and the degree of popliteal node enlargement in (WAGXLEW)F1 
hybrids (see Table 7 .5). 
The results showed that the assay is indeed suitable to monitor WAG-anti-LEW 
immunity and that intravenous injection of LEW antigen leads to a significantly 
reduced specific immune competence. Furttcrmore, it was found that transfer of 
relevant antigens (LEW) via donor to recipient leads to a significantly reduced 
specific immune competence as compared to the results obtained after transfer of 
irrelevant antigen (Brofo ). These results convincingly show that theW AG recipient 
has a nmemory~• for the third party transfusion given to the graft donor. However, 
the transfe:t.of antigen via the graft, resulting in this "memory'' in the recipient, can 
not be hold responsible for the donor transfusion phenomenon, as the recipients 
employed did not show the donor transfusion effect (the grafts were not rejected). 
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In conclusion, it was found that transfusion of the donor leads to a specific 
immune response in the recipient, which is not responsible for the donor 
transfusion phenomenon. This finding is corroborated by the results in the cardiac 
transplantation study where peroperative transfusion did not enhance graft 
survival in the model employed. 
7.5 Summary 
In the first part of the present experiments it was studied in rats whether a 
peroperative transfusion with third party blood did influence heart allograft 
survival in a model in which donor transfusion clearly showed to be effective. It was 
found that this was not the case. In the second part it was tested in rats in a popliteal 
lymph node (PLN) assay whether transfusion of the donor leads to a specific 
immune response in the recipient. It was observed that transfer of third party 
antigen via the donor to the recipient led to a reduced specific immune competence, 
however it was also noticed that this tranfer of antigen via the graft was not 
responsible for the donor transfusion phenomenon. 
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CHAPTER 8 
THE ROLE OF PASSENGER LEUKOCYTES IN THE MANIFESTATION 
OF THE DONOR-SPECIFIC TRANSFUSION (DST) PHENOMENON 
This chapter has been published in Transplant. Proc. 1985: 17: 821. 
8.1 Introduction 
The beneficial effect of third party and donor-specific blood transfusions on 
organ graft survival has been confirmed in numerous studies in animals and man 
(Marquet era!.. 1971: van Es era! .. 1977: Opelz and Terasaki, 1980; Salvatierra er 
a! .. 1980). 
The mechanism underlying the transfusion phenomenon is not yet clarified. 
Evidence for the involvement of suppressor cells in prolonged survival by donor-
specific transfusions (DST) was obtained (Marque! and Heystek, 1981; Marquet er 
a!.. 1982). Unresponsive recipients with long-term surviving hearts did develop T-
suppressor cells which could upon adoptive transfer. impose the unresponsiveness 
to naive WAG hosts. Furthermore, retransplantation of long-surviving BN hearts 
to normal WAG recipients resulted in permanent survival in the secondary hosts. 
These findings suggested that the unresponsive state is maintained by suppressor 
cells and graft modification. This hypothesis was tested and found valid (Marque! 
er a! .. 1985). 
A different approach to improve graft survival is to reduce the immunogenicity 
of the graft. In several earlier and recent studies in animals it has been shown that a 
major component of the sensitizing stimulus for allograft rejection is the presence 
and release from the parenchyma of bone-marrow derived cells. the so called 
passenger leukocytes or dendritic cells (Steinmuller. 1967: Elkins and Guttmann. 
1968: Guttmann and Lindquist 1969: Steinmuller and Hart, 1971: Hart and Fabre. 
198lc, Leichler and Bachelor, 1982). Attempts to eliminate these antigen-
presenting cells by treatment of the donor with irradiation, antilymphocyte 
globulin or cytotoxic drugs (Guttmann and Lindquist, 1969: Freeman era!.. 1971: 
Steinmuller era!.. 1971: Stuart er al .. 197la: 197lb; Zincke and Woods, 1974) as 
well as by in vitro culture (Lafferty era!., 1975; Naji era!.. 1979; Lacy era!., 1982) 
have resulted in prolongation of allograft survival in animals. The clinical results of 
donor pretreatment are, however, inconclusive (Guttmann et a!., 1975: Dienst, 
1977; Zincke era!.. 1978: Jeffery era!.. 1978; Guttmann era/., 1980). 
Marquet ~r a/.. (1981) found that in the BN toW AG rat donor/host combination 
modific3.tion of immunogenicity of the cardiac graft by treatment of the donor with 
cyclophosphamide interfered with the enhancing effect of donor-specific blood 
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transfusions. It was assumed that the reduced immunogenicity of the graft causes 
an insufficient triggering of the mechanisms of active immunologic enhancement. 
However. they could not exclude the alternative hypothesis that donor drug-pre-
treatment leads to transfer of a small amount of drug to the host thus interfering 
with the response of host lymphocytes (Lafferty eta/.. 1975; van de Linden eta/., 
!98la). The effect of the residual drug on the immune capacity of the host would 
then account for the observed phenomenon. 
The aim of the present study was to investigate whether passenger leukocytes 
play an important role in the donor-specific transfusion phenomenon. The possible 
role of residual drug after donor pretreatment was excluded by investigating 
whether modification of the immunogenicity of the graft by irradiation would have 
the same effect. The passenger leukocyte population was irradiated at a dose 
(10 Gy) known to abrogate leukocyte proliferation capacities. without interference 
with their immunogenic properties (Elves. 1969). The functional properties of the 
passenger leukocytes were modulated at different periods before transplantation to 
differentiate between the immunogenic properties.and proliferative function of 
these cells. 
The results show that reduction of graft immunogenicity (absence of passenger 
leukocytes) can indeed diminish the favourable effect ofDST. We suggest that the 
dendritic cells in the graft contribute to the induction of specific unresponsiveness 
as initiated by the donor-specific transfusion to the host. 
8.2 Experimental Protocol 
Two different groups of experiments can be distinguished as shown in Table 8.1. 
In the first experimental group the effect of irradiation of the donor with 10 Gy 
5 days before grafting on the DST phenomenon was investigated. In the second 
experimental group the effect of irradiation of the donor with 10 Gy on the day of 
grafting on the DST phenomenon was investigated. In all experiments one blood 
transfusion to the host consisted of I ml fresh pooled hoparinized whole blood. 
Cardiac function was assessed as evaluated in chapter 3.2.2.2. The results were 
analyzed using the chi-square test. 
8.3 Results 
The survival times of the various experimental groups are presented in Table 8.2 
and Figures 8.1 and 8.2. 
In the first group of experiments it is shown that a single BN blood transfusion of 
1 ml given to WAG hosts 7 days before transplantation led to permanent 
acceptance of BN heart allografts (group 2). Control animals rejected their grafts in 
8-9 days (group 1). Pretreatment of the donor with irradiation 5 days before heart 
transplantation resulted in a slight, but significant prolongation of graft survival in 
unconditioned hosts. The grafts were rejected in 8-11 days (group 3. p < 0.05). If 
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Table 8.1. Experimental protocol. 
Experiment Group 
2 
Donor/Host Donor treatment 
combination 
BN/WAG 
BN/WAG 
3 BN/WAG day -5. irradiated 
Host treatment 
day -7. BN 1 ml 
4 BN/WAG day -5. irradiated day -7. BN 1 ml 
······················································································· 
II BN/WAG 
2 BN/WAG day -7. BN 1 ml 
5 BN/WAG day 0. irradiated 
6 BN/WAG day 0. irradiated day -7. BN 1 ml 
donor pretreatment with irradiation. 5 days before transplantation and transfusion 
of the recipient with I ml of BN blood were combined, BN heart allografts were 
rejected in 5, 10, 15. 15 and 29 days. Three grafts were accepted permanently. Thus, 
in more than 60% of the cases the beneficial effect of DST was abrogated (p < 0.05, 
group 4) (see Table 8.2 and Figure 8.1). 
In the second group of experiments it is shown that pretreatment of the donor 
with irradiation on the day of grafting led to graft survival in the unconditioned 
hosts similar to the survival in the control animals (group 1 and group 5). If donor 
pretreatment with irradiation on the day of grafting and DSTwere combined there 
was no significant influence on the beneficial transfusion effect. Almost all grafts 
survived permanently (group 2 and group 6) (see Table 8.2 and Figure 8.2). 
8.4 Discussion 
The results show that pretreatment of the donor with irradiation (10 Gy) 5 days 
before transplantation leads to a significant dimunition of the DST effect. 
However. irradiation of the donor on the day of transplantation did not abrogate 
the beneficial effect of DST. 
Studies in a variety of experimental models have demonstrated that leukocytes 
carried in transplanted organs (passenger leukocytes or dendritic cells) play an 
important role in recipient sensitization (Steinmuller, 1967: Elkins and Guttmann, 
1968: Guttmann and Lindquist, 1969: Steinmuller and Hart, 1971: Hart and Fabre, 
!981c: Lechler and Bachelor. !982). These cells are !a positive and according to 
Hart and Fabre (Hart and Fabre, 1981a: 198lb) are the only site carrying class II 
antigens in the rat heart. The development of anti-Ia monoclonal antibodies has 
created the possibility to visualise these cells and they have been demonstrated in 
the heart (Hart and Fabre. 1981c: Bouwman eta! .. 1985). It has been demonstrated 
that 24 hr after treatment with 10 Gy the number of dendritic cells in rat hearts were 
normal (Hat! and Fabre. 1981c: Bouwman era!.. 1985). The numbers then declined 
rapidly, although some dendritic cells still were present at 3 days after irradiation. 
By day 5 few or no dendritic cells could be seen. The radiation dose employed (10 
Table 8.2. The effect of irradiation of the BN donor at different intervals before transplantation on heart allograft survival in the donor-specific 
transfused WAG recipient. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
I BN - WAG - 10 8,8,8,8,8,8 ,8,8 ,9 ,9 
2 BN 
- WAG day -7, BN I ml 25 permanent 
3 DN day -5, irradiated WAG - 10 8,9,9,9,10,10,10,11,11,11 
4 BN day -5, irradiated WAG day -7, BN 1 ml 8 5,10,15,15,29, permanent 3X 
5 DN day 0, irradiated WAG - 5 8,8,9,10,11 
6 BN day 0, irradiated WAG day -7, BN I ml 8 12, permanent 7X 
The donors were irradiated (10 Gy) at day -5 or 0 before transplantation. The recipients were transfused at day -7 with I ml of BN blood. 
'0 
"' 
---nontransfused 
------ nontransfused 
. ·······-at day -5 irradiated 
-·-·-·-·-·-at day -5 irradiated 
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BN donor, non transfused WAG host ( n=l O) 
BN donor, donor-specific transfused WAG host ( n=25) 
BN donor, non transfused WAG host ( n=1 0) 
BN donor, donor-specific transfused WAG host ( n= 8) 
~ graft survival 
'"=======>---- ---------------------------------~.:..:-.. ~--.-,:;-.=~-~----···· 
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Figure 8.1. The effect of irradiation at day -5 of the BN donor on heart allograft survival in the donor-
specific transfused WAG recipient (see Table 8.2). 
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-·------at day 0 irradia-ted 
'b graft survival 
BN donor, nontransfused WAG host ( n=l O) 
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Figure 8.2. The effect of irradiation at day 0 of the donor on heart allograft survival in the donor-specific 
transfused WAG recipient (see Table 8.2). 
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.Gy).-~ known to abrogate leukocyte proliferative capacities, without interfering 
with their immunogenic properties (Elves. 1969). The different timing of irradiation 
in the current study made it possible to differentiate between the presence of the 
passenger leukocytes and the role of the proliferative capacity of these cells for the 
manifestation of the beneficial DST effect. 
Irradiation of the donor 5 days before grafting, thus virtually depleting the donor 
of its dendritic cell population. led to a moderate prolongation of graft survival in 
the unconditioned host. This reduction of the immunogenicity of the graft did 
diminish the effect of a donor-specific transfusion in the conditioned host. It can be 
assumed that the !a-antigen bearing dendritic cells are necessary for the triggering 
of the specific unresponsiveness initiated by transfusion of the host with donor 
blood. This assumption is further corroborated by the finding that irradiation of 
the donor on the day of grafting. when Ia antigen is still present (Hart and Fabre. 
198lc: Bouwman et a! .. 1985) does not abrogate the effect of a donor specific 
transfusion. Almost all transfused recipients survived permanently. 
Very recently we confirmed these results when we used the OX~6 monoclonal 
antibody (OX-6 reacts with Ia antigens which are abundantly expressed on 
dendritic cells). Donor hearts were perfused and incubated (30 minutes) in the OX-
6 monoclonal antibody and subsequently washed directly prior to transplantation 
into DST treated recipients. It was found that all hearts were rejected (Bouwman et 
a!.. 1985). 
Although it has been demonstrated that enhancement of allografts with 
antibodies directed against class I associated antigen is possible (Jeekel eta/ .. 1977). 
there is abundant evidence that passive transfer of alloantibodies directed against 
donor class II antigens can cause the enhancement of rat heart (Davies and Aikins. 
1974). rat kidney (Soulillou eta! .. 1976: Catto eta! .. 1977). and mouse skin (Archer 
eta! .. 1974: Staines eta!.. 1974) allografts. Strom eta! .. (1977) have suggested that 
active enhancement of organ allografts may be achieved by transferring donor 
lymphoid cells to the recipient prior to transplantation. They tested the hypothesis 
that enhancement requires the development of anti-class II immunity. Their 
experimental data support the concept that enhancement states require active or 
passive immunity against donor class II MHC antigens at the time of transplan-
tation (Strom et a!.. 1977). Batchelor eta/. (1979) and Hart eta/. (1980) have 
reported that recipients of long~term surviving allografts behave very similarly in 
terms of graft survivaL antibody response. and histology of rejection to passively 
enhanced recipients of fresh allografts. These authors raised the possibility that the 
interstitial dendritic cell might be the major target for passive enhancement. They 
hypothesized that the immune response to a long-term surviving allograft. being 
devoid of dendritic cells (Batchelor et a! .. 1979: Hart eta! .. 1980). should not be 
susceptible to further suppression by passive enhancement. Indeed Hart and Fabre 
(1982) presented data showing evidence for an interaction of enhancing antibody 
with donor interstitial dendritic cells during the induction phase of passive 
enhancement. They proposed that passive enhancement. donor pretreatment and 
Ia matching might operate by the same final mechanism. Thus. it can be assumed 
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that matching for class II antigens or killing of class II antigen-carrying-cells results 
in a diminishment of target for the specific unresponsiveness inducing anti-class II 
antibodies. 
Experimental data suggest that this is indeed the case (vanEs and Bainer, 1979; 
Bijnen era/., 1982). In a kidney transplantation model in the rhesus monkey vanEs 
and Bainer (1979) found that matching for D/DR antigens interfered with the 
beneficial effect of blood transfusion on kidney graft survival. They speculated that 
because of sharing of DR antigens. the trigger for suppressor cell induction was 
absent. Bijnen era/. ( 1982) have confirmed these results in a kidney transplantation 
model in the dog. They observed that the beneficial effect of blood transfusion is 
dependent on the degree of matching and suggested that while blood transfusions 
are on the whole beneficial for unmatched kidneys, they are likely to have no effect, 
and even to be harmful, for matched kidneys. In the present experiments we too 
found that class II antigen-carrying cells of the graft. the passenger leukocytes, 
contribute to the induction of enhancement by DST in the experimental model 
employed. In clinical transplantation however, most authors have reported that the 
positive effect ofHLA-DR matching on cadaver graft survival is independent of the 
recipient having received pretransplant blood transfusion or not (Ting and Morris, 
1980; Albrechtsen eta! .. 1981; Goeken er a!., 1982; Moen el a!.. 1983). Only Persijn 
eta!. ( 1981) found that matching for DR antigens gives a less pronounced effect of a 
blood transfusion to the recipient. They suggest that the effect of pretransplant 
blood transfusions might be more outspoken in the group of patients who receive a 
cadaveric graft with two HLA-DR mismatches. 
Finally our data confirm those obtained by v.d. Linden el a/. (1981b) who 
showed in a kidney transplantation model in the dog that preoperative transfusions 
cannot successfully be combined with donor pretreatment as commonly practised 
in man. These findings are a possible explanation for the conflicting data on donor 
pretreatment in man (Guttmann er a/.. 1975; Dienst, 1977: Zincke er a! .. 1978; 
Jeffery et al .. 1978; Guttmann era/.. 1980). The clinical data obtained by donor pre-
treatment should be re-evaluated taking in account the differences in blood 
transfusion policy between the various centres. 
8.5 Summary 
It was observed in rats that pretreatment of the donor with irradiation (10 Gy) 5 
days before transplantation led to a significant dimunition of the donor specific 
transfusion (DST) effect, whereas irradiation of the donor on the day of transplan-
tation did not. From these experiments it is concluded that reduction of the 
immunogenicity of the graft by dendritic cell elimination (irradiation) can diminish 
the beneficial effect of DST. It is suggested that the dendritic cells in the graft 
contribute to the induction of specific unresponsiveness as initiated by the DST to 
the host. 
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CHAPTER 9 
THE ROLE OF PASSENGER LEUKOCYTES IN THE MODIFICATION 
OF ALLOGRAFT SURVIVAL IN RATS BY BLOOD TRANSFUSION 
TO THE DONOR 
This chapter has been accepted for publication in Transplant. Proc. 
9 .I Introduction 
It has been reported in rats that blood transfusion(s) given to the donor can 
markedly influence cardiac and kidney allograft survival if the immune response of 
the recipient has been modulated (Jeekel et a/.. 1982; Heineman eta! .. I983a. 
1983b ). When the recipient was pretreated with a donor-specific transfusion, which 
leads depending on the donor-host combination employed, to a shortened, 
prolonged or even permanent graft survival, the effect of blood transfusions to the 
donor on cardiac graft survival was predominantly detrimental. When the cardiac 
or kidney allograft recipient had been treated with a single injection of respectively 
15 mg/kg CsA or 5 mg/kg CsA on the day of operation. the effect of blood trans-
fusions to the donor was beneficial. 
We obtained evidence that third party derived leukocytes are responsible for the 
induction of this donor transfusion phenomenon (Heineman eta/.. 1983a, I983b ). 
Previous work from other authors has demonstrated that these transfused 
allogeneic leukocytes home in small quantities in the graft (van Schilfgaarde eta!., 
1979). Based on these studies our hypothesis was that the mechanism responsible 
for the donor transfusiOn effect might be an interaction between leukocytes from 
the transfusate and the passenger leukocytes in the graft, leading to altered 
immunogenicity of these cells. 
In the present study attempts were made to substantiate the role of the passenger 
leukocytes. In the BN toW AG heart transplantation model the functional proper-
ties of the passenger leukocytes were modulated by irradiation at a dose of 10 Gy 
known to abrogate the proliferative capacities of lymphocytes without interfering 
with their immunogenic properties (Elves. 1969). The functional properties of the 
passenger leukocytes were modulated at different periods before transplantation to 
differentiate between the immunogenic properties and proliferative function of 
these cells. 
The results obtained indicate that the beneficial effect of blood transfusions to 
the donor on graft survival in the model employed. can be abrogated by irradiation 
of the donor before transplantation. The data suggest a vital role of passenger 
leukocytes in the manifestation of the donor transfusion phenomenon. 
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9.2 Experimental protocol 
Two different groups of experiments can be distinguished as shown in Table 9.1. 
In the first experimental group the effect of irradiation and third party 
transfusion of the BN donor on heart allograft survival in the unmodified WAG 
recipient was investigated. The donors were transfused intravenously at different 
intervals (day -1 and/or -2) with I ml of whole Brofo blood and/or irradiated with 
10 Gy whole body radiation at day -5. 
In the second experimental group the effect of irradiation at different intervals 
before transplantation and third party transfusion of the BN donor on heart allo-
graft survival in the Cyclosporin A (CsA) treated WAG host was studied. The 
donors were transfused intravenously at different intervals (day -1 and -2) with 1 
ml of whole Brofo blood and/or irradiated with 10 Gy whole body radiation at day 
-5 or 0. The recipients were injected on the day of grafting intramuscularly in the leg 
with CsA in a dose of 15 mg/kg body weight. Cardiac function was assessed as 
evaluated in chapter 3.2.2.2. Statistical .analysis of the data was performed by using 
the Wilcoxon-rank sum test. 
9.3 Results 
The survival times of the various experimental groups are presented in Tables 9.2 
and 9.3 and Figures 9.1. 9.2 and 9.3. 
In the first group of experiments the effect of irradiation and third party trans-
fusion of the donor on heart allograft survival in the unmodified recipient was 
studied. It was found that a single Brofo transfusion to the donor at 2 days before 
transplantation had no effect on graft survival if the recipient was not immuno-
suppressed. Similarly as in the control animals. the hearts were rejected in 8-9 days 
(group I and 2). 
In the subsequent two experimental groups the donors were irradiated 5 days 
before grafting. This irradiation led to a moderate. but significant prolongation of 
graft survival in 60% of the cases. Grafts were rejected in 8-11 days (group 3, 
p < 0.05). 
Third party transfusions given to the donor at 2 days and 1 day before grafting in 
combination with irradiation at 5 days before grafting did lead to graft survival 
times ranging from 8-12 days (group 4). Graft survival was extended in 60% of the 
cases as compared to the non-irradiated transfused controls (group 4 vs. group 2: 
p < 0.05). however there was no further prolongation of graft sJrvival as compared 
to the irradiated non-transfused animals (group 4 vs. group 3: p > 0.05) (see Table 
9.2 and Figure 9 .I). 
In the second group of experiments the effect of irradiation before or after donor 
transfusion on heart allograft survival in rats treated postoperatively with CsA was 
studied. When using an unmodified donor. a single injection of 15 mg/kg CsA led 
to graft survival times ranging from 9-15 days (group 5). This group forms the 
control group. 
Table 9.1. Experimental protocol. 
Experiment Group Donor/Host 
combination 
BN/WAG 
2 BN/WAG 
3 BN/WAG 
4 BN/WAG 
II 5 BN/WAG 
6 BN/WAG 
7 BN/WAG 
8 BN/WAG 
9 BN/WAG 
10 BN/WAG 
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Donor treatment 
day -2. Brofo 1 ml 
day -5. irradiated 
day -5. irradiated 
day -2,-L Brofo 1 ml 
day -2.-l. Brofo 1 ml 
day -5. irradiated 
day -5, irradiated 
day -2.-L Brofo 1 ml 
day 0, irradiated 
day -2.-1. Brofo 1 ml 
day 0, irradiated 
Host treatment 
day 0. CsA 15 mg/kg 
day 0. CsA 15 mg/kg 
day 0. CsA 15 mg/kg 
day 0. CsA 15 mg/kg 
day 0. CsA 15 mg/kg 
day 0. CsA 15 mg/kg 
If the donor was transfused with third party blood at 2 days and I day before 
transplantation. the effect of CsA treatment on graft survival was enhanced. Trans-
fusion of the donor led to prolonged graft survival in 75% of the cases (group 6 vs. 
group 5. p < 0.05). 
In the subsequent four experimental groups the donors were irradiated. Irra-
diation of tlie donor on day -5 or day 0 did not lead to a significant prolon-
gation of graft survival (group 7 and 9). Irradiation on day -5 or 0 combined with 
transfusions at 2 days and 1 day before transplantation led to abrogation of the 
donor transfusion phenomenon (group 8 and 10). Graft survival times in these 
groups were almost similar to the survival times observed in the control group 
(group 5) (see Table 9.3 and Figures 9.2 and 9.3). 
Table 9.2. The ertect of irradiation (10 Gy) and third party transfusion of the donor on heart allograft survival in the unmodified recipient in the 
BN to \VAG donor-host combination. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
I BN - WAG - 10 8,8 ,8 ,8,8,8 ,8 ,8 ,9 ,9 
2 BN day -2, Brofo 1 ml WAG - 6 8,8,8,9,9,9 
3 BN day -5, irradiated WAG - 10 8,9,9,9,10,10,10,11,ll ,II 
4 BN day -5, irradiated WAG - 10 8,8,9,9,10,10, I I ,12, I2, I 2 
day -2 and -1, Brofo 1 ml 
The donors were transfused intravenously at different intervals (day -I and/or -2) with 1 ml of whole Brofo blood and/or irradiated with 10 Gy 
whole body radiation at day -5. 
-0 
0 
---non transfused 
------~at day -2 Brofo transfused 
·············-at day -5 irradiated 
-----·-at day -5 irradiated and 
at day -2 and -1 transfused 
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Figure 9.1. The effect of irradiation ( 10 Gy) and third party transfusion of the donor on heart allograft 
survival in the unmodified recipient in the BN to WAG donor-host combination (see Table 9.2). 
9.4 Discussion 
The present study shows that in the employed model the beneficial effect of 
donor transfusion on graft survival can be abrogated by irradiation either before or 
after transfusion. 
As has already been mentioned in several of the previous chapters it has been 
demonstrated in a variety of experimental models that leukocytes carried in trans-
planted organs (passenger leukocytes or dendritic cells) play an important role in 
recipient sensitization (Steinmuller. 1967: Elkins and Guttmann. 1968: Guttmann 
and Lindquist. 1969: Steinmuller and Hart, 1971; Hart and Fabre, 1981c: Lechler 
and Batchelor, 1982). These cells are !a positive and according to Hart and Fabre 
(Hart and Fabre, 1981a: 1981 b) are the only site carrying class II antigens in the rat 
heart. The development of anti-Ia monoclonal antibodies has created the 
possibility to visualize these cells and they have been demonstrated in the heart 
(Hart and Fabre, 1981c; Bouwman et a!.. 1985). Hart and Fabre (1981c) and 
Bouwman eta/. (1985) investigated in the BN rat the effect of irradiation on the 
dendritic cell population of the graft. Their results showed that 24 hr after 
Table 9.3. The effect of irradiation ( 10 Gy) and third party transfusion of the donor on heart allograft survival in the BN to WAG donor* host 
combination after treatment of the recipient with CsA. 
Group Donor Donor treatment Recipient Recipient treatment Number Survival in days 
5 DN - WAG day 0, CsA 15 mg/kg 12 9, 10, II, 12,13, 13,13, 14, 14, 
14,15,15 
6 DN day ~2 and -I, Brofo 1 m\ WAG day 0, CsA 15 mg/kg 8 II ,12, 18, 19,22,26,28, 
permanent IX 
7 BN day -5, irradiated WAG day 0, CsA 15 mg/kg 10 12, 12,12, 12,13, 14,22,23, 
29,32 
8 BN day -5, irradiated WAG day 0, CsA 15 mg/kg 7 9,11,11 ,12,12,13, 
day -2 and -1, Brofo I ml permanent IX 
9 BN day 0, irradiated WAG day 0, CsA 15 rug/kg 7 9,11 ,11,11,11,12,13 
10 BN day -2 and -1, Brofo I ml WAG day 0, CsA 15 mg/kg 8 II, II, II, II, 12,13,13,14 
day 0, irradiated 
The donors were transfused intravenously at different intervals (day -I and -2) with I ml of whole Brofo blood and/or irradiated with 10 Gy whole 
body radiation at day -5 or 0. The recipients were injected on the day of grafting intramuscularly in the hind leg with Cyc\osporin A (CsA) in a dose 
of 15 mg/kg body weight in a volume of 0.1 mi. 
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treatment with 10 Gy the number of dendritic cells in the heart was normal. The 
numbers then declined rapidly, by the 5th day after irradiation few or no dendritic 
cells could be seen. 
Our hypothesis concerning a mechanism possibly responsible for the donor 
transfusion phenomenon was that third party transfusion derived cells (leukocytes) 
interact with the graft dendritic cell population in such a way that these are 
modified and as a consequence have an altered immunogenicity. Some indirect 
evidence for this hypothesis could be deduced from our finding that transfusions to 
the donor did have opposite effects (detrimental or beneficial) depending on the 
way the recipient had been treated (Heineman et al .. 1983b). In the strain 
combination employed, a donor-specific transfusion to the recipient leads to 
permanent graft survival (Marquet era!.. 1971). It has been demonstrated that this 
transfusion effect is abolished by treatment of the donor with cyclophosphamide 
(Marquet eta! .. 1981), irradiation (Heineman eta!.. 1985) or anti-Ia monoclonal 
antibodies (Bouwman et a!.. 1985). From these experiments it can be concluded 
that reduction of the immunogenicity of the graft either by dendritic cell 
elimination (cyclophosphamide, irradiation) or by shielding or alteration of 
dendritic cell antigens (labeling with anti-Ia monoclonal antibodies) diminishes the 
beneficial effect of the donor specific transfusion. A similar detrimental influence 
on the beneficial donor specific transfusion effect has been reported after trans-
fusion of the donor. The third party cells might have interacted with the dendritic 
cells in such a way that this abrogated the beneficial donor specific transfusion 
effect. Recipients treated with CsA however, did benefit from donor transfusion. 
The CsA interacts with the recipient~s immune system. These two modifications 
-transfusion of the donor and CsA treatment of the recipient - did prove to be 
additive. 
The irradiation experiments in the current study were meant to substantiate the 
role of these passenger leucocytes or dendritic cells in the expression of the donor 
transfusion phenomenon. 
In the first group of experiments (summarized in Table 9.2) recipients were not 
immunosuppressed. As has been published previously (Heineman eta!.. 1983b) the 
donor transfusion phenomenon in the donor-host combination employed is only 
manifest in conjunction with a minimally immunosuppressed host. The aim of this 
group of experiments was to determine whether the appearance of the donor trans-
fusion phenomenon could be facilitated by irradiation of the donor. Apparently 
this was not the case as the combined treatment with irradiation and donor trans-
fusion gave similar results as irradiation alone. 
In the second group of experiments(summarized in Table 9.3) the recipients were 
moderately immunosuppressed with CsA. This immunosuppression of the host 
allows for the expression of the donor transfusion phenomenon in a significant 
number of cases (Heineman eta!., 1983b). 
Irradiation of the donor 5 days before grafting, thus virtually depleting the donor of 
its dendritic cell population, led to a moderate. though not significant. prolon-
gation of graft survival. 
105 
Subsequently. transfusions were given to the donor 3 days after irradiation. This led 
to graft rejection in the same fashion as in non-irradiated non-transfused control 
animals. This result indicates that passenger leukocytes need to be present in the 
donor for the transfusion phenomenon to become manifest. 
In two experimental groups donor animals were irradiated shortly before trans-
plantation. The survival time of grafts in the group which received irradiation 
only was at the control level. This result is in accordance with other reports which 
show that irradiation of the donor has little or no effect on graft survival if grafts are 
harvested only a few hours after treatment (Stuart et a/.. 197\a). In the last 
experimental group the donor animals were transfused and subsequently irradiated 
shortly before transplantation. The graft survival times rec01::ded were entirely at 
the control level. The irradiation again resulted in abrogation of the otherwise 
beneficial transfusion effect. The timing of irradiation only resulted in abrogation 
of the proliferative capacities of the passenger leukocytes without interference with 
their immunogenic properties (Elves, 1969). This leads to the conclusion that not 
only the presence. but also the intact proliferative capacity of the passenger 
leukocyte population of the donor is essential for the manifestation of the donor 
transfusion effect. This sug,iests that transfusion of the donor provokes a reaction 
in the passenger leukocytes resulting in a modified activity of these cells towards the 
responsive cells of the host. 
9.5 Summary 
It has been shown in rats that third party blood transfusions given to the donor 
can markedly influence allograft survival if the immune response of the recipient 
has been modulated by donor-specific transfusion or treatment with Cyclosporin A 
(CsA). Based on these and other studies our hypothesis was that the mechanism 
responsible for this effect might be an interaction between leukocytes from the 
transfusate and the passenger cell population in the graft leading to an altered 
immunogenicity of these cells. In the present study attempts were made to 
substantiate the role of the passenger leukocytes. It was observed that irradiation 
(10 Gy) of the donor either 5 days before transplantation or on the day of trans-
plantation did abrogate the otherwise beneficial donor transfusion effect in the 
model employed. These results indicate that the presence and intact proliferative 
capacity of the passenger leukocyte population of the donor is essential for the 
manifestation of the donor transfusion effect. This suggests that transfusion of the 
donor provokes a reaction in the passenger leukocytes resulting in a modified 
activity of these cells towards the responsive cells of the host. 
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CHAPTER 10 
GENERAL DISCUSSION AND CONCLUDING REMARKS 
I 0.1 Introduction 
There is now wide acceptance that pretransplant blood transfusions to the 
recipient produce a strikingly beneficial effect on the post-transplant course and 
eventual outcome of cadaveric and living related kidneys (Opelz era!., 1981b; 
Salvatierra era!., 1983). Only recently studies have appeared concerning the effect 
on graft survival of transfusions given to the donor. 
Jeekel era!. (1980) were the first authors to describe an effect of blood trans-
fusions given to the donor on kidney graft survival. They described that in the dog 
prolonged kidney graft survivaL which could be induced by one peroperative blood 
transfusion to the recipient. was reduced to control level by transfusion of the 
donor on day -1 with 100 ml third party blood. Subsequently 7 retrospective 
clinical studies on the effect of blood transfusions given to the donor on cadaveric 
kidney graft survival have been performed. In 4 studies it was reported that blood 
transfusions to the donor prior to nephrectomy positively influenced graft survival 
(Jeekel eta!., 1980; 1981; Frisk eta!., 1981; 1983; Harder eta!.. 1984). In 3 studies no 
beneficial effect could be observed (Berg et a!.. 1982; Bock et a!.. 1984; Opelz, 
1985a). 
The many questions raised by these retrospective studies made it necessary to 
experimentally investigate them in controlled studies. In this thesis experiments in 
rats are described which had the following objectives: to study the effect of different 
whole blood transfusions and transfusions of blood components to the donor on 
graft survival: to determine, in case such an effect was apparent. the underlying 
mechanism(s); and finally to contemplate possible implications for clinical trans-
plantation. 
10.2 Donor transfusion in the rat cardiac and kidney allograft model: summary of 
the findings 
In rats, it was investigated whether third party transfusion(s) to the donor would 
influence the survival of heterotopically transplanted hearts in nontransfused, 
transfused and CsA treated recipients. The effect of third party transfusion(s) to the 
donor on graft survival in the unmodified host was tested in the BN toW AG and 
the Rl to ·WAG donor/host combination. It was found that there was no 
measurable effect of third party (Brofo) transfusion to the donor on heart allograft 
survival when the WAG hosts did not receive immunosuppression, even if there was 
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compatibility for class I antigens between donor and host, like in the Rl toW AG 
combination. 
The effect of third party transfusion(s) to the donor on heart allograft survival in 
DST transfused recipients was tested in three different donor/host combinations, 
the BN to WAG, the reverse WAG to BN, and the BN to LEW combination. 
From the results obtained it was concluded that third party (Brofo or LEW) 
transfusion(s) of the donor had an effect on cardiac allograft survival in hosts 
pretreated with DST. It was clearly shown that this effect was not confined to one 
single donor-host combination, but that it was manifest when different donors and 
different hosts were employed. Furthermore. in all these combinations it was found 
that, in DST transfused recipients, grafts from transfused donors fared worse than 
grafts from nontransfused donors. Thus. a detrimental influence of third party 
donor transfusion on graft survival was observed, whereas in the clinical setting, a 
beneficial effect of blood transfusions to the donor had been reported (J eekel eta/., 
1980; 1981; Frisk eta/., 1981; 1983; Harder eta/., 1984). However, the results in one 
experiment showed that third party blood transfusion to the donor had a beneficial 
effect on graft survival when the recipient had been treated with CsA on the day of 
operation. Brofo transfusions to the BN donor led to prolongation of allograft 
survival in 75% of the cases; LEW transfusions to the BN donor had this effect in 
even 100% of the CsA treated WAG animals. 
The influence of third party transfusions to the donor on the function and 
survival of heterotopically transplanted kidneys was also investigated. It was 
observed that a beneficial effect of third party transfusions to the donor on graft 
function and survival could be elicited under the condition that the recipient was 
moderately immunosuppressed with CsA. When the host was not treated no effect 
on graft function or survival could be recorded. Furthermore, it was noticed that 
there was a dose dependancy of the effect in this model. This was in contrast with 
the results in the heart transplantation model where we did not notice a difference in 
graft survival after different volumes of transfused third party blood. 
Investigating which characteristics of the transfusate are required to elicit a 
donor transfusion effect, it was found that the donor transfusion phenomenon was 
only manifest if viable third party leukocytes were part of the transfusate. Third 
party erythrocytes or irradiated third party blood did not have ail effect on graft 
survival. For the induction of the phenomenon. mere third party antigen 
presentation was not sufficient: viable leukocytes appeared to be mandatory. 
Moreover, it was observed that histoincompatibility for class I antigens between 
blood donor and graft recipient seemed to be of importance. 
10.3 Possible mechanism responsible for the donor transfusion effect 
Different mechanisms responsible for the donor transfusion phenomenon have 
been proposed. 
It has been speculated that, if there is an effect of peroperative recipient blood 
transfusion, transplantation of a kidney from a transfused donor might represent 
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an additional peroperative transfusion of random third party donor leukocytes 
(Berg et a/., !982). 
Furthermore. it has been suggested that the presence of passenger leukocytes of two 
origins in the kidney at the time of transplantation, i.e. donor leukocytes and third 
party cells from the blood donor, may be responsible for an altered immunologic 
reactivity either in the graft or in the host (Frisk eta/., !983: Jeekel era/., 1983). 
Finally, Bachelor has offered the hypothesis that dendritic cells in the donor kidney 
might be mobilized in response to a transfusion, thereby rendering the graft 
depleted of dendritic cells and less immunogenic (Opelz and van Rood, !983). The 
first two of these hypothesis have been tested by the author. the third one is under 
investigation and a few preliminary data are at our disposal. 
The data on the influence of transfusion during transplantation surgery are 
somewhat conflicting. Several authors have reported that patients without pre~ 
transplant transfusions who have been transfused during operation did as well as 
those transfused prior to transplantation (Stiller era/., 1978: Williams eta/., !980). 
Others however, have reported transfusions to be effective only when given prior to 
transplantation (Hourmant et a/., 1979; Opelz and Terasaki, !981: Glass eta/., 
1982: Opelz, 1985a). In the monkey, dog and rat, it has been found that a single 
pertransplant third party transfusion had a beneficial effect on allograft survival 
(vanEs eta! .. 1977: Obertop eta/., !981: Soulillou era/., 1984). 
We studied whether a peroperative transfusion with third party blood did 
influence heart allograft survival in a model in which donor transfusion clearly 
showed to be effective. The results obtained show that peroperative third party 
transfusion· has no enhancing effect on graft survival when the recipient has been 
treated with CsA. whereas donor transfusion clearly resulted in a significant 
beneficial effect in the same model. Thus. the suggestion of Berget a!. (1982) that 
transplantation of a graft from a transfused donor might represent an additional 
peroperative transfusion of random donor leukocytes, resulting in a beneficial 
effect on graft survivaL does not seem to be the explanation for the donor 
transfusion phenomenon. 
In a next experiment concerning the role of in the graft "stown away" third party 
leukocytes. it was tested whether transfusion of the donor leads to a specific 
immune response in the recipient which might be held responsible for the observed 
effect of donor transfusion. The test employed was a local graft versus host (GvH) 
assay, called the popliteal lymph node weight (PLN) assay, described by Ford eta/. 
(1970). In the experiments (WAG x LEW) F 1 hybrids were used to monitor specific 
cell mediated immunity of WAG rats subjected to various treatments and allograft-
ing. Spleen cells of the animals to be tested were injected into the hind footpads of 
F, rats. The results showed that the assay is indeed suitable to monitor WAG-anti-
LEW immunity and that intravenous injection of LEW antigen leads to a 
significant reduced specific immune competence. Furthermore, it was found that 
transfer of relevant antigen (LEW) via donor to recipient leads to a significantly 
reduced specific immune competence as compared to the results obtained after 
transfer of irrelevant antigen (Brofo ). These results convincingly show that the 
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WAG-recipient has a ""memory"" for the third party transfusion given to the graft 
donor. However, the transfer of antigen via the graft, resulting in this "memory" in 
the recipient, can not be hold responsible for the donor transfusion phenomenon, 
as the recipients employed did not show the donor transfusion effect. In conclusion, 
it was found that transfusion of the donor leads to a specific immune response in the 
recipient, which is however not responsible for the donor transfusion phenomenon 
This finding is corroborated by the results in the cardiac transplantation study 
where peroperative transfusion did not enhance graft survival in the model 
employed. 
It has been suggested that the change in graft survival after transfusion of the 
donor might be explained by attributing a crucial role to the so-called passenger 
leukocyte or. more specifically. to the dendritic cell. Interstitial dendritic cells are 
found in the connective tissues of kidney. heart. liver and all other tissues 
investigated except brain (Hart and Fabre, !981c: Daar e1 a!.. 1983). These cells are 
of hemopoietic origin and stain intensily for class II major histocompatibility 
complex antigens: they probably arise from a differentiation pathway distinct from 
known myeloid and lymphoid elements (Tew el a! .. 1982). Similar cells isolated 
from rodent lymphoid tissues (Tew e1 a/ .. 1982) have been shown to stimulate 
allogeneic T lymphocytes strongly (Steinman and Witmer. 1978) and interstitial 
dendritic cells have been suggested to be the significant bone-marrow-derived 
passenger leukocyte contributing to graft antigenicity (Hart and Fabre. 198lc: 
Lafferty e1 a/., !983a). Indeed, long-surviving rat renal allografts lack donor strain 
dendritic cells (Hart and Fabre, 198!d) and these kidneys show substantially 
reduced immunogenicity (Bachelor e1 a!., 1979: Hartel a!.. 1980) on retransplan-
tation into fresh recipient strain animals. Hart and Fabre (198lc) and Bouwman e1 
a!. (1985) investigated in the BN rat the effect of irradiation on the dendritic cell 
population of the graft. Their results showed that 24 hr after treatment with 10 Gy 
the number of dendritic cells in the heart was normal. The numbers then declined 
rapidly, by the 5th day after irradiation few or no dendritic cells could be seen. 
It has also been demonstrated that transfused allogeneic lymphocytes home in 
small quantities in the graft (van Schilfgaarde e1 a!.. 1979). One hypothesis 
concerning a mechanism possibly responsible for the donor transfusion phenome-
non is that third party transfusion derived cells (leukocytes) interact with the graft 
dendritic cell population in such a way that these are modified (Frisk e1 a!., 1983: 
Jeekel e1 a!., 1983). 
Indirect evidence for this hypothesis can be deduced from the following 
observations. First. we observed that the donor transfusion effect needs three times 
more whole third party blood to be elicited in the kidney transplantation model as 
compared to the cardiac allograft model. Several authors have demonstrated that 
the BN kidney contains at least four times as many passenger leukocytes as the BN 
heart (van Schilfgaarde era!.. 1979: Bouwman, personal communication). Thus, 
assuming that transfused third party blood does in equal quantities reach the 
different organs and that there is indeed an interaction between third party blood 
derived cells and the passenger leukocytes in the graft. then it can be understood 
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that the kidney graft needs more third party blood than the cardiac graft. This is 
indeed what we observed and this finding lends support to the role of passenger 
leukocytes in the manifestation of the donor transfusion phenomenon. Secondly, it 
was found that transfusions to the donor did have opposite effects (detrimental or 
beneficial) depending on the way the recipient had been treated. In the strain 
combination employed, a donor-specific transfusion to the recipient leads to 
permanent graft survival (Marquet eta!., 1971). We demonstrated that this trans-
fusion effect is abolished by treatment of the donor with irradiation. This is a 
confirmation of an earlier report of Marquet eta!. (1981) who treated the donor 
with cyclophosphamide. and of a recent report of Bouwman eta!. (1985), who used 
anti-Ia monoclonal antibodies. From these experiments it can be concluded that 
reduction of the immunogenicity of the graft either by dendritic cell elimination 
(cyclophosphamide. irradiation) or by shielding or alteration of dendritic cell 
antigens (labeling with anti-Ia monoclonal antibodies) diminishes the beneficial 
effect of the donor specific transfusion. A similar detrimental influence on the 
beneficial donor specific transfusion effect has been reported after transfusion of 
the donor. The third party cells might have interacted with the dendritic cells in 
such a way that this abrogated the beneficial donor specific transfusion effect. 
Recipients treated with CsA however. did benefit from donor transfusion. The CsA 
interacts with the immune system of the recipient. These two modifications- trans~ 
fusion of the donor and CsA treatment of the recipient- did prove to be additive. 
The irradiation experiments in the current study were meant to substantiate more 
directly the role of passenger leukocytes in the expression of the donor transfusion 
phenomenon. The radiation dose employed (10 Gy) is known to abrogate 
leukocyte proliferative capacities, without interfering with their immunogenic 
properties (Elves. 1969). Different timing of irradiation in this study made it 
possible to differentiate between the presence of the passenger leukocytes and the 
role of the proliferative capacity of these cells for the manifestation of the donor 
transfusion effect. It was observed that irradiation of the donor either 5 days before 
transplantation or on the day of transplantation did abrogate the othervvise 
beneficial donor transfusion effect in the model employed. These results indicate 
that the presence and intact proliferative capacity of the passenger leukocyte 
population of the donor is essential for the manifestation of the donor transfusion 
effect. This suggests that transfusion of the donor provokes a reaction in the 
passenger leukocytes resulting in a modified activity of these cells towards the 
responsive cells of the host. In the light of this result it is worthwhile to contemplate 
the report from Berg et a/. (1982) about the effect of transfusion of the donor on 
allograft survival. In the clinical situation they failed to show any beneficial effect of 
donor transfusion. From their data it can be deduced that the donors studied were 
previously included in a prospective trial on donor pretreatment with cyclophos-
phamide and methyl prednisolone (Corry eta/ .. 1980). Such a donor pretreatment 
regimen aims at the elimination of the passenger leukocytes. From our data it will 
be understood that this way of donor pretreatment does interfere with the reported 
beneficial effect on allograft survival of donor transfusion (J eekel eta/., 1980; 1981; 
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1982; 1983; Frisk eta/., 1981; 1983; Harder et al .. 1984). We suggest that their 
retrospective study would have shown quite different results if this factor would 
have been included in the analysis. 
A third hypothesis concerning the mechanism responsible for the donor trans-
fusion phenomenon has been offered by Batchelor. He suggested that dendritic 
cells in the graft might be mobilized in response to a transfusion. thereby rendering 
the graft depleted of dendritic cells and less immunogenic (Opelz and van Rood. 
1983). Preliminary data (Bouwman and Marquet, personal communication) show 
that this is very unlikely. The effect of transfusion on the number of dendritic cells 
in cardiac grafts has been investigated with anti-Ia monoclonal antibodies. No 
significant increase or decrease in the number of Ia staining dendritic cells after 
syngeneic or allogeneic transfusions could be demonstrated. 
In conclusion, the studies concerning the mechanism of the donor transfusion 
effect provide evidence that radiosensitive cells. within grafts. being almost 
certainly the significant passenger leukocytes, are essential for the manifestation of 
the donor transfusion phenomenon. Furthermore, it was demonstrated that these 
cells need to be present in the graft and need to have an intact proliferative capacity. 
It was also observed that viable leukocytes that differ from the host for at least 
class I antigens are responsible for the induction of the donor transfusion effect. To 
understand the interactions that might take place in response to donor transfusion. 
we accept the stimulator cell model of lymphocyte activation. as proposed by 
Lafferty ( 1980). as the relevant model for allograft rejection. Lafferty ( 1980) makes 
two postulates concerning the process of immunocyte activation. First. it is 
proposed that two signals are required for lymphocyte activation. Signal 1 is 
provided by antigen binding to the potentially responsive lymphocyte. Signal 2 is 
provided by an inductive molecule (probably interleukin 1). which is said to possess 
costimulator activity. A corollary of the postulate is the notion that a stimulator cell 
is required for lymphocyte activation. The stimulator cell is the cell that provides 
the source of costimulator activity. According to this model. antigen-presenting 
cells are stimulator cells. The second postulate is "the control postulate": a control 
molecule on the surface of the stimulator cell regulates production and/or release 
of costimulator activity. Costimulator activity is released only when the control 
structure is engaged by the potentially responsive lymphocyte. We hypothesize that 
third party transfusion of the donor leads to an interaction between third party 
derived cells, presumably leukocytes as shown by our experiments. and the 
passenger leukocyte population of the graft. This interaction causes an activation 
of the passenger leukocyte. This activation bears the characteristics of the 
transfusate given to the donor and is specific. After transplantation~_of the 
transfused graft signal I is provided by passenger leukocyte antigen binding to the 
T-cell receptor. This view is supported by the finding that transfusion does not 
cause a significant change in Ia staining of dendritic cells (Bouwman and Marquet. 
personal communication). The provision of the essential signal 2 however. is 
influenced by the specific metabolic engagement of the passenger leukocyte. We 
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propose that the T-cell response involving the recognition of the control structure 
on the surface of the passenger leukocyte and thus, the release of costimulator 
activity (signal 2). is blocked by this specific metabolical engagement of the 
passenger leukocyte (Figure 10.1). As a result the route of alloimmunization is 
changed. The recipient's own antigen presenting cells are handling the alloantigen. 
This alloantigen is finally presented to the recipient's T helper cells. This indirect 
antigen presentation to the recipient's immune system is much less efficient than the 
process of direct antigen handling (Batchelor et a!.. 1978), and can lead to 
enhancement of graft survival (Lafferty and Prowse, 1984). 
signal 
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Figure IO.l. Activation ofT -cells by antigen-presenting cells influenced by donor transfusion. 
Finally. it is of special interest to mention that when the outlined hypothesis 
holds true, it can be understood why donor transfusion and CsA treatment of the 
recipient showed an additive, enhancing effect on graft survival. for it has recently 
been reported that CsA has an inhibitory effect on the production of interleukin 2 
(Hess. 1985). These two modifications, transfusion of the donor, leading to 
interleukin 1 blockade and CsA treatment of the recipient, leading to inhibition of 
interleukin 2 production, were obviously synergistic in frustrating the rejection 
reaction. It remains puzzling however. what exactly happens when a transfused 
donor graft is transplanted into a DST -treated recipient which leads to a 
detrimental effect on graft survivaL 
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10.4 Concluding remarks 
In this thesis retrospective clinical observations. showing a significant effect on 
graft survival of transfusion of the donor. are confirmed by data obtained in 
controlled experimental studies. The hypothesis concerning the responsible 
mechanism points clearly towards the elimination of one of the signals required for 
lymphocyte activation, in particular the switch off of the second signal which is 
provided by an inductive molecule. probably interleukin I. It is proposed that as a 
result of donor transfusion the route of alloimmunization is changed and that the 
much less efficient indirect antigen presentation to the recipient's immune system 
takes place. Further experimental work is necessary to confirm this hypothesis. Of 
special interest seems to be the effect on graft survival of'"anti-interleukins'" (agents 
blocking the production and/ or action of interleukins) either given to the donor. to 
the graft. or to the recipient. If the hypothesis holds true this might have interesting 
consequences for clinical transplantation as clearly at present donor pretreatment 
in any form several days prior to transplantation is not clinically applicable. 
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SUMMARY 
It is widely accepted that pretransplant blood transfusions to the recipient 
produce a significant beneficial effect on the post-transplant course and eventual 
outcome of cadaveric and living related kidneys. Only recently studies have 
appeared concerning the effect on graft survival of transfusions given to the donor. 
Seven retrospective clinical studies on the effect of blood transfusions given to the 
donor on cadaveric kidney graft survival have been performed. In 4 studies it was 
reported that blood transfusions to the donor prior to nephrectomy positively 
influenced graft survival, in 3 studies no beneficial effect could be observed, The 
many questions raised by these retrospective studies made it necessary to 
experimentally investigate them in rigidly controlled studies, The effects of donor 
blood transfusion in the rat cardiac and kidney allograft model and efforts to 
unravel the mechanism are described in this thesis. 
In chapter 1, a review is given of the history and present state of transplantation. 
Special emphasis is made to describe the several clinical approaches to immune 
modulation and ample attention is paid to the background of donor pretreatment. 
The details of the available seven retrospective clinical studies on the effect of 
blood transfusion given to the donor on cadaveric kidney graft survival are 
described in chapter 2. Furthermore, the objectives for the experimental studies and 
the design of the experiments are formulated. 
The various materials and methods used are described in chapter 3. 
Chapter 4 deals with the effect of third party whole blood transfusion(s) of the 
donor on heterotopic heart allograft survival in rats. The following variables were 
studied: the effect of donor transfusion in different donor~host combinations; the 
effect of donor transfusion in relation to different types of immune modulation of 
the host~ and finally, the effect of varying number and timing of donor transfusion. 
It was found that blood transfusion(s) given to the donor did markedly influence 
graft survival in transfused or immunosuppressed recipients. When the recipient 
was pretreated with a donor-specific transfusion~ which leads, depending on the 
donor-host combination employed, to a shortened, prolonged or even permanent 
graft survival. the effect of blood transfusions to the donor on graft survival was 
predominantly detrimental. When the recipient had been treated with a single 
injection of 15 mg/kg CsA on the day of operation, the effect of blood transfusions 
to the donor was beneficial. The donor transfusion phenomenon was not linked to 
one particular donor-host combination. Furthermore, the donor transfusion 
phenomenon was not linked to one single type of blood. Different sources of third 
party derived blood did have the same influence on graft survival. Finally, there was 
no difference in graft survival after a single or multiple transfusions of the donor, 
nor was there an effect of timing. 
In chapter 5 the donor transfusion phenomenon was studied in a rat kidney 
allograft model. It was observed that a beneficial effect of third party blood trans-
fusions to the donor on graft function and survival could be elicited under the 
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condition that the recipient was moderately immunosuppressed with CsA. When 
the host was not treated no effect on graft function or survival could be recorded. 
Furthermore, it was shown that the appearance of the phenomenon was dose 
dependant. It was discussed that this finding lends support to the role of passenger 
leukocytes in the manifestation of the donor transfusion phenomenon, as the rat 
kidney contains at least four times as many passenger leukocytes as the rat heart. 
Experiments studying the characteristics of the transfusate. required to elicit a 
donor transfusion effect. were described in chapter 6. More in particular the 
importance of the presence of leukocytes in the transfusate and of the degree of 
compatibility for MHC antigens between transfusate and host were studied. It was 
found that the donor transfusion phenomenon seems to be mediated by viable 
leukocytes and that the phenomenon is preferentially induced by blood donors that 
differ from the graft recipient for class I antigens. 
One of the hypothesis concerning the mechanism responsible for the donor trans-
fusion phenomenon is that the effect can be ascribed to a peroperative recipient 
blood transfusion and that transplantation of a graft from a transfused donor 
might represent an additional peroperative transfusion of random donor leukocy-
tes. This hypothesis is tested in chapter 7. In the first part of the experiments it was 
studied whether a peroperative transfusion with third party blood did influence 
heart allograft survival in rats in a model in which donor transfusion clearly showed 
to be effective. It was found that this was not the case. In the second part it was 
tested in a popliteal lymph node assay whether transfusion of the donor led to a 
specific immune response in the recipient. It was observed that transfer of third 
party antigen via the donor to the recipient led to a reduced specific immune 
competence, however. it was also noticed that this transfer of antigen via the graft 
was not responsible for the donor transfusion phenomenon. 
In chapter 8 it was investigated whether passenger leukocytes play an important 
role in the donor-specific transfusion (DST) phenomenon. The passenger leukocyte 
population was irradiated at a dose (10 Gy) known to abrogate leukocyte 
proliferative capacities. without interference with their immunogenic properties. 
The functional properties of the passenger leukocytes were modulated at different 
periods before transplantation. It was observed that pretreatment of the donor with 
irradiation (10 Gy) 5 days before transplantation led to a significant dimunition of 
the DST effect. whereas irradiation of the donor on the day of transplantation did 
not. From these experiments it was concluded that reduction of the immunogenici-
ty of the graft by passenger leukocyte elimination (irradiation) diminished the 
beneficial effect of DST. It was suggested that the passenger leukocytes in the graft 
contributed to the induction of specific unresponsiveness as initiated by the DST to 
the host. 
It has been suggested that the presence of leukocytes of two origins in the graft at 
the time of transplantation, i.e. donor passenger leukocytes and third party cells 
from the blood donor, may be responsible for an altered immunologic reactivity in 
the graft and/or the host. The role ofleukocytes in the third party transfusate has 
been outlined in chapter 6. In chapter 9 attempts were made to substantiate the role 
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of these passenger leukocytes. Indirect evidence for the importance of passenger 
leukocytes was deduced from the following observations. First. it was observed in 
chapter 5 that the donor transfusion effect needs three times more whole third party 
blood to be elicited in the kidney transplantation model as compared to the cardiac 
allograft model. Several studies have demonstrated that the BN kidney contains at 
least four times as many passenger leukocytes as the BN heart. Thus, assuming that 
transfused third party blood does in equal quantities reach the different organs and 
that there is indeed an interaction between third party derived cells and the 
passenger leukocytes in the graft, then it can be understood that the kidney graft 
needs more third party blood than the cardiac graft. This is indeed what we 
observed in chapter 5 and this finding lends support to the role of passenger 
leukocytes in the manifestation of the donor transfusion phenOmenon. Secondly, it 
was found in chapter 4 that transfusions to the donor did have opposite effects 
(detrimental or beneficial) depending on the way the recipient had been treated. In 
the strain combination employed, a DST to the recipient led to permanent graft 
survival. It was demonstrated that this transfusion effect was abolished by treat-
ment of the donor with irradiation (chapter 8). From this experiment it was 
concluded that reduction of the immunogenicity of the graft diminished the 
beneficial effect of a DST. A similar detrimental influence on the beneficial DST 
effect was reported after transfusion of the donor. It was suggested that the third 
party cells interacted with the passenger leukocytes in such a way that this 
abrogated the beneficial DST effect. Recipients treated with CsA however, did 
benefit from donor transfusion. The CsA interacts with the recipient's immune 
system. Here these two modifications, transfusion of the donor and CsA treatment 
of the recipient. did prove to be additive (chapter 4). The irradiation experiments in 
the current study were meant to substantiate the role of these passenger leukocytes 
in the expression of the donor transfusion phenomenon. It was observed that 
irradiation (10 Gy) of the donor either 5 days before transplantation or on the day 
of transplantation did abrogate the otherwise beneficial donor transfusion effect in 
the model employed. These results indicated that the presence and intact pro~ 
liferative capacity of the passenger leukocyte population of the donor was essential 
for the manifestation of the donor transfusion effect. These data suggest that trans~ 
fusion of the donor provoked a reaction in the passenger leukocytes which resulted 
in a modified activity of these cells towards the responsive cells of the host. 
In the final chapter 10 the results as obtained in the previous chapters are 
discussed. It is concluded that, taken the stimulator cell concept as the relevant 
model for allograft rejection, the results point towards the elimination of one of the 
signals required for lymphocyte activation as the most likely explanation of the 
mechanism of the donor transfusion phenomenon. It is especially suggested that 
the switch off of the second signal which is provided by an inductive molecule. 
probably interleukin Lis responsible for the described phenomenon. It is suggested 
that as a result the route of alloimmunization is changed and that the much less 
efficient indirect antigen presentation to the recipient's immune system takes place. 
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Finally, it is concluded that further experimental work is necessary to confirm this 
hypothesis. Of special interest seems to be research on the effect on graft survival of 
"anti-interleukinsH either given to the donor, to the graft,· or to the recipient. 
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SAMENVATTING 
Het is algemeen bekend dat bloedtransfusies, welke v66r transplantatie aan de 
ontvanger worden gegeven: een gunstig effect hebben op de overleving van zowel 
cadaver- als familie-nieren. Recent zijn een 7-tal retrospectieve klinische studies 
verschenen betreffende het effect op de transplantaat-overleving van transfusies 
gegeven aan de donor. In vier van deze onderzoekingen werd een positief effect van 
donor-transfusie gevonden~ in drie onderzoekingen werd geen effect waargenomen. 
Deze studies wierpen een aantal vragen op, die het beste b~antwoord konden 
worden door gebruik te maken van een preklinisch proefdiermodel. 
Het onderzoek dat in dit proefschrift wordt beschreven, omvat experimenten bij 
ratten en had tot doe I het effect te onderzoeken van bloedtransfusies aan de donor 
op de overleving van hart- en nier-transplantaten. Bovendien werd gepoogd het 
mechanisme dat ten grondslag ligt aan zo'n effect te ontrafelen. 
In hoofdstuk 1 worden de geschiedenis en huidige stand van zaken betreffende 
weefsel en orgaan transplantatie besproken. Bijzondere aandacht is geschonken 
aan de verschillende manieren waarop in de kliniek wordt gepoogd de afstotings-
reactie te be"invloeden: verder wordt de achtergrond van donor voorbehandeling 
aan de orde gesteld. 
In hoofdstuk 2 worden de gegevens van de retrospectieve klinische studies naar 
het effect van donor-transfusie besproken. De doelstellingen van bet experimentele 
onderzoek en het antwerp van de experimenten worden geformuleerd. 
De gebruikte materialen en methoden zijn beschreven in hoofd.stuk 3. 
In hoofdstuk 4 word! bet effect van derde partij bloed (bloed afkomstig van een 
stam niet verwant aan donor of ontvanger) aan de donor op de overleving van een 
heterotoop getransplanteerd hart beschreven. De volgende variabelen werden 
bestudeerd: het effect van donor-transfusie in verschillende donor-gastheer 
combinaties: het effect van donor-transfusie in relatie tot immunosuppressieve 
behandeling van de ontvanger: en tot slot het effect van het aantal en het tijdstip van 
transfusies. Het bleek dat bloedtransfusies een duidelijk effect hadden op de 
overleving in ontvangers welke waren getransfundeerd of behandeld met een 
immunosuppressivum. Afbankelijk van de donor-gastheer combinatie leidt een 
donor-specifieke transfusie van de ontvanger tot een verkorte, verlengde of zelfs 
permanente overleving van het transplantaat. In deze donor-specifiek getrans-
fundeerde ontvangers had transplantatie van een hart afkomstig van een getrans-
fundeerde donor, vrijwel altijd een negatief effect op de overleving. Wanneer daar-
entegen de ontvanger was behandeld met het immunosuppressieve geneesmiddel 
Cyclosporine A in een dosis van 15 mg/kg lichaamsgewicht, dan bleek dat trans-
fusie van de donor een gunstig effect had. Het bleek dat het v66rkomen van bet 
donor-transfusie effect niet beperkt was tot een enkele donor-gastheer combinatie, 
maar in tegendeel, in verschillende combinaties kon worden geinduceerd. Verder 
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werd vastgesteld. dat bloed van verschillende rattestammen bet effect in vergelijk-
bare mate kon bewerkstelligen. Tot slot werd vastgesteld. d?t noch het aantal trans-
fusies aan de donor, noch het tijdstip van transfusie, in bet gebruikte model van 
belang waren. 
In hoofdstuk 5 is bet donor-transfusie effect bestudeerd in een niertransplantatie 
model in de rat. Er werd gevonden. dat een derde partij bloed transfusie van de 
donor een gunstig effect kan hebben op zowel de functie als de overleving van bet 
niertransplantaat. Hierbij was bet noodzakelijk. dat de ontvanger een beperkte 
hoeveelheid Cyclosporine A ontving. Indien dit niet werd gegeven. werd geen effect 
van transfusie van de donor op de transplantaat-overleving waargenomen. In bet 
niertransplantatie model werd verder gevonden. dat het effect afhankelijk was van 
de hoeveelheid getransfundeerd bloed. Mede op basis van de bevinding dat, om een 
vergelijkbaar effect te verkrijgen, er 3 maal zoveel bloed moest worden toegediend 
in het niertransplantatie-model dan in bet harttransplantatie-model, werd de 
hypothese geponeerd. dat de zgn. "passenger"leukocyten een rol zouden spelen in 
de manifestatie van dit fenomeen. Achtergrond voor deze suggestie vormde het 
gegeven. dat de ratte-nier tenminste 4 maal zoveel "passenger" leukocyten bevat 
dan bet ratte-bart. 
In hoofdstuk 6 zijn experimenten beschreven waarin is onderzocht aan welke 
karakteristieken het transfusaat moet voldoen. om een donor-transfusie effect te 
sorteren. In het bijzonder werd bet be lang van leukocyten in het transfusaat en van 
de graad van compatibiliteit voor MHC antigenen tussen transfusie donor en 
transplantaat ontvanger bestudeerd. Er werd gevonden, dat het donor-transfusie 
effect tot stand lijkt te komen via levende leukocyten in het transfusaat. Bovendien 
leek het fenomeen bij voorkeur te worden geinduceerd door bloed afkomstig van 
donoren welke tenminste van de ontvanger voor klasse I antigenen verschillen. 
Er zijn diverse hypothesen opgesteld over het mechanisme dat aan het optreden 
van het donor-transfusie effect ten grondslag zou kunnen liggen. Een zo'n 
hypothese luidt. dat het effect van donor-transfusie terug te brengen is tot een 
peroperatieve transfusie aan de ontvanger. Transplantatie van een ''getrans-
fundeerd transplantaat" zou een peroperatieve transfusie betekenen van gemi-
greerde leukocyten uit bet transfusaat. Deze hypothese is in hoofdstuk 7 getoetst. In 
het eerste deel is onderzocht of een peroperatieve transfusie met derde partij bleed, 
een effect heeft op de overleving van harten in een model waarvan bekend is. dat 
transfusie van de donor een duidelijk resultaat geeft. Er werd geen effect gevonden. 
In het tweede dee! is, gebruik makend van de "popliteal lymph node assay" 
bestudeerd, oftransfusie van de donor leidt tot een specifieke immuun reaktie in de 
ontvanger. Er werd gevonden, dat transport van derde partij antigenen via de 
donor naar de ontvanger plaatsvindt en daar aanleiding geeft tot een verminde-
rende specifieke immunologische reaktiviteit. Echter. tegelijkertijd werd geconsta-
teerd, dat dit transport van antigeen en de verandering in immunologische 
reaktiviteit niet verantwoordelijk kunnen zijn voor het donor-transfusie effect. 
Concluderend kan gesteld worden, dat geen aanknopingspunten zijn gevonden 
voor de juistheid van de hypothese, dat het donor-transfusie effect terug te brengen 
zou zijn tot een peroperatief transfusie fenomeen. 
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In hoofdstuk 8 is onderzocht of '"passenger'"leukocyten een rol spelen bij het tot 
stand komen van een donor-specifiek transfusie (DST) fenomeen. De '"passenger'" 
leukocyten populatie in bet transplantaat werd belnvloed door de donor te 
bestralen met 10 Gy. Dit heeft tot gevolg dat de proliferatie van deze cellen wordt 
gerernd maar de immunogene eigenschappen ongemoeid blijven. Vijf dagen na 
bestraling zijn de meeste ''passenger'"leukocyten uit bet transplantaat verdwenen. 
Waargenomen werd. dat bestraling van de donor 5 dagen v66r transplantatie, 
aanleiding gaf tot een negatieve beinvloeding van bet gunstige DST effect. Echter, 
bestraling van de donor op de dag van transplantatie had geen effect. Deze 
rcsultaten leidden tot de conclusie. dat vermindering van de immunogeniciteit van 
bet transplantaat door de "passenger"" leukocyten uit te schakelen. bet gunstige 
effect van DST te niet doet. Dit gegeven is aanleiding tot de veronderstelling, dat de 
"passenger" leukocyten een belangrijke rol spelen in de inductie van donor-
specifieke tolerantie. zoals wordt bereikt door bet geven van DSTs. 
Een tweede hypothese omtrent bet mechanisme van bet donor-transfusie effect 
is. dat bet wordt veroorzaakt door de aanwezigheid ten tijde van transplantatie van 
leukocyten van twee verschillende origines. nl. donor "passenger" leukocyten en de 
cellen afkomstig uft bet transfusaat. Deze twee populaties zouden zodanig met 
elkaar intervenieren. dat als gevolg hiervan de immunologische reaktiviteit in bet 
transplantaat of in de ontvanger zou worden veranderd. Het be lang van leukocyten 
uit bet transfusaat voor bet optreden van een donor-transfusie effect is reeds aan de 
orde gesteld in hoofdstuk 6. In hoofdstuk 9 is gepoogd de rol van de .. passenger"' 
leukocyten nader te definieren. Indirekt werd bet belang van deze "passenger" 
leukocyten gedestilleerd uit de volgende bevindingen. Ten eerste werd. zoals 
beschreven in hoofdstuk 5. gevonden. dat. om een donor-transfusie effect te 
kunnen induceren. in bet nier-model drie maal zoveel bloed nodig is dan in bet hart-
model. In diverse studies is aangetoond. dat de gebruikte BN nier ten minste vier 
maal zoveel "passenger" leukocyten bevat dan bet BN hart. Ervan uitgaande. dat 
bet getransfundeerde bloed de verschillende organ en in gelijke mate bereikt. en dat 
er inderdaad een interactie is tussen leukocyten uit bet transfusaat en de 
"passenger" leukocyten in bet transplantaat, kan derhalve worden verondersteld, 
dat denier meerderde partij bloed nodig heeft dan het hart om een donor-transfusie 
effect te laten zien. Dit is inderdaad wat in hoofdstuk 5 werd gezien. en dit gegeven 
verleent steun aan de hypothese. dat "passenger" leukocyten een belangrijke rol 
spelen bij bet tot stand komen van bet donor-transfusie effect. Ten tweede werd in 
hoofdstuk 4 beschreven hoe transfusies aan de donor tegengestelde effecten 
(ongunstig versus gunstig) op de transplantaat-overleving hadden, afbankelijk van 
de wijze waarop de ontvanger was behandeld. In de gebruikte donor-gastheer 
combinatie geeft een DST aanleiding tot een permanente overleving. In hoofdstuk 
8 werd beschreven hoe dit DST effect te niet word! gedaan door bestraling van de 
donor. Hieruit werd geconcludeerd. dat verminderingvan de immunogeniciteit van 
bet transpl~mtaat een negatief effect heeft op bet gunstige gevolg van een DST. 
Eenzelfde ongunstige invloed werd gevonden na transfusie van de donor. Er is 
gesuggereerd. dat de derde partij afkomstige cellen zodanig reageerden met de 
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''passenger'' leukocyten, dat het gunstige effect van DST werd verstoord. 
Ontvangers daarentegen welke met Cyclosporine A werden behandeld. vertoonden 
een gunstig effect van donor-transfusie. Het is bekend. dat Cyclosporine A met het 
immuun systeem van de ontvanger intervenieert. Hier hebben deze twee modifi-
caties, nl. transfusie van de donor en Cyclosporine A behandeling van de 
ontvanger. additief gewerkt (hoofdstuk 4). De bestralingsproeven in dit hoofdstuk 
zijn bedoeld om de rol van de '"passenger"leukocyten bij bet tot stand komen van 
het donor-transfusie effect verder te onderzoeken. Gevonden is, dat bestraling ( 10 
Gy) van de donor danwel 5 dagen v66r transplantatie. danwel op de dag van 
transplantatie. het gunstige effect van donor-transfusie in het gebruikte modeL 
verloren doet gaan. Deze resultaten geven aanleiding te veronderstellen. dat de 
aanwezigheid. dus immunogene eigenschappen. en de intacte proliferatieve. dus 
immunocompetente eigenschappen van de "passenger" leukocyten populatie van 
de donor essentieel is voor de manifestatie van bet donor-transfusie effect. Deze 
gegevens leidden tot de veronderstelling, dat transfusie van de donor een reactie 
heeft veroorzaakt in/bij de "passenger"leukocyten. welke heeft geresulteerd in een 
veranderde activiteit van deze cell en ten opzichte van de responderende cell en in de 
gastheer. 
In het laatste hoofstuk 10 worden de resultaten. uit de voorafgaande hoofd-
stukken, besproken. Het zogenaamde "stimulator cell" concept wordt geaccep~ 
teerd als een goed model om transplantaat afstoting te beschrijven. Met dit model 
voor ogen wordt geconcludeerd. dat transfusie van de donor mogelijk leidt tot uitw 
schakeling van een van de signalen van de antigeen presenterende "passenger" 
leukocyt, hetgeen aanleiding geeft tot een vertraging in de activering van de T lym-
phocyten. Er wordt met name verondersteld, dat bet "uitzetten" van bet tweede 
signaal. dat wordt gegeven dooreen "inductive" molecuul, mogelijk interleukine I, 
verantwoordelijk is voor bet beschreven fenomeen. Ten gevolge hiervan zou de weg 
waarlangs immunisatie plaats vindt en dus de afstotingsreactie op gang komt. 
worden gewijzigd in de veel minder effectieve, indirecte weg van antigeen 
presentatie. Ten slotte wordt gesteld, dat toetsing van deze hypothese verder 
experimenteel werk behoeft. Van bijzonder be lang lijkt hicrbij onderzoek naar het 
effect op transplantaat-overleving van interleukines en anti-interleukines. 
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